Chemotherapy-related cardiovascular morbidity in testicular cancer patients:markers &amp; mechanisms by Altena, Renske
  
 University of Groningen
Chemotherapy-related cardiovascular morbidity in testicular cancer patients
Altena, Renske
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Altena, R. (2011). Chemotherapy-related cardiovascular morbidity in testicular cancer patients: markers &
mechanisms. [S.n.].
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




in Testicular Cancer Patients 
Markers & Mechanisms 
Chemotherapy-related Cardiovascular Morbidity 
in Testicular Cancer Patients 
Markers & Mechanisms 
Renske Altena 






� .. , 
c., r -.I � � 
c:j,- ./ 
For the publication of this thesis, financial sponsoring ot'1he \foUCi>Wfng institutions is gratefully acknowledged: 
Stichting Werkgroep lnterne Oncologie, University of Groningen 
Cover design: Thomas NM Bijen, www.spatialdesign.nl 
Cover illustration: Tablecloth representing Flora surrounded by flowers. Maximiliaan van der Gucht, Delft, estimated 
1650-1675. Property of Rijksmuseum, Amsterdam. In the 1960's restoration was performed for preservation of the 
fabric. Over the following decades the glue used for this preservation caused deterioration of the condition of this 
cloth. Thereafter, extensive research at the Conservation Department of the Rijksmuseum was done to investigate 
the causes of this damage and methods to restore the condition of the cloth. 
Lay-out: Renske Altena 












Chemotherapy-related Cardiovascular Morbidity in Testicular Cancer Patients 
Markers & Mechanisms 
Proefschrift 
ter verkrijging van het doctoraat in de 
Medische Wetenschappen 
aan de Rijksuniversiteit Groningen 
op gezag van de 
Rector Magnificus, dr. E. Sterken, 
in het openbaar te verdedigen op 
maandag 9 mei 2011 
om 14.45 uur 
door 
Renske Altena 









Prof. dr. J.A. Gietema 
Prof. dr. E.G.E. de Vries 
Dr. J. Meijer 
Dr. J.D. Lefrandt 
Prof. dr. R. de Wit 
Prof. dr. T.P. links 
Prof. dr. D.J. van Veldhuisen 




Chapter 1 Introduction and outline of the thesis 9 
Chapter 2 Cardiotoxicity caused by cancer treatment: strategies for 17 
early detection 
Lancet Oncology, 2009;10:391-9 
Chapter 3 A comprehensive biomarker panel for chemotherapy- 31 
related endothelial damage detection in testicular 
cancer patients 
Submitted 
Chapter4 Prospective evaluation of cardiac function after cisplatin- 49 
based treatment for testicular cancer 
British Journal of Cancer, 2009;100:1861-6. 
Chapter 5 Longitudinal changes in cardiac function after cisplatin- 59 
based chemotherapy for testicular cancer 
Submitted 
Chapter 6 Raynaud's phenomenon after chemotherapy for testicular 71 
cancer is associated with accelerated atherosclerosis 
Submitted 
Chapter 7 Metabolic syndrome in testicular cancer survivors 83 
develops early after platinum-based chemotherapy 
Submitted 
Chapter 8 Genes and pathways associated with cisplatin- and 97 
bleomycin-induced endothelial damage: a preliminary report 
Chapter9 Summary, discussion and future perspectives 111 
Chapter 10 Summary in Dutch 121 
Acknowledgments (Dankwoord) 127 
Bibliography 131 

Introduction and outline of the thesis 
•· 
Chapter 1 
Testicular germ cell tumours, the most common solid malignancy in men in their 2nd to 4th 
decades, are diagnosed in around 700 patients each year in the Netherlands.1 Initial 
management consists of orchidectomy and evaluation for metastases by measurement of 
serum tumour markers and imaging of the abdomen and thorax. Without signs of metastases 
at the moment of orchidectomy, a watchful wait-and-see policy is initiated. If metastases are 
present, or when they arise during follow-up, systemic treatment with platinum-based 
chemotherapy is indicated. 2 Currently, the standard regimen consists of three or four 3-weekly 
cycles of Bleomcyin, Etoposide and Cisplatin (BEP) combination chemotherapy. Classification 
into a prognosis group [good, intermediate or poor International Germ Cell Cancer 
Collaboration Group (IGCCCG)] is based on levels of the serum tumour markers aFP, bHCG and 
LOH, 3 and dictates the number of chemotherapy courses. Stage of disease is based on size and 
sites of distant metastases. 
Since the introduction of platinum-based chemotherapy regimens in the late 1970's, 4 
metastatic testicular cancer has become the paradigm of a highly curable malignancy with a 
10-year survival rate of around 80%.2'5 As a result of this favourable prognosis, together with 
the increasing incidence of testicular cancer in the Western world, 1'5 the population of 















Figure 1. Incidence and mortality of testicular cancer in the Netherlands over the past three decades (data from the 
Netherlands Cancer Registry, www.ikcnet.nl) 
Survivorship issues: chemotherapy-related cardiovascular morbidity 
As testicular cancer survivors are thought to have a normal life-expectancy once cured from 
their malignancy, the importance of the risk for treatment-related complications in these 
patients is now increasingly recognised.2'6 Important examples of these late effects are 
infertility, neurotoxicity, second malignancies and cardiovascular disease (CVD). 6'7 Recognition 
and possibly prevention of these issues is needed to achieve an optimal health status of the 
cancer survivor population. The development of CVD is a gradual process that progresses from 
subclinical changes to clinical morbidity, and therefore, early interventions might be effective 
to slow down or stop development towards overt CVD. 
The time of occurrence of vascular damage and complications related to chemotherapeutic 
treatment in testicular cancer patients has two peaks; acute toxicity can manifest during of 
shortly after chemotherapy, whereas chronic consequences can arise up to decades after 
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completion of treatment. During or shortly after completion of treatment, arterial and venous 
thrombo-embolic events occur in around 10% of patients treated with BEP-chemotherapy.8'9 
As a more subtle sign of vascular toxicity, over 30% of testicular patients report Raynaud's 
phenomenon after treatment with bleomycin- and platinum-containing chemotherapy.10 
Bleomycin-induced pneumonitis occurs in 0-10% of patients treated with bleomycin-containing 
chemotherapy, depending on the criteria used for the diagnosis, and is fatal in approximately 
1-3% of all patients treated with bleomycin.11 
long-term testicular cancer survivors have a higher incidence of CVD compared to the general 
population and stage I patients, treated with orchidectomy only.1•12•14 In a cohort of >2,500 
Dutch testicular cancer survivors, the estimated 20-year risk for CVD was 18.1%.15 In a 
Norwegian cohort of long-term testicular cancer survivors, treatment with BEP-chemotherapy 
resulted in a 5.7-fold higher risk {95% Cl 1.9-17.1) for coronary artery disease, compared to 
stage I patients.16 In this cohort, 8.0% of patients had developed one or more atherosclerotic 
events at median 21 years of follow-up. In 10-year testicular cancer survivors in the United 
Kingdom, treatment with chemotherapy was associated with a relative risk of 2.59 for cardiac 
events compared to stage I testicular cancer patients and healthy subjects.12 From a previous 
study in 14-year chemotherapy-treated testicular cancer survivors from our own institution, 
6% had developed an ischemic cardiac event, with an observed-to-expected ratio of 7.1 (95% 
Cl 1.9-18.3) compared to the general population.13 Moreover, cisplatin-based chemotherapy is 
associated with an elevated risk for cardiovascular mortality, with an standardized mortality 
rate of 1.20 {95% Cl 1.00-1.50) compared to the general population.17 
Next to overt CVD, testicular cancer survivors have a higher rate of cardiovascular risk factors 
like dyslipidemia, obesity, hypertension and insulin resistance, compared to healthy controls 
and stage I testicular cancer patients.18'19 Moreover, they have an enhanced rate of early signs 
of atherosclerosis, such as albuminuria and elevated inflammatory markers when compared to 
controls.19•21 These subclinical signs of vascular dysfunction may progress to overt CVD over 
the course of years. This hypothesis was supported by a recent study in a Norwegian cohort of 
long-term chemotherapy-treated testicular cancer survivors, where higher levels of systemic 
inflammation (i.e. plasma levels of high-sensitivity C-reactive protein) were associated with a 
2.79 fold (95% Cl 1.22-6.34) higher risk for cardiovascular events during follow-up. 
Mechanisms contributing to chemotherapy-related cardiovascular damage 
Different mechanisms have been associated with the development of treatment-related 
cardiovascular complications in testicular cancer patients. In vitro studies show that both 
cisplatin and bleomycin can induce endothelial cell death. 22•24 In addition, these drugs change 
endothelial cell function, including the increased expression of adhesion molecules, 24-26 
production of pro-inflammatory cytokines27 and induction of pro-coagulant activitity.22'24 Early 
signs for vascular damage, e.g. rises in endothelial activation markers and an increase in lntima 
Media Thickness {IMT) of the carotid artery, were previously reported in testicular cancer 
patients treated with cisplatin-based chemotherapy.8 Chronic low-grade vascular damage may 
persist on the long term, as testicular cancer survivors were found to have levels of circulating 
platinum from years to decades after chemotherapy.28 Over the course of years, this 
endothelial damage may progress to accelerated atherosclerosis and overt CVD.29•30 
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In addition to direct chemotherapy-induced endothelial damage, other factors can contribute 
to the development of vascular complications after testicular cancer treatment. Firstly, the 
development of cardiovascular risk factors, which have a higher prevalence in chemotherapy­
treated testicular cancer patients than in controls, 18'19 can lead to accelerated atherosclerosis 
and secondary vascular complications. Furthermore, several metabolic changes are associated 
with the development of an unfavourable risk profile for CVD.31 In testicular cancer patients, 
(subclinical) hypogonadism related to unilateral orchidectomy, might further contribute to the 
development of cardiovascular risk factors, as low testosterone levels are associated with 
metabolic disturbances and thereby an increased risk for CVD in the general male population.32 
Additional metabolic changes related to cancer treatment, e.g. obesity, dyslipidemia and 
hypothyroidism, may contribute to the development of CVD in successfully treated testicular 
cancer su rvivors.18'19'31 
Early biomarkers for vascular damage in testicular cancer patients: a potential strategy to 
reduce the development of cardiovascular complications 
When testicular cancer survivors develop cardiovascular risk factors or overt CVD, treatment 
recommendations based on guidelines from general cardiovascular medicine for initiation of 
primary or secondary prevention apply. However, patients at risk for these complications 
should ideally be identified prior to the development of overt morbidity, in order to avoid the 
development of irreversible complications. The occurrence of CVD is a gradual process that 
progresses from subclinical damage to clinical morbidity. Therefore, early biomarkers may aid 
to identify patients at increased risk for vascular complications after chemotherapy. Different 
types of cardiovascular biomarkers can be discerned for this purpose, as summarised in Table 
1.
33 
In cardiovascular medicine, the use of biomarkers for diagnostic, interventional and prognostic 
purposes is widely studied and increasingly used in clinical practice. A recent definition from 
the National Institutes of Health described a biomarker as 'a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention'.34 By the identification of 
biomarkers for chemotherapy-related cardiovascular damage, treatment and follow-up 
schedules for patients can be optimised and individualised. In addition, specific biomarkers 
may increase understanding in the pathogenesis of vascular complications, and thereby 
provide possible targets for intervention. Furthermore, biomarkers can serve as surrogate 
markers for disease pro- or regression, and thereby facilitate studies that are aimed to 
decrease the incidence of chemotherapy-related CVD, e.g. intervention studies. 
-13 -
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VASCULAR 
BIO MARKER REPRESENTS EXAMPLE 
- Lipid profile (cholesterol, high-densitiy/low-density lipoproteins, 
triglycerides) 
Vascular 




- Endothelial activation (van Willebrand Factor, soluble adhesion 
molecules) 
- Direct endothelial damage (Circulating Endothelial Cells) 
Blood 
- Pro-thrombotic state (tissue Plasmlnogen Activator, Plasminogen 
vulnerability 
Activator Inhibitor type 1, van Willebrand Factor, fibrinogen) 
- Repair capacity (Endothelial progenitor cells) 
Cardiac 
- Elevated filling pressures (atrial and brain natriuretic peptides) 
biomarkers 
- Direct cardlomyocyte damage (troponin I and T) 
- Cardiac fibrosis (galectin-3) 
Structural marker 
Subclinical - Carotid artery lntima Media Thickness 
atherosclerosis - Coronary calcification score 
- Blood pressure 
Functional marker 
Endothelial - Endothelial dysfunction (Flow-mediated vasodilatation, brachia! 
function artery reactivity, carotid artery compliance and distensibility) 
- Microalbuminuria 
Table 1. Cardiovascular biomarkers represent (combinations of) different aspects of cardiovascular 
pathophysiology, and may aid in early detection of cardiovascular damage related to cancer treatments. Adapted 
from Vasan, Circulation 2006. 33 
AIM OF THE THESIS 
The studies described in this thesis aim to search for early biomarkers of subclinical treatment­
related cardiovascular damage in testicular cancer patients treated with cisplatin-based 
chemotherapy. 
OUTLINE OF THE THESIS 
Different strategies can be used to evaluate treatment-related cardiovascular damage during 
or after cancer treatments. Early changes may point to subclinical cardiovascular damage prior 
to the development of clinical morbidity. In Chapter 2 conventional and contemporary 
methods for early detection of cardiovascular damage related to cancer treatments are 
summarised and graded based on their Level of Evidence.35 The emphasis is on detection of 
treatment-related cardiotoxicity, as most studies so far have focussed on this type of damage. 
Previously, early changes in endothelial activation and vascular structure in testicular cancer 
patients shortly after cisplatin-based chemotherapy were described.8 In Chapter 3 changes in a 
comprehensive panel of vascular biomarkers are measured, including Circulating Endothelial 
-14-
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Cells in blood, and plasma markers for endothelial activation, inflammation and pro­
thrombotic state. Levels of these markers are prospectively assessed in a cohort of testicular 
cancer patients before, during and up to one year after completion of cisplatin-based 
combination chemotherapy. Changes in biomarkers are related to early clinical cardiovascular 
events and changes in vascular structure. 
Cardiac abnormalities, particularly diastolic dysfunction, are found more frequently in 
chemotherapy-treated long-term testicular cancer survivors, when compared to healthy 
controls and stage I testicular cancer patients.13'36 In Chapter 4 early changes in systolic and 
diastolic echocardiography parameters and serum levels of the cardiac biomarker N-terminal 
Pro-Brain Natriuretic Peptide are assessed in a cohort of testicular cancer patients, before start 
of chemotherapy and within median 10 months after completion of treatment. Baseline 
measurements are compared to age-matched healthy males. In Chapter 5 longitudinal follow­
up of cardiac status in this cohort of testicular cancer survivors is described. Changes in 
echocardiography parameters and cardiac biomarkers at median 7 years post-treatment are 
related to earlier cardiac assessments and patient characteristics. 
Long-term testicular cancer survivors treated with chemotherapy have an higher rate of 
endothelial dysfunction21 and overt CVD, 13 compared to healthy controls and stage I testicular 
cancer patients. In Chapter 6 longitudinal follow-up of vascular status is presented in a cohort 
of testicular cancer patients median 7 years after treatment with cisplatin-based 
chemotherapy. The progression of subclinical signs for atherosclerosis over time is estimated, 
and factors that contribute to the progression of vascular dysfunction are explored. 
Chemotherapy-treated testicular cancer survivors have a higher incidence of the metabolic 
syndrome, a cluster of unfavourable cardiovascular risk factors.19'21 In Chapter 7 the 
prevalence and timing of the metabolic syndrome is investigated, and associated features of 
vascular status, as well as of circulating vascular biomarkers in testicular cancer survivors with 
the metabolic syndrome are explored. 
Both cisplatin and bleomycin can induce endothelial cell activation and apoptosis, 24•27 which 
contributes to the development of CVD in testicular cancer patients. Insight in molecular 
events may provide enhanced understanding and identification of biomarkers for 
chemotherapy-related endothelial damage. In Chapter 8 preliminary results from cDNA 
microarray experiments performed in an endothelial cell line model exposed to cisplatin or 
bleomycin are described. Findings from this pre-clinical study are translated to a clinical setting 
by measurement of candidate biomarker levels in testicular cancer patient plasma samples. 
Data from this thesis are summarised in Chapter 9, and potential strategies that can be 
pursued to reduce chemotherapy-related endothelial damage are discussed. Findings from the 
current work are put into perspective according to these potential strategies, and 
recommendations for future research are presented. 
-15 
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Cardiovascular toxicity caused by 
cancer treatment: strategies for early detection 
Renske Altena1, Patrick J Perik2, Dirk J van Veldhuisen2, 
Elisabeth G E de Vries1, Jourik A Gietema1 
1Department of Medical Oncology, 2Department of Cardiology, 
University of Groningen and University Medical Center Groningen, the Netherlands 
Lancet Oncology, 2009;10(4):391-9 
Early Detection of Cardiovascular Toxicity 
SUMMARY 
Cardiovascular toxicity is one of the most devastating complications of cancer treatment and 
can arise during or shortly after treatment, or even several years later. Identification of the left 
ventricular ejection fraction {LVEF) is the most common method to screen for toxic effects on 
the heart; however, this approach underestimates cardiac damage and additional strategies 
for the monitoring of treatment-induced cardiotoxicity are being explored. Guidelines for 
monitoring have been formulated for several cancer treatments; however, appropriate 
underlying evidence is still largely absent. In this Review, we summarise conventional and 
contemporary methods for early detection of cardiotoxicity and designate a level of evidence 




Methods for detection and treatment of different types of cancer have developed impressively 
in the past 20 years. Life-expectancy for patients with cancer is steadily improving, with an 
age-adjusted 10-year survival of 70% for breast cancer, 80% for Hodgkin's disease, and 90% for 
testicular cancer.5 Around 3 million patients are diagnosed with cancer in Europe each year, 
which means there is a large group at risk of treatment-related complications.37 Long-term 
complications include development of second malignancies and cardiovascular disease, but up 
to now, the incidence and extent of these complications in adults are largely unknown. By 
contrast, studies of childhood cancer survivors have produced many more data on long-term 
complications of treatment. 38 
In trials of adjuvant anthracycline-based treatment for breast cancer, 5-year incidence of 
chronic heart failure is between 0% and 3.2%, depending on the combination regimen and 
cumulative dose of anthracycline.39 However, long-term follow up of cardiovascular morbidity 
and mortality is not available. A large meta-analysis of the Early Breast Cancer Trialists' 
Collaborative Group, in which 42,000 patients with breast cancer participated in 78 
randomised trials, found that patients treated with radiotherapy had a high rate of non-breast 
cancer mortality, mainly from heart-disease (rate ratio 1.12). This high rate of heart disease 
was observed during the first 5 years after treatment and continued for up to 15 years.40 
However, data are partly based on outdated radiation-techniques in use from 1976 until 1995. 
10 years ago, we reviewed methods for detection of anthracycline-induced cardiotoxicity.41 
Improvements have since resulted in more sensitive monitoring strategies (Figure 1). Changes 
in cancer treatment have introduced both, more as well as less, potentially cardiotoxic 
regimens, through the increased use of anthracyclines, platinum compounds, radiation 
therapy, and introduction of monoclonal antibodies such as trastuzumab and bevacizumab. 
Figure 1. Fused computed tomography with llllndium-DTPA-trastuzumab single photon emission tomography 
(SPECT) image performed in a patient with metastatic osteosarcoma three weeks after 6 cycles after completion of 
doxorubicin (96 hours post tracer injection). Fusion of the images shows increased uptake of the tracer in the 
characteristic horseshoe shape of the myocardium of the left ventricle. 
Although monitoring guidelines exist for several potentially cardiotoxic treatments, little data 
are available to formulate evidence-based screening and follow-up recommendations for 
treatment-induced cardiotoxicity. In 2007, the American Society of Clinical Oncology (ASCO) 
Survivorship Expert Panel clearly stated the need for such recommendations.42 
In this Review, we give an update of the methods available for early detection of cardiac 
damage caused by cancer treatment. Each method is assigned a level of evidence backing up 
its applicability, according to the system used by the Oxford Centre of Evidence Based 
- 19 -
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Medicine (Table 1).35 Level la evidence is viewed as definite and level 5 as weak. Most studies 
reviewed in this paper were not designed to assess the sensitivity of monitoring strategies as a 
primary goal, which implies that level of evidence is based on indirect evidence or 
retrospective data. 
Level 1 a Systematic review of randomised controlled trials 
b Single randomised controlled trial 
2 a Systematic review of cohort studies 
b Individual cohort study 
C "Outcomes" research 
3 a Systematic review of Case-Control studies 
b Individual Case-Control study 
4 Case-series 
5 Expert opinion 
Table 1. Levels of Evidence according to the Oxford Center of Evidence Based medicine. 35 
Detection of treatment-induced cardiotoxicity 
Cardiac function is monitored during a potentially cardiotoxic cancer treatment to identify 
patients who are susceptible to this toxicity as early as possible and prevent morbidity and 
mortality. Efforts to prevent further complications include intensified monitoring, initiation of 
preventive measures, or changes to cancer treatments. Detection of possible toxicity should 
not result in holding back an essential treatment, which would compromise effectiveness. 
Mitani and colleagues43 did a retrospective analysis of 265 patients treated with doxorubicin 
who had serial assessments of left ventricular ejection fraction (LVEF) during treatment. 
Changes in LVEF were associated with chronic heart failure up to 3 years after treatment. 
Patients were identified as being at risk (decrease in LVEF of >10% to <50%) or at low risk of 
cardiotoxicity. 15 cases of chronic heart failure were prevented by stopping cancer treatment 
when patients met the criteria for being at risk. Mitani and colleagues43 concluded that 
monitoring of cardiac function to identify at-risk patients was effective in preventing 
progression to chronic heart failure. 
The possibility of preventing cardiotoxicity should be viewed in light of possible loss of benefit 
to cancer outcome, although it is unclear how this issue should be interpreted. This is 
especially difficult for trastuzumab-induced cardiotoxicity because data on long-term outcome 
are unavailable. 
Several guidelines for monitoring of cardiovascular effects during and after cancer treatment 
are available. The American Heart Association (AHA) recommends close monitoring of cardiac 
function during anthracycline treatment but does not specify how often or by which means.44 
The absence of data on the role of routine monitoring to prevent cardiac disease in 
asymptomatic adult survivors of cancer was emphasised in a recent ASCO clinical evidence 
review.42 For survivors of childhood cancer, the Children's Oncology Group has devised risk­
based guidelines for follow-up of late effects, such as cardiac morbidity.45 Available guidelines 
are not consistent in their recommendations and seem to be based on modest evidence. 
- 20 -
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Moreover, none of the guidelines define an approach to long-term follow-up of cardiac 
function in adult survivors of cancer, although cardiac morbidity can become apparent up to 
several years after treatment. 
-Genetic susceptibility 
-Pre-existent risk factors for cardiovascular disease 
-Factors associated with an Increased risk for treatment-Induced toxicity 
LVEF 
Lower limit of 
normal 
l cancer treatment 





-Targeted nuclear Imaging 
' 
time 
Eady changes Pces1Jct1ye toe liUec cardJoyasculac morbJdlty 
-Echocardlography 
-Electrocardiography 
-Targeted nuclear Imaging 
-cardiac MRI 
Figure 2. Schematic, hypothetical representation of changes in left ventricular ejection fraction (LVEF) and timing of 
detection with several screening strategies during and after cancer treatment. (I) late onset cardiotoxicity (e.g. 
radiotherapy, anthracyclines);46'47 {II) reversible cardiotoxicity (e.g. trastuzumab: dotted line as long-term 
consequences are still unknown);48 (Ill) irreversible cardiotoxicity during treatment (e.g. anthracyclines).46'49 
LVEF 
Measurement of LVEF with multiple gated acquisition (MUGA) scintigraphy and 
echocardiography,so gives an assessment of systolic cardiac function and is the most common 
method of monitoring cardiac function during cancer treatment. However, LVEF can 
underestimate actual cardiac damages1 because of the compensatory reserve of the 
myocardium that enables adequate ventricular output even in the presence of dysfunctional 
myocytes. With left ventricular dysfunction, deterioration of diastolic cardiac function can be 
present in the absence of systolic impairment, and subclinical diastolic dysfunction precedes a 
drop in systolic function in many patients.52 Thus, adequate LVEF can mask actual cardiac 
damage and therefore other methods to assess cardiac function during cancer treatment are 
being investigated.s3 Several approaches towards early detection of cardiovascular toxicity 
might be useful for this purpose, including estimation of the baseline risk of cardiovascular 
complications, detection of temporary events (eg, release of troponins or natriuretic peptides), 
or identification of subclinical changes, such as changes in diastolic function (Figure 2). 54•57 
Decreases in LVEF resulting from treatment might vary with different types of treatment, 
hindering the interpretation of cardiac function assessments. 
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Although guidelines are available for the monitoring of cardiovascular effects during and after 
cancer treatment, the underlying evidence is of medium quality. Furthermore, the time after 
completion of treatment for which cardiovascular follow-up is needed is unknown. 
Methods for assessment of cardiovascular function 
Strategies for early detection of potential cardiovascular damage from cancer treatment will 
be addressed. Advantages, disadvantages, and level of evidence behind each strategy are 




- Reliable calculation of Left 
- LVEF insensitive for early, 
Multiple Gated 
Ventricular Ejection Fraction (LVEF) 
subclinical cardiotoxicity 
Acquisition 
- Low intra-individual and inter-
- Limited information on diastolic 2b 
Scintigraphy function 
observer variation 
- Radiation exposure 
- No side effects, non-invasive 
- Preload-dependence of several 
- Systolic and diastolic function 
Echocardiography 
- Tissue Velocity Imaging, Strain and 
parameters 
2b 
Strain Rate promising for detecting 
- Expertise and interpretation of 
early (subclinical) changes 
echocardiographist 
- No information on left 
- Availability 
ventricular function 
- QTc only investigated parameter 
- No side effects, non-invasive 
- Variation in inter-observer 
Electrocardiography - Computerized analysis enables 
interpretation 2b 
standardized serial assessment 
- Timing of ECG changes in the 
- Prolonging QTc-time may be an 
early marker 
course of cardiotoxicity unknown 
- Interference with other 
medication 
- Easy analysis, possible 
quantification 
- Exact predictive value not 





- Normal / abnormal values not 
- Low inter-observer variability 
definite 
- Rises in levels probably relate to 
early toxicity 
- Pathogenic factor in toxicity - Exact predictive value not 
- Assessment of structural and certain 
Endothelial damage 
functional parameters - Unknown which marker reliably 
- Rises in serum/plasma levels represents cardiovascular toxicity 2b 
possibly relate to early toxicity - Intra-individual variation of 
- Identification of cardiac and functional parameters 
vascular toxicity 
- Pre-treatment identification of 
- Numerous SNPs, difficulty of Genetic variations 
susceptibility to toxicity 
identifying most relevant 
4 
- Minimal invasive 
- Information on structural features 
- Availability 




- Radiation exposure 
2b 
imaging 
- Early changes in metabolic 
- Exact predictive value not 
certain 
processes can be visualized 
- Mainly older data 
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- Detailed information of anatomy 
with high resolution and contrast 
- No radiation exposure 
- Reliable calculation of LVEF 
- Combination with late gadolinium 
enhancement for detailed 




- Unknown whether early cardiac 
changes can be visualized 






Table 2. Strategies for early detection of cancer treatment-induced cardiovascular toxicity; overview of (dis-) 
advantages and levels of evidence. 
MUGA scintigraphy 
With high reproducibility and low interobserver and intraindividual variability, MUGA 
scintigraphy is the gold standard for assessing LVEF. Together with echocardiography MUGA 
scintigraphy is the most widely accepted method to assess patients' LVEF during cancer 
treatment;50 although guidelines do not specify which is preferred. 
In a combined analysis of three phase Ill trials, with a total of 630 patients treated with 
doxorubicin, serial measurements of LVEF were retrospectively analysed and compared with 
clinical symptoms of cardiotoxicity. During treatment, 149 patients were judged to have a 
decrease in LVEF (>30% from baseline), whereas 32 patients developed chronic heart failure 
during follow-up. Only 11 of the 32 patients with chronic heart failure had a preceding 
decrease in LVEF. The authors concluded that early changes in LVEF are inadequate to predict 
anthracycline-induced heart failure.54 
A prospective study of 120 patients with breast cancer recorded LVEF up to 3 years after 
treatment with anthracycline. 11 of the 12 most severe reductions in LVEF (decrease of >35% 
from baseline) happened more than 3 months after treatment stopped, and cardiac systolic 
function showed a slowly progressive deterioration in the 3 years of follow up. 55 This study 
indicates that prolonged monitoring of cardiac function after stopping of treatment is 
necessary to detect treatment-related cardiotoxicity, and monitoring of LVEF is insensitive to 
early changes in cardiac function during a potentially cardiotoxic treatment. 
Nousiainen and co-workers56 studied 28 patients treated with doxorubicin for non-Hodgkin 
lymphoma who had successive LVEF assessments at increasing cumulative doses. A MUGA 
scan showing a decrease in LVEF of at least 4% after a cumulative doxorubicin dose of 200 
mg/m2 had 90% sensitivity and 72% specificity for predicting development of chronic heart 
failure.56 
MUGA scintigraphy is a reliable and widely used method for assessment of LVEF, but it is 
somewhat insensitive for detecting subtle changes in cardiac function. Therefore, MUGA 
scintigraphy has limited value for early detection of cardiotoxicity. Nousiainen and co­
workers56 small prospective study found early changes on MUGA scintigraphy predictive for 
later development of chronic heart failure, but a large retrospective analysis identified no 
association between clinical findings and LVEF.54 Changes in LVEF indicative of cardiac damage 
can only be identified when serial measurements are compared and related to baseline 
ejection fraction. This should be taken into account because the LVEF has a broad range of 
values in healthy individuals, which can lead to masking or overestimation of possible 
cardiotoxicity. 
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Echocardiography 
Echocardiography allows assessment of systolic and diastolic cardiac function. Diastolic 
measurements are probably the most sensitive to early changes in cardiac function. Commonly 
used diastolic measurements include the E/ A ratio (peak early atrial divided by peak late atrial 
velocities) and recent techniques such as tissue velocity imaging of the early diastole, strain, 
and strain rate. These contemporary techniques are reliable measures of diastolic function 
because they are less subject to interobserver variation than the E/A-ratio.57'58 
Several studies of early changes in cardiac function during and after anthracycline treatment 
found primarily diastolic function impairment, rather than systolic dysfunction.59-61 Diastolic 
impairment was also observed in 16 patients with breast cancer within 24 h of first high dose 
of cyclophosphamide.62 In a prospective study of 16 patients treated with anthracycline, the 
mean strain and strain rate decreased after low cumulative doses of epirubicin (<200 mg/m2), 
without changes in other systolic or diastolic echocardiographic variables. 63 Other small 
prospective studies compared conventional echocardiography with doppler echocardiography, 
which assesses blood-flow velocities and myocardial structures, during and shortly after 
anthracycline-treatment. In these studies, doppler imaging enabled enhanced detection of 
subclinical cardiac changes.59'64'65 
Lotrionte and colleagues66 are investigating doppler echocardiography for detecting changes in 
systolic and diastolic measures as primary endpoints for cardiotoxicity during treatment with 
anthracycline. Data from this randomised clinical trial, in which patients are given doxorubicin 
or liposomal doxorubicin, will hopefully help identify measures that are sensitive to early 
changes in cardiac function during cancer treatment. 
Echocardiography is mainly used to assess changes in LVEF during cancer treatment. Several 
reports indicate that newer diastolic measures such as tissue velocity imaging of the early 
diastole, strain, and strain rate enable early detection of subclinical changes in cardiac function 
during cancer treatment, 59'63-65 although their predictive value is unclear. 
Electrocardiography 
Electrocardiography (ECG) is a convenient and inexpensive method to screen for conduction 
disturbances and signs of cardiomyopathy. Several chemotherapeutics can induce cardiac 
problems that might lead to changes in an ECG, such as repolarisation abnormalities and 
prolongation of the corrected QT interval. Cardiomyopathy is indicated on an ECG by low QRS 
voltages. so 
Most prospective studies on the role of ECG in screening for cardiotoxicity measured changes 
in the corrected QT interval, possibly because this variable is easily assessed and compared. 
Corrected QT interval was prolonged with each successive course of anthracycline-based 
treatment in 21 adults, but no information was given on long-term cardiac function in this 
group.67 Nakamae and co-workers68 showed a long corrected QT interval to be predictive of 
subacute (potentially fatal) cardiac failure in 19 patients who received high-dose 
cyclophosphamide. The same authors found an association between prolonged corrected QT 
interval and decline in systolic function in 72 adults after treatment with anthracycline,69 
suggesting that a prolonging corrected QT interval might indicate cardiotoxicity. Large studies 
of the predictive value of changes in corrected QT interval have not been done. Other drugs 
used in supportive care can also affect the corrected QT interval and hinder its interpretation. 
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Few data are available on changes in other ECG variables. Decreases in QRS voltage within 24h 
were observed in six of 16 patients with breast cancer given high-dose cyclophosphamide, but 
follow-up longer than 24 h was not provided. 62 Little evidence is available to define a role for 
ECG in the assessment of potential cardiotoxicity. Several individual cohort studies suggest 
that a prolonging corrected QT interval is an early marker, 68'69 but the accuracy for prediction 
of late cardiac disease is not established. 
Biochemical cardiac markers 
Measurement of serum biomarkers is an attractive strategy for the monitoring of 
cardiotoxicity because samples can be taken in a minimally invasive way and there is low 
interobserver variability in their interpretation. Natriuretic peptides (n-terminal pro-brain 
natriuretic peptide, brain natriuretic peptide, and atrial natriuretic peptide) are used as 
predictive markers for severity of heart failure, 70 and they are released from cardiomyocytes in 
response to increased ventricular wall stretch. Concentrations of cardiac troponins T and I 
relate to the extent of acute myocardial damage.71 Concentrations of plasma atrial natriuretic 
and brain natriuretic peptide were prospectively assessed in 13 adults with leukaemia during 
doxorubicin treatment and related to LVEF. Three patients developed chronic heart failure and 
five developed an asymptomatic LVEF decrease after chemotherapy. In all patients with 
cardiac dysfunction, the concentrations of plasma brain natriuretic peptide increased above 
the normal limit before the LVEF deteriorated, whereas this did not change in patients without 
cardiotoxicity. Concentrations of plasma atrial natriuretic peptide were unrelated to changes in 
LVEF.72 
In 27 adults treated with anthracycline for different types of malignancy, N-terminal pro 8-type 
natriuretic peptide was increased without clinical signs of cardiotoxicity. 73 Increased 
concentrations of natriuretic peptides were not associated with changes in LVEF in a 
prospective study of 40 patients with breast cancer treated with anthracycline.74 Mean N­
terminal pro 8-type natriuretic peptide concentrations were higher after 24 h in 21 adults 
given anthracycline than in those who were not, without changes in serum concentrations of 
cardiac troponin T.67 Sandri and colleagues75 assessed concentrations of N-terminal pro 8-type 
natriuretic peptide in 52 adults undergoing high-dose chemotherapy for various malignant 
diseases. Patients with persistently high concentrations of N-terminal pro 8-type natriuretic 
peptide had more cardiac (systolic and diastolic) dysfunction 1 year later than did patients with 
transient increases or stable concentrations. 75 
Serum concentrations of cardiac troponin T and N-terminal pro 8-type natriuretic peptide 
were prospectively assessed by Dodos and co-workers76 and compared with changes in LVEF in 
100 adults treated with anthracycline. Only minor increases in cardiac troponin T 
concentrations were found and transient increases in N-terminal pro 8-type natriuretic peptide 
were seen in 15 patients after the first cycle of anthracycline, which was not associated with 
cardiac dysfunction.76 
In a prospective study of 703 adults, cardiac troponin I concentrations were assessed 
immediately after and 1 month after completion of high-dose chemotherapy regimens for 
different tumour types. Patients with high cardiac troponin I concentrations at either 
assessment had a high incidence of cardiac events (37% at one assessment time, 84% at both 
times) during 3 years follow-up compared with those without raised troponin I. 77 
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A predictive role for biomarkers of cardiotoxicity caused by cancer treatment is not defined 
well enough to include them as routine screening measurements, although persistent 
increases in cardiac troponin 177 or N-terminal pro B-type natriuretic peptide75 concentrations 
seem to identify patients at risk for cardiotoxicity. Therefore, these biomarkers might aid in 
early detection of subclinical damage. A useful approach is to assess baseline biomarker 
concentrations in every patient and measure periodically during and after a potentially 
cardiotoxic cancer treatment. Increases in concentrations of these markers might signal the 
need for further cardiac assessment. 
Markers of endothelial damage 
Structural, functional, or biochemical indicators of endothelial damage might be useful 
markers for early detection of cardiovascular toxic effects. Endothelial activation leads to 
disturbance of the physiological balance of the endothelium and might progress to endothelial 
dysfunction and accelerated atherosclerosis. 29'78 Vasoactive factors involved in these 
endothelial effects include cytokines27 and adhesion molecules, which might be used as early 
markers (Figure 3).25'26'79 Vascular parameters such as carotid intima-media thickness might 
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Figure 3. Overview of factors involved in cancer treatment-induced endothelial activation. Several 
chemotherapeutic agents as well as radiotherapy can initiate a cascade of events, which may ultimately lead to 
accelerated atherosclerosis.29 Factors involved in these processes, e.g. adhesion molecules, cytokines, endothelial­
derived microparticles or coagulatory and fibrinolytic proteins, may be early markers of endothelial toxicity. 
Several clinical studies have analysed endothelial damage during cancer treatment. In 45 
patients with testicular cancer who received cisplatin and bleomycin-based regimens, serum 
concentrations of von Willebrand factor and carotid intima-media thickness were increased 10 
weeks after treatment compared with baseline recordings.8 Circulating endothelial-derived 
micro particles are thought to have a pro-thrombotic role. A prospective study80 found high 
serum concentrations of these microparticles in 18 patients during treatment with cisplatin, 
suggesting that such increases might contribute to the risk of cerebrovascular events. In 
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another study, 21 survivors of testicular cancer had microalbuminuria and unbalance in 
concentrations of the plasma fibrinolytic proteins tissue-type plasminogen activator (tPA) and 
plasminogen activator inhibitor type 1 (PAl-1) at 7 years after treatment. Additionally, 
survivors of testicular cancer in another study20 had high serum concentrations of intercellular 
adhesion molecule-1 (ICAM-1) 5 years after chemotherapy compared with testicular cancer 
survivors who had not had chemotherapy. In 40 patients with breast cancer who were treated 
with anthracycline-based regimens, no association was found between plasma concentrations 
of apoptosis markers and clinical cardiotoxicity.81 
Individual cohort studies have indicated variables that suggest subacute treatment-induced 
endothelial activation (von Willebrand factor and intima-media thickness), 8'82 but the 
predictive role for these factors is unknown. If proven predictive, such markers of early 
detection might be used as intermediate endpoints for cardiovascular toxicity in intervention 
trials. 
Genetic variation 
Genetic variation might modulate the risk of cardiovascular toxicity from cancer treatment. 
Pharmacogenomics are increasingly investigated in general cardiology in the search for genetic 
variations that contribute to the development of cardiovascular disease. 
Several investigators aimed to identify single nucleotide polymorphisms as an explanation for 
differences in sensitivity to cytotoxicity caused by cancer treatment. 83"85 Genome-wide 
screening and candidate gene methods identified several single nucleotide polymorphisms 
associated with genetic predisposition for increased sensitivity to chemotherapy. Five single 
nucleotide polymorphisms were linked with early or late doxorubicin-induced cardiotoxicity in 
87 patients and were absent in 363 asymptomatic patients treated with anthracycline (odds 
ratio 2·0-3·6).86 The single nucleotide polymorphisms included a variant of the NADPH oxidase 
subunit NCF4, the His72Tyr polymorphism in the p22phox subunit, and polymorphism in the 
RAC2 subunit of the same enzyme. The Gly671 Val variant of the doxorubicin efflux transporter 
multidrug resistance protein 1 (MRPl) and the Val1188Glu-Cys1515Tyr haplotype of the 
functionally similar MRP2 were also associated with cardiotoxicity. These genes are all involved 
in doxorubicin metabolism and formation of reactive oxygen species, supporting the relevance 
of this finding. 
The most common ERBB2 polymorphism is codon lle655Val. In 61 patients with breast cancer 
who were treated with trastuzumab, all treatment-related cardiotoxicity was in patients 
heterozygous for lle655Val, whereas no cardiotoxicity was recorded in wildtype lle655lle 
patients.87 
Although the sensitivity and predictive value of single nucleotide polymorphisms are uncertain, 
further investigation might enable pretreatment identification of patients with a genetic 
susceptibility for cardiovascular toxicity, for whom more intensive screening or even 
preventive strategies should be initiated. 
Targeted cardiac imaging 
Nuclear techniques can assess structural and functional processes in the heart and might be a 
sensitive method to detect cardiotoxicity. Apart from MUGA scintigraphy, discussed earlier, a 
range of other targeted tracers are used in cardiology practice, including 111-
indiumantimyosin88 and 123-iodine-metaiobenzylguanidine. 89 
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111-lndiurn-antimyosin enables in-vivo visualisation of myocardial necrosis, which has been 
investigated in the setting of anthracycline-induced cardiotoxicity. 17 of 20 patients with 
breast cancer90 and 27 of 30 patients with sarcoma91 had cardiac uptake of 111-indium­
antimyosin. In both studies, tracer uptake was increased in patients with low LVEF. In a 
prospective study of 24 patients treated with anthracycline for various malignant diseases, 
Valdes and colleagues92 found tracer uptake in patients without changes in systolic or diastolic 
function. Uptake was more intense with increasing cumulative dose of anthracycline. In a 
prospective study of 36 patients treated with doxorubicin, Carrio and co-workers93 showed 
that patients with higher antimyosin uptake at intermediate cumulative doses tended to have 
more severe cardiac functional impairment at maximum cumulative doses. 123-lodine­
metaiobenzylguanidine is used to investigate the functionality of the myocardial adrenergic 
neurotransmitter system, which can be affected by anthracycline.94 In two studies of 57 
patients treated with anthracycline, tracer-uptake decreased with increasing cumulative doses 
of anthracycline and preceded changes in LVEF.93•95 
Other potentially useful nuclear tracers are available. For example, imaging with radiolabelled 
fatty acids to show myocardial-cell metabolism has been investigated in other specialties of 
cardiology.96 Radiolabelling and imaging of molecular directed anticancer drugs is another 
possibility; ERBB2 expression can be visualised with 111-indium-trastuzumab and single­
photon emission CT (SPECT; Figure 1). De Korte and colleagues97 reported myocardial uptake 
of tracer in five of ten patients with different types of malignancy within 4 weeks of 
anthracycline-based treatment. This finding suggests that the presence or even upregulation of 
ERBB2 soon after anthracycline-treatment might pose a patient at risk of trastuzumab-induced 
cardiotoxicity. In an earlier study, 98 myocardial uptake of the same tracer was found in only 
one of 15 patients with breast cancer at a median of 11 months after anthracycline treatment. 
However, no association with clinical evidence of cardiotoxicity was found. Radiolabelling of 
molecular targets to visualise pathways involved in treatment related complications could be 
used to investigate other drugs that potentially cause cardiotoxicity (eg, imatinib or sunitinib). 
It is unknown how targeted cardiac imaging can be used to detect early changes in cardiac 
function during or shortly after cancer treatment. For both 111-indiumantimyosin and 123-
iodine-metaiobenzylguanidine, scintigraphy showed associations between tracer uptake and 
subsequent decreases in LVEF,90-93,95 but most techniques were investigated over a decade ago, 
and despite promising preliminary results, these strategies have not been incorporated in 
standard clinical practice. Contemporary imaging techniques, as shown with radiolabelled 
trastuzumab, could be used to detect changes in the myocardium. 
MRI 
MRI is a reliable and reproducible method to assess cardiac structural features, including the 
coronary arteries and pericardium, and enables consistent calculation of LVEF. MRI combined 
with late gadolinium contrast enhancement can detect subtle areas of irreversibly damaged 
myocardium. Therefore, MRI is increasingly useful in cardiology. 99 In a recent case study of ten 
patients with breast cancer-who had previously received anthracycline and had low LVEF on 
MUGA scintigraphy or echocardiography during trastuzumab treatment- structural MRI 
abnormalities throughout the myocardium were suggestive of myocarditis in all patients.100 As 
this result suggests, cardiac MRI might be practical for early detection of treatment-related 




The identification of patients who are at an increased risk of cardiovascular damage caused by 
cancer treatment can be achieved by detection of early changes in cardiovascular function and 
estimation of a baseline risk of late morbidity {Figure 2). Current guidelines and monitoring 
strategies for detection of cardiovascular toxicity caused by cancer treatment are mostly 
derived from medium-level evidence-true even for MUGA scintigraphy (Table 2). 
LVEF is the most widely used measure in the monitoring of cardiac toxicity but might 
underestimate actual cardiac damage because patients with a healthy LVEF can have 
subclinical changes in cardiac function. On the basis of insights from different types of 
cardiomyopathy, it is likely that diastolic dysfunction happens before the deterioration of 
systolic function. Therefore, echocardiography with newly developed measures of diastolic 
function such as like tissue velocity imaging of the early diastole, strain, and strain rate, might 
permit earlier detection of subclinical signs of cardiac dysfunction. Serum cardiac biomarkers, 
such as troponins and natriuretic peptides, have shown promising results to identify patients 
at risk for later cardiotoxicity and might be a screening strategy for early cardiovascular 
damage. These biomarkers should be further investigated prospectively. Moreover, cardiac 
MRI, combined with gadolinium enhancement, is a promising new strategy to screen for 
potential cardiotoxicity that warrants further investigation. 
Care for long-term survivors of cancer is a new part of practice in oncology, with cancer 
increasingly regarded as a chronic disease. Studies that assess reliable and sensitive monitoring 
strategies for early detection of cardiovascular toxic effects should be encouraged, so that 
timely recognition of cancer treatment-related consequences is possible, without 
compromised antitumour efficacy. 
Search strategy and selection criteria 
Articles for this Review were found through searches of PubMed and Embase by use of the 
terms "cardiovascular toxicity", "cardiotoxicity", "cancer treatment", "chemotherapy", 
"biochemical", "endothelial damage", "genetic variations", "electrocardiography", 
"echocardiography", "Multiple Gated Acquisition Scan", "Magnetic Resonance Imaging", 
"Positron Emission Tomography", and "Single Photon Emission Tomography". Trials with 
highest quality study design were selected. Only studies of adults, written in English, and 
published between January, 1985, and June, 2008, were included. 
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ABSTRACT 
Purpose 
Chemotherapy-related endothelial damage causes cardiovascular morbidity in testicular 
cancer patients. Early identification of patients at risk for these effects is needed to guide 
preventive strategies. We therefore studied changes in a comprehensive panel of biomarkers 
involved in vascular pathobiology. 
Methods 
In metastatic testicular cancer patients before, during, 1 month and 1 year after cisplatin­
based chemotherapy, CD146+, CD105+, DAPI+, CD45- circulating endothelial cells (CECs) and 
plasma markers for endothelial activation [von Willebrand Factor (vWF), soluble intra-cellular 
and vascular adhesion molecule (slCAM-1, sVCAM-1)], inflammation (fibrinogen, high­
sensitivity C-reactive protein) and fibrinolysis [plasminogen activator inhibitor type 1, tissue­
type plasminogen activator] were measured. Carotid intima media thickness (IMT) was 
determined before and at both post-treatment visits. 
Results 
Fourty-one patients were included. Compared to baseline, CECs and endothelial activation 
markers increased during treatment, and were persistently higher 1 month post­
chemotherapy. One year post-treatment CECs had normalized, while endothelial activation 
markers remained elevated. Markers for inflammation and fibrinolysis increased during 
treatment and normalized post-chemotherapy. Median IMT did not change. Changes in CECs 
correlated with vWF and slCAM-1 (rs for areas under the curve=0.63; P=0.001 and rs=0.40; 
P=0.03), and were larger in 17 patients with increased IMT and five patients with 
cardiovascular events. 
Conclusions 
Within this comprehensive panel of biomarkers, changes in CECs and vWF as well as carotid 
IMT point to testicular cancer patients with augmented endothelial damage. These biomarkers 
should be included in studies addressing the late effect phenotype of cisplatin-based 





Since the introduction of platinum-based chemotherapy, metastatic testicular cancer has 
become a highly curable disease. In the growing group of these cancer survivors we now also 
learn the downside of this success, namely chemotherapy-related complications such as the 
increased risk for cardiovascular disease (CVD).2•6•1•12•13•101 CVD can manifest during or shortly 
after treatment, 9'102 as well as years to decades thereafter.12-14•16•103 
Chemotherapy-related mechanisms contribute to this vascular damage, as pre-clinical data 
show that both cisplatin and bleomycin induce endothelial cell death. 22-24 Moreover, these 
drugs change endothelial function, including increased expression of adhesion molecules, 24-26 
production of pro-inflammatory cytokines27 and pro-thrombotic activitity.22'24 Ultimately, it will 
be this endothelial activation that progresses to accelerated atherosclerosis and overt CVD 
over time. 
In order to develop cardiovascular preventive strategies in testicular cancer survivors, a more 
profound insight in the mechanisms and kinetics of vascular complications is needed. In this 
respect, availability of biomarkers specific for early chemotherapy-related endothelial damage 
will be critical. Until now, only few reports have investigated this. A study investigated some 
candidate vascular biomarkers in patients treated with cisplatin-based regimens.8 Here, the 
carotid lntima Media Thickness (IMT) increased within 10 weeks post-chemotherapy. Others 
measured biomarkers for atherosclerosis in long-term testicular cancer survivors.21 In both 
studies, cisplatin-based chemotherapy was associated with elevated von Willebrand factor 
(vWF) levels.8'21 This is of interest as vWF, released from activated endothelial cells, is a known 
predictive marker for cardiovascular events in the general population.104 
Additional candidate biomarkers for chemotherapy-related endothelial damage include factors 
involved in endothelial pathobiology, such as inflammation and fibrinolysis. Furthermore, 
circulating endothelial cells (CECs) in blood may be a sensitive biomarker. CECs, normally 
present in the circulation in low quantities, 105 have consistently increased levels in 
cardiovascular, malignant and inflammatory diseases.106 Recently, elevated CECs and soluble 
inter-cellular adhesion molecule-1 levels (slCAM-1) were reported in testicular cancer 
survivors.20 It can be concluded that only limited and scattered data exist on vascular 
biomarkers for chemotherapy-related endothelial damage in testicular cancer patients. 
We therefore performed a prospective study in testicular cancer patients to investigate 
changes in a comprehensive panel of biomarkers covering different aspects of vascular 
pathobiology. This panel includes CECs, plasma markers for endothelial activation, 
inflammation and pro-thrombotic state and carotid IMT. By measuring levels before, during, 1 
month and 1 year after start of cisplatin-based chemotherapy we explored changes in kinetics 
of these biomarkers. Moreover, associations with clinical cardiovascular events and changes in 
IMT, a putative early marker of atherosclerosis, were investigated. 
PATIENTS AND METHODS 
Patients 
Eligible for the study were patients with metastatic testicular cancer, 18-50 years old, receiving 
first line cisplatin-based chemotherapy at the University Medical Center Groningen, the 
Netherlands. Exclusion criteria were previous chemo- or radiotherapy, presence of CVD, use of 
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erythropoietin and glomerular filtration rate <60 ml/minute. The local ethics committee 
approved the study, and written informed consent was obtained from all participants. 
Patients received, depending on their International Germ Cell Cancer Collaborative Group 
(IGCCCG) prognosis group, 3 or 4 3-weekly BEP-courses [bleomycin (30 USP, days 2, 8 and 15), 
etoposide (100 mg/m2, days 1-5) and cisplatin (20 mg/m2, days 1-5)]. During the first 6 days 
patients were hydrated with 4 L NaCl 0.9%/day and received daily anti-emetic therapy 
(dexamethasone, ondansetron). 
Timing and contents of study-related investigations 
Blood samples were drawn before chemotherapy administration at day 1, 8 and 15 [cldl (= 
baseline), cld8, cld15, c2dl, etc.] of each BEP-course, 1 month after completion of 3 or 4 BEP­
courses and 1 year after start of treatment. 
A comprehensive panel of biomarkers was composed of factors involved in different aspects of 
vascular pathobiology. These included CECs and plasma markers for endothelial activation 
[vWF, slCAM-1, soluble vascular adhesion molecule (sVCAM-1)], inflammation [fibrinogen, 
high-sensitivity C-reactive protein (hsCRP)] and fibrinolysis [plasminogen activator inhibitor 
type 1 (PAl-1), tissue-type plasminogen activator (tPA)]. Carotid IMT was determined as 
structural vascular biomarker. 
CECs, vWF, fibrinogen, PAl-1 and tPA were determined at all visits; hsCRP, slCAM-1 and 
sVCAM-1 on day 1 and 8 of the first 3 courses, and at both follow-up visits. Patients who 
developed refractory disease or a relapse were excluded from that moment on. 
Biomarkers 
CECs 
Blood for CECs was collected after discarding the first tube, in CellSave Preservative Tubes 
(Veridex LLC, Raritan, NJ). Samples were kept at room temperature, shipped overnight the 
Veridex laboratory (Enschede, the Netherlands), and processed within 96 hours with the 
CellTracks• AutoPrep• System using the CellSearch• Circulating Endothelial Cell Kit. 105 This 
system immunomagnetically enriches CECs from 4 ml blood using CD146 conjugated 
ferrofluids. Enriched cells are stained with the nuclear dye 4,6-diamidino-2- phenylindole 
(DAPI), phycoerythrin (PE)-conjugated CD105, and allophycocyanin (APC)-conjugated CD45. 
Next, by placing the sample cartridge on the CellTracks• Analyzer II System fluorescence 
images for DAPI, PE and APC are acquired. CD146+, DAPI+ objects are classified as CECs when 
they have the morphological appearance of cells that express CD146, DAPI, CD105 and lack 
CD45.105 
For reference value, CECs were determined in a random selection of age-matched healthy 
males (n=72). 
Endothelial activation 
vWF (reference values 50-150%) was measured in citrate plasma, as described earlier.8,21 The 
soluble adhesion molecules sVCAM-1 and slCAM-1 were assessed in EDTA-plasma using a 
multiplex assay for Luminex technology (Fluorkine MAP• Human Adhesion Molecule Base Kit, 




The inflammatory proteins fibrinogen (reference values 1.7-4.0 g/L) and hsCRP (reference 
values <3.0 mg/L) were determined in citrate and EDTA-plasma, respect;ively, as described 
earlier.21 
Pro-thrombotic state 
The pro-thrombotic PAl-1 (reference values 3-43 µg/L) and the fibrinolytic tPA (reference 
values 1.5-10 µg/L) were in citrate plasma measured by ELISA.8 PAl-1/tPA-ratio was calculated; 
increases indicate enhanced pro-thrombotic activity. 
Vascular structure: /MT 
IMT of the right common carotid artery was measured as described earlier8 at baseline and 
both follow-up visits. An IMT �0.02 mm higher than baseline was regarded an increase. To 
exclude high intra- and inter-assessment variability, intra-individual I MT-measurements with a 
standard deviation >0.1 mm were excluded. 
Cardiovascular R isk F actors 
Risk factors were estimated at baseline and follow-up visits. Hypertension was defined as 
blood pressure (BP) systolic �150 mmHg and/or diastolic �95 mmHg, or use of anti­
hypertensive medication. Body Mass Index (BMI) �27.8 kg/m2 was defined as obesity; fasting 
total cholesterol �6.5 mmol/L and/or use of lipid-lowering medication as dyslipidemia; and 
diabetes mellitus as fasting glucose >7.0 mmol/L and/or use of glucose-lowering medication. 
Statisti cs 
Statistical analyses were performed in SPSS software package version 16.0 (SPSS Inc., Chicago, 
IL). Non-normally distributed data were represented as median (range). For comparisons 
between groups the non-parametric Mann-Whitney U test or Kruskal-Wallis test was applied, 
as appropriate. The Wilcoxon's signed rank test was used for intra-individual changes. 
Correlations were calculated with Spearman's correlation (r5) .  To assess cumulative changes in 
time, area under the curve (AUC) values for biomarkers at sequential sampling points were 
calculated in the software package Graphpad Prism version 4.03 (Graphpad Software Inc., La 
Jolla, Ca). AUCs were calculated for absolute changes in biomarkers during the whole 
chemotherapy period up to one month post-chemotherapy (all time-points - day 1). Two­
sided P-values SO.OS were considered significant. 
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RESULTS 
Patients 
Between May 2006 - June 2009, 41 patients were included (Fig 1). 
Original population (n = 78) 
Metastasized testicular cancer 
Cisplatin-based chemotherapy 
May 2006 -June 2009 
Patients approached for study 
participation 
(n = 53) 
Study participation 
(n = 41) 
Study complete until median 49 
days (range 28-98) after 
completion of chemotherapy (n 
= 39) 
Study complete until median 391 
days (range 322-536) after start 
of chemotherapy 
(n = 35) 
I 
Exclusions (n = 25) 
Age >50 or <18 yrs (n = 8), history 
of cardiovascular disease (n = 1), 
mentally retarded (n = 4), poor 
prognosis group requiring start of 
treatment <24h (n = 11), 
previous radiotherapy (n = 1) 
No informed consent (n = 12} 
Study not completed (n = 2) 
Refractory disease (n = 1) 
Relapse (n = 1) 
Study not completed (n = 4) 
Relapse (n = 3) 
Withdrawal (n = 1) 
Figure 1. Patient accrual and timing of study-related investigations. 
Table 1 summarizes patient characteristics and baseline cardiovascular risk factors. During 
follow-up, 39 patients were evaluable for the first visit at a median of 49 days (range 28-98), 
and 35 for the second visit at a median of 391 days (range 322-536) from baseline. Reasons for 
not completing all visits are provided in Figure 1. 
Number of patients 
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4 cycles BEP 
4 cycles EP 


















Table 1 - continued 
Red blood cell transfusion during treatment 
Yes 
No 




Diabetes Mellitus § 













Table 1. Patient- and treatment-related characteristics. Abbreviations: International Germ Cell Cancer Collaborative 
Group (IGCCCG); bleomycin-etoposide-cisplatin chemotherapy (BEP). 
(*) Hypertension: systolic blood pressure .? 150 mmHg I diastolic blood pressure .? 95 mmHg, and/or use of anti­
hypertensive medication; (t) Dyslipidemia: fasting total cholesterol > 6.50 mmol/l and I or use of lipid-lowering 
medication; (:t) Obesity: body moss index .? 27.8 kg/m2; (§) Diabetes mellitus: fasting glucose > 7.0 mmol/L and/or 
use of glucose-lowering medication 
B iomarkers 
Median levels of the vascular biomarker panel at baseline and both follow-up visits are 
summarized in Table 2. Supplementary Table I shows results for CECs, vWF and IMT in 
individual patients. 
Baseline 
One month after One year after 
completion of BEP Start of BEP Correlation with CECs* 
Median Range Median Range Median Range Baseline l mo 1 yr AUC 
CECs 
58+ 14 t:j: 
(cells/4 ml) 
25 6-75 23-316 4-41 
vWF 
{%) 100 42-297 130 t 56-249 115 ft: 49-218 0.12 0.34 § 0.02 0.63 1 
sVCAM-1 
583 t 601 + 0.46 1 
(ng/ml) 
552 279-913 335-1173 296-1088 0. 07 -0.23 0.13 
slCAM-1 
318+ 285 t 0.40 § 
(ng/ml) 
242 116-476 119-867 136-581 0.05 0.29 -0.14 
Fibrinogen 





2.0 0.2-87.1 2.2 0.4-29.1 1.5 0.2-14.3 -0.02 -0.19 0.13 
PAl-1 
(µg/L) 
27 4-98 32 6-126 23 + 8-55 -0.361 -0.14 0.13 -0.22 
tPA 
8.7 + -0.461 
(µg/L) 
7.7 3.9-12.4 7.8 3.7-28 4.2-17.0 -0.24 0.07 -0.07 
PAl-1/tPA 
4.2 1.0-11.7 4.2 0.8-12.6 2.8+:I= 0.1-5.9 -0.25 -0.07 0.00 -0.23 
ratio 
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Table 2 - continued 
Baseline 
One month after One year after 
completion of BEP Start of BEP Correlation with CECs• 
Median Range Median Range Median Range Basellne l mo 1 yr AUC 
IMT mean 
(mm) 
0.53 0.44-0.82 0.52 0.43-0.76 0.53 0.39-0.79 -0.38§ -0.07 -0.21 0.27 * 
Systolic BP 
(mmHg) 130 120-150 121 100-160 120 H 100-150 
Diastolic 
BP (mmHg) 81 67-100 80 60-100 75 t 60-100 
Cholesterol 
(mmol/L) 4.8 2.7-7.5 5.1 3.4-7.1 5.2 1.4-6.8 
BMI 
(kg/m
2) 25.2 20.3-35.8 25.8 21.5-34.3 25.9 t 20.8-33.8 
Table 2. Vascular biomarkers, lntima Media Thickness and cardiovascular risk factors at baseline, one month after 
completion and one year after start of cisplatin-based chemotherapy for testicular cancer, and correlation 
coefficients with (changes) in CECs. Abbreviations: bleomycin-etoposide-cisplatin chemotherapy (BEP); circulating 
endothelial cells (CECs); von Willebrand Factor (vWF); soluble inter cellular adhesion molecule (slCAM-1); soluble 
vascular cellular adhesion molecule (sVCAM-1); plasminogen activator inhibitor type 1 (PAl-1); tissue-type 
plasminogen activator (tPA); high-sensitivity c-reactive protein (hsCRP); intima media thickness of the common 
carotid artery (IMT); blood pressure (BP); body mass index (BMI); area under the curve (AUC). 
(*) Spearman correlation coefficients for correlation between CECs and markers/lMT at baseline, one month after 
completion and one year after start of treatment, and for AUC for changes in time throughout treatment [delta /MT 
(baseline-one month; baseline-one year)]; (t)P <O .01 compared to baseline, Wilcoxon signed rank test; (:t) P <O .01 
compared to one month after completion of treatment, Wilcoxon signed rank test; (§} significance for correlation P < 
.OS; (fl) Significance for correlation P < .01. 
CECs 
Baseline CECs were independent of age (rs = -0.25; P=0.15), IGCCCG prognosis group [good: 
median 22 CECs/4 ml (range 6-75), intermediate: median 31 CECs/4 ml (range 14-54), poor: 
25 CECs/4 ml (n=l); P=0.66], or smoking status [active smokers: median 23.5 CECs/4 ml (range 
7-74), lifelong non-smokers: median 27 CECs/4 ml (range 6-75), ex-smokers: median 22 CECs/4 
ml (range 6-54); P=0.58]. 
Compared to baseline, CECs significantly increased over consecutive BEP-courses (Fig 2A), with 
a median 5.6-fold maximal increase (range 1.2-34.6). The median intra-individual maximal 
CECs peaked on c3d8 (range c1d8-1 month post-chemotherapy). CECs were persistently higher 
than baseline 1 month post-chemotherapy. One year post-chemotherapy CECs declined 
compared to baseline, and equaled healthy males (Fig 3A). 
Excluding data from CECs in patients receiving granulocyte-colony stimulating factor (n=4) and 
red blood cell transfusions (n=5) did not change the results. CEC-levels were not different 
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Figure 2. Circulating endothelial cells (CECs, A), von Willebrand Factor (vWF, B), soluble vascular adhesion molecule 
1 (sVCAM-1, C), soluble intra-cellular adhesion molecule 1 (slCAM-1, D), fibrinogen (E), high-sensitivity C-reactive 
protein (hsCRP, F), plasminogen activator Inhibitor 1 (PAl-1, G) and tissue-type plasminogen activator (tPA, H) 
before, during and after completion of cisplatin-based chemotherapy for testicular cancer. The sample at cldl is 
drawn before initiation of chemotherapy. The box-and-whisker plots show the 10th, 25th, 50th, 75th and 90th 
percentile. Levels of markers in n = 11 patients during the 4th BEP-course are indicated in light blue. 
(*) P<0.05 compared to baseline value or indicated time-point (Wilcoxon signed rank test); the grey areas comprise 
reference values. References values/or CECs (1-20 CECs/4 ml) are based on a study in 249 healthy individuals.105 
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Markers for endothelial activation 
Baseline endothelial activation markers did not differ between IGCCCG-groups. Baseline 
slCAM-1, but not vWF or sVCAM-1, levels were higher in smokers [active smokers: median 
348.9 pg/ml (range 116.9-438.8), lifelong non-smokers: median 215.9 pg/ml (range 137.0-
475.5) ex-smokers: median 225.1 pg/ml (range 200.7-423.8); P=0.02]. 
vWF, sVCAM-1 and slCAM-1 levels increased during BEP-courses (Fig 2B, 2C, 2D). The median 
maximal increase in vWF-levels was 2.2-fold (range 1.0-4.6), median intra-individual maximal 
vWF-levels were reached on c3dl (median; range baseline-c4d8). Compared to baseline, 
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Figure 3A. Levels of CD146+, CD105+, DAPI+, CD45- circulating endothelial cells (CECs) in testicular cancer (TC) 
patients [median age 32 years (range 19-47); median CECs 14 cells/4 ml (range 4-41)] one year after start of BEP­
chemotherapy, compared to healthy age-matched males [median age 33 years (range 21-47); median CECs 16 
cells/4 ml (range 0-57)]. 
Figure 3B. Maximal levels of CECs in testicular cancer patients with an increase in IMT of > 0.02 mm compared to 
baseline [median 180 cells/4 ml (range 54-294)), versus patients without an increase in IMT [median 103 cells/4 ml 
(range 29-933); P=0 .004]. Lines indicates median level of CECs/4 ml in each group; P-value are calculated with the 
Mann-Whitney U test. 
Markers for inflammation 
Patients in the IGCCCG intermediate prognosis group had higher baseline fibrinogen and hsCRP 
levels [fibrinogen/hsCRP: good prognosis: median 2.7 g/L (range 1.5-5.4)/ median 1.5 mg/L 
(range 0.2-87.1); intermediate prognosis: median 4.3 g/L (range 3.1-5.8)/ median 18.6 mg/L 
(range 0.7-39.6); poor prognosis: median 3.7 g/L / median 5.4 mg/L (n=l patient); 
P=0.003/0.03]. Levels were not different in smokers. 
Inflammatory markers decreased during the first week of each BEP-course, which concurred 
with administration of steroids as anti-emetic (Fig 2E, 2F). Post-chemotherapy, fibrinogen and 
hsCRP levels were not different from baseline. 
Markers for pro-thrombotic state 
Baseline levels of PAl-1, tPA or PAl-1/tPA-ratio did not differ between IGCCCG prognosis 
groups or between smokers and non-smokers. 
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Levels of PAl-1 and tPA changed during the BEP-courses {Fig 2G, 2H). One year post­
chemotherapy, PAl-1/tPA-ratio was lower than baseline {Table 2), indicating a less pro­
thrombotic state. 
Marker for vascular structure 
At baseline, IMT was related to age (rs=0.35; P=0.04) and BMI {rs=0.52; P=0.002), but not to BP 
or cholesterol. These correlations were absent during follow-up. Median IMT for the group as 
a whole did not change over time {Table 2). 
R ela tions betw een CECs a nd pla sma bioma rkers 
Table 2 summarizes correlations between CECs and other biomarkers. Baseline vWF and CECs 
were not related, whereas they moderately correlated 1 month post-chemotherapy. One year 
post-chemotherapy, CECs correlated with hsCRP. When all markers were taken into account at 
each time-point, CECs correlated with vWF {rs=0.33; P <0.0001) and fibrinogen {rs=0.15; 
P=0.001), 
During the first 3 BEP-courses, changes in CECs and vWF followed a similar pattern (Fig 2A, 2B, 
supplementary Fig I). Median percentual levels of CECs and vWF at each subsequent time­
point strongly correlated {rs=0.76; P=0.005). 
Cumulative changes in CECs during all BEP-courses up to 1 month post-chemotherapy 
correlated with vWF and slCAM-1 (rs for AUC=0.63; P=0.001 and rs=0.40; P=0.03; Table 2). 
Cumulative changes in tPA and PAl-1 (rs for AUC=0.37; P=0.02) and fibrinogen and hsCRP {rs for 
AUC=0.42; P=0.007) throughout all SEP-courses up to 1 month post-chemotherapy correlated. 
R ela tions betw een increa ses in IMT a nd CECs a nd pla sma bioma rkers 
During follow-up visits, IMT increased in 17 patients {41.5%, Supplementary Table I). Patients 
with an increase in IMT had higher maximal CECs {Fig 3B) and larger cumulative changes in 
CECs. Patients with an increase in IMT had a median CEC-AUC of 7,359 {range 1,994-30,083), 
while the others had a median CEC-AUC of 5,299 {range 1,107-14,322; P =0.044). Patient- or 
treatment characteristics, cardiovascular risk factors and {changes in) other biomarkers were 
not related to increases in IMT. 
Ca rdiova scula r  events a nd risk fa ctors 
One patient presented with pulmonary embolism prior to chemotherapy. Five out of 41 
patients (12.2%) developed a cardiovascular event during or after completion of 
chemotherapy {Table 3). Overall, median percentage changes in CECs were significantly larger 
in the patients with a vascular event since start of chemotherapy, compared to the other 
patients {Fig 3C). In three of them CECs did not increase before but directly after the event. 
Patterns of changes in the other biomarkers were not distinctive in patients with vascular 
events. 
Compared to baseline, median systolic and diastolic BP and BMI were higher 1 year post­
chemotherapy (Table 2). Patient- or treatment characteristics, (changes in) vascular 
biomarkers or IMT were not related to changes in risk factors. 
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Figure 3C. Median percentage changes in CD146+, CD105+, DAPI+, CD45- Circulating Endothelial Cells {CECs) in 
patients with (dark line) and without cardiovascular events (light line) during or after SEP-chemotherapy, compared 
to baseline (= 100%). Median changes are larger in patients with cardiovascular events during or after completion of 
chemotherapy (P=0.001, Mann Whitney U test). Dotted lines indicate changes in patients (n = 11) during 4th course. 
Timing of the events is indicated with an arrow, numbers correspond with patients in Table 3, where details 
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During second course Recovery without 
residual impairments 
During third course; Recovery without 
accidental finding on residual impairments 
CT-scan 
During fourth course Recovery without 
residual impairments 
During fourth course Died from progressive 
disease eight months 
after start of 
chemotherapy 
12 months after start Recovery without 
of treatment residual impairments 
Table 3. Characteristics of testicular cancer patients with vascular events during or after completion of BEP­
chemotherapy. Patient numbers correspond with the numbers indicated in Supplementary Fig I. Abbreviations; 
cardiovascular disease (CVD), computed tomography (CT) scan 
DISCUSSION 
In this prospective study in metastatic testicular cancer patients we evaluated changes in a 
comprehensive panel of factors involved in vascular pathobiology. Within this panel, CECs 
appeared of interest as candidate biomarker for early chemotherapy-related endothelial 
damage. Changes in CECs correlated with changes in the endothelial activation markers vWF 
and slCAM-1, and were larger in patients with increases in their carotid IMT and in those with 
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early vascular events. Another promising marker from this panel of biomarkers was vWF, with 
increases in plasma vWF-levels during chemotherapy that persisted up to one year after 
treatment. 
CECs are considered promising real-time cellular biomarkers for different vascular damage 
conditions, as these cells are considered to have detached from damaged vessel walls.106 This 
opinion is underscored by the finding that CECs are generally low in healthy individuals, but 
raised in inflammatory, malignant and cardiovascular diseases.105-107 
However, as technologies and definitions currently used to measure CECs vary, it is unlikely 
that the same events are scored in the studies reported until now.106•108 Here we used a 
standardized and validated method that defines CECs as cells that express both CD146 and 
CD105, lack the pan-leukocyte marker CD45 and have a nucleus present. This automated 
method selects cells with typical endothelial cell gene expression, 109 that peak upon vascular 
damage110 and correlate with vascular damage biomarkers.107 Increases in this cell population 
occur during chemotherapy, i.e. docetaxel for metastatic prostate cancer.111 
Although we found no relation between baseline CECs and IGCCCG-prognosis group, the CEC­
level can be influenced by neovascularization related to the metastatic malignancy. This is 
underscored by the finding that CEC-levels were lower than baseline at one year post­
chemotherapy, and comparable to healthy age-matched males. The cumulative increase in 
CECs that we observed during chemotherapy can be a resultant of several factors. Firstly, CECs 
will likely be released from tumor vessels in response to effective treatment. As most patients 
had normalization of tumor markers after one chemotherapy course, at that early time-point 
the tumor load was already substantially decreased. Therefore, other factors will also play a 
role, like chemotherapy-induced damage that causes shedding of endothelial cells from 
systemic vasculature. This is apparent from a recent study reporting rises in CECs in cancer 
patients receiving adjuvant chemotherapy.112 Furthermore, repeated venipunctures and the 
vacuum blood drawing may increase CECs. To our knowledge it is unknown whether drugs 
used to alleviate side effects of chemotherapy, such as steroids, induce changes in CECs. 
Another promising marker in our biomarker panel is the endothelial activation marker vWF. 
Plasma vWF-levels increased during BEP-courses, in line with an earlier study.8 The patterns of 
rises in CECs and vWF were similar in our study, and cumulative changes in CECs, vWF and 
slCAM-1 correlated. Similar correlations between CECs and vWF have been reported in several 
other vascular damage conditions, 113'114 supporting the hypothesis that changes in these 
biomarkers reflect chemotherapy-related endothelial damage. Additionally, levels of vWF and 
soluble adhesion molecules remained higher than baseline up to 1 year post-treatment, 
suggesting persisting endothelial activation. As endothelial activation is a first step in vascular 
pathophysiology, this can progress to accelerated atherosclerosis.30 Within our panel of 
vascular biomarkers we also observed changes in markers for inflammation and pro­
thrombotic state during BEP-chemotherapy, suggesting that these phenomena add to the 
development of vascular complications. 
Changes in IMT are used as intermediate endpoint in cardiovascular intervention trials.115-117 
Earlier, we observed a 0.02 mm increase in IMT ten weeks after 4 BEP-courses.8 Absence of 
change in median IMT in the current study is likely due to the lower cumulative cisplatin dose 
administered in the majority of our patients (73% received 3 BEP-courses). Although we did 
not find differences in vascular biomarkers between patients treated with 3 or 4 BEP-courses, 
it is plausible that a higher cumulative dosis of chemotherapy induces more vascular damage. 
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In this study increases in IMT �0.02 mm, as observed in 17 patients, related to higher maximal 
CEC-levels and larger cumulative changes in CECs. This suggests that patients with larger 
increases in both CECs and IMT represent a subgroup with augmented vascular damage, which 
may progress to accelerated atherosclerosis in the long term. 
There are two known peaks in occurrence of vascular complications in testicular cancer 
patients; acute events manifest during or shortly after chemotherapy,9•102 whereas chronic 
consequences arise up to decades post-treatment.12-14'16•103 In the current study, changes in 
CECs, but not in other biomarkers, were larger in patients with early vascular events. Large 
increases in CECs may point to patients in whom intervention to prevent progression towards 
endothelial dysfunction and CVD is indicated. The relatively large inter-individual variation in 
CEC-levels which we observed still hampers the definition of an optimal cut-off level from 
these data. It is known from studies in the general population that !MT-measurement has a 
relatively large inter-measurement varation,118 implying that changes in IMT in individual 
patients over a short follow-up period is not suitable as predictive vascular biomarker. 
In this study in a comprehensive panel of vascular biomarkers, changes in levels of CECs and 
vWF as well as carotid IMT may point to testicular cancer patients with augmented endothelial 
damage. These biomarkers should be included in studies addressing the cisplatin 
chemotherapy-related damage phenotype in testicular cancer patients, consisting of 
accelerated atherosclerosis and cardiovascular morbidity. In extended follow-up studies this 
will reveal the predictive value of early rises in CECs and persistent endothelial activation for 
late CVD in this patient cohort. Eventually, such a marker panel should identify patients in 
whom active intervention to alleviate or prevent chemotherapy-related CVD is indicated. 
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Supplementary Figure I. Median relative changes in CD146+, CDlOS+, DAPI+, CD45- circulating endothelial cells 
(CECs) and von Willebrand Factor (vWF) during, one month after completion and one year after start of BEP­
chemotherapy, compared to baseline (= 100%). The dark line represents median changes in CECs, the light line vWF. 
Changes in CECs and vWF in n = 11 patients during the 4th course are indicated as a dotted line. 
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Supplementary Table I. Age, disease characteristics [disease stage, International Germ Cell Cancer Collaborative Group (IGCCCG) prognosis group] and occurrence of cardiovascular 
events during or after BEP-chemotherapy, individual levels of CD146+, CDlOS+, DAPI+, CD45- circulating endothelial cells (CECs), levels of von Willebrand Factor (vWF) and intima 
media thickness of the common carotid artery (IMT) at baseline, maximum level throughout the whole study period, timing of maximum level, levels at one month after completion 
and one year after start of cisplatin-based chemotherapy. (nd = not done) 
at Disease Vascular 
baseline step IGCCCG durlnt/after IIEP CECs(cells/4ml.) vWF (%) IMT(mm) 
Increase 
Maximum l1mlng of Maximum Tlmlnfl of >0.02 
Baseline level max level l mo  1 yr Baseline level max level l mo  lyr Baseline l mo  l yr  mm 
18 4 Good no 43 218 c2d8 48 7 53 195 c3d8 70 69 n.d. 0.61 0.49 n.d. 
19 2 Good no 17 57 cld8 32 31 62 230 c3d8 56 69 0.51 0.51 0.53 no 
22 2 Good no 60 180 c2d8 147 26 86 192 c3d15 135 102 0.47 0.51 0.56 yes 
22 3 Intermediate no 27 933 c3d15 66 9 122 278 c2d8 159 131 0.49 0.46 0.45 no 
23 2 Good no 16 54 c2d8 34 10 42 89 c3d8 84 60 0.55 0.66 0.62 yes 
23 3 Intermediate no 25 129 c4d15 40 16 so 175 cld8 75 49 0.53 0.43 0.47 no 
25 2 Good no 29 54 c2d8 44 6 101 464 c3d8 122 155 0.47 0.45 0.50 yes 
26 2 Intermediate no 34 47 c3d8 26 n.d. 159 263 c3d8 146 135 0.67 n.d. n.d. n.d. 
26 4 Good no 27 94 c2d8 80 41 98 187 c3d8 n.d. 114 0.47 0.47 n.d. no 
26 2 Good no 42 145 c3d8 78 37 121 419 c3d8 195 164 0.47 0.46 0.44 no 
27 4 Intermediate no 54 320 c3d8 n.d. n.d. 156 239 c4d8 n.d. n.d. 0.47 n.d. n.d. n.d. 
27 4 Poor Pulm.embolism 25 221 c2d15 23 12 99 224 c4d8 148 96 0.48 0.57 0.53 yes 
27 2 Good no 38 135 c2d15 95 20 51 131 c3d8 n.d. 61 0.44 0.44 0.47 yes 
27 2 Good no 7 111 c3d8 121 23 111 211 c3dl 150 121 0.66 0.57 0.53 no 
28 2 Good CVA 8 175 c3d8 46 11 137 284 c3d8 211 169 0.63 0.72 0.70 yes 
28 2 Good no 22 50 c2d8 44 22 92 190 c2d8 107 101 0.66 n.d. 0.66 no 
29 2 Good no 42 48 c4dl 71 21 72 207 c2d15 124 107 0.51 0.53 0.55 yes 
29 2 Intermediate no n.a. 124 cld8 29 8 297 297 c4d8 137 127 0.59 0.53 0.56 no 
30 3 good no 25 109 cld8 38 29 99 229 c4d8 123 115 0.54 0.47 0.47 No 
31 2 good no 38 663 c3d8 64 11 93 250 c3dl 160 122 0.73 0.69 0.58 No 
31 2 good no 57 66 c3d15 51 4 96 202 c3d8 138 108 0.67 0.59 0.57 No 
33 2 good no n.d. 52 cld8 52 10 109 297 c2d8 124 105 0.45 0.56 0.51 Yes 
33 2 good no 21 147 c2d8 35 n.d. n.d. 374 c3d8 217 n.d. 0.56 0.48 n.d. No 
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at Disease Vascular 
stap IGCCCG durlnt/llfler BEP CECs (calls/4ml.) vWF (%J IMT(mm) 
Increase 
Maximum Tuning of Maximum of max >0.02 
level max level l mo  lyr Basellne level level l mo  lyr Basellne l mo  l yr mm 
34 2 good no 44 294 c2d8 45 n.d. 256 360 c2dl 158 n.d. 0.51 0.63 n.d. Yes 
34 2 good no n.d. 162 one mo 162 14 162 369 c3d8 196 156 0.53 0.49 0.39 No 
34 2 good no 10 29 one mo 29 13 so 107 c2d8 63 76 0.46 0.45 0.42 No 
35 2 good Pulm.emboUsm n.d. 241 c2d8 126 n.d. 76 304 c2d8 122 123 0.55 0.53 0.60 Yes 
35 2 good no 6 96 c3d8 n.d. 10 80 209 c2d15 108 76 0.63 0.52 0.59 No 
36 4 intermediate no 51 256 one mo 256 23 115 363 cld15 88 91 0.53 0.56 0.54 Yes 
36 2 good no 15 192 one mo 192 n.d. 149 292 c3d15 174 n.d. 0.58 0.63 n.d. Yes 
37 3 good no 14 109 c3d15 82 n.d. 147 316 c3d8 219 184 0.54 0.45 0.53 No 
38 4 good no 30 38 cld15 34 4 78 126 c3dl 62 73 0.79 n.d. 0.79 No 
38 2 good no 74 395 c3d8 168 25 100 150 cld8 n.d. 152 0.54 0.57 0.86 Yes 
41 4 good no 28 115 c3d8 116 13 161 440 c3dl 249 218 0.46 0.45 0.51 Yes 
41 2 good no 22 188 cld15 40 6 81 210 c3d8 107 101 0.76 0.76 0.74 No 
42 2 good no 75 316 one mo 316 18 148 394 c3dl 213 146 n.d. n.d. n.d. n.d. 
42 2 good no 18 121 c2d8 n.a. 22 n.ii. 272 c3dl 120 119 0.56 0.66 n.a. Yes 
43 2 intermediate CVA 14 195 c3d8 42 19 145 311 c4d15 179 149 0.75 0.75 0.54 No 
43 2 good no 21 77 c4d15 144 13 160 318 c3d8 119 183 0.68 0.60 0.79 Yes 
45 2 good CVA 10 69 one mo 69 n.d. 146 262 c3d15 200 n.d. 0.82 n.d. n.d. n.d. 
46 2 good no 6 181 c3dl 132 31 72 253 c3d8 109 61 0.45 0.44 0.55 Yes 
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Early Changes in Cardiac Function 
ABSTRACT 
Long-term cardiovascular morbidity is increasingly observed in chemotherapy-treated 
testicular cancer survivors, but little is known of early sub-clinical changes in cardiac function. 
We prospectively evaluated cardiac function by echocardiography. Systolic (Wall Motion Score 
Index) and diastolic [E/ A-ratio and Tissue Velocity Imaging (TVI)] parameters, and serum levels 
of N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) were assessed before start of 
chemotherapy and one year later. Echocardiography data were compared with an age­
matched group of healthy controls. 42 patients treated with Bleomycin, Etoposide and 
Cisplatin were evaluated (median age 27 yrs, range 18-50). Systolic function and E/A-ratio did 
not change, whereas the median TVI decreased (12.0 Vs 10.0 cm/s; p=0.002). Median levels of 
NT-proBNP increased (5 Vs 18 pmol/L, p=0.034). Compared with controls, TVI before the start 
of chemotherapy was not significantly different. In conclusion, at a median of 10 months after 
cisplatin-based treatment for testicular cancer, TVI decreased significantly, indicating a 
deterioration of diastolic cardiac function. Serum levels of NT-proBNP increased. The 




Testicular cancer (TC), the most frequent type of solid malignancy in young male adults, has 
become a highly curable disease since the late seventies with the introduction of cisplatin­
containing chemotherapy regimens. In the growing population of TC survivors, the occurrence 
of long-term treatment induced organ damage is increasingly recognized as an important 
cause of morbidity.2 Compared with the general population, long-term TC survivors have a 
higher incidence of second malignant neoplasms and cardiovascular disease.1•12•14 
In earlier studies, investigating cardiac morbidity in long-term TC survivors median 7 to 14 
years after chemotherapy, we found diastolic dysfunction in 17-33% of patients.13'36 Sub­
clinical signs of vascular toxicity were found in a prospective study in TC patients 10 weeks 
after cisplatin-based chemotherapy.a Still, little is known about (sub-) acute cardiotoxicity in TC 
patients, and to our knowledge, no studies report on early cardiotoxicity. Furthermore, it is not 
established which parameters are useful in the early assessment of cardiac damage. 
In addition to obtaining insight in the extent and timing of cardiac complications of 
chemotherapeutic treatment for TC, evaluation of parameters for early (sub-clinical) cardiac 
dysfunction may enable identification of patients at risk for future cardiovascular events. 
Echocardiography is a convenient and frequently used method to assess cardiac function, 
enabling evaluation of both systolic and diastolic function parameters. Biochemical markers 
can also be used to evaluate cardiac status. N-Terminal pro-Brain Natriuretic Peptide (NT­
proBNP) is produced by ventricular cells in response to increased mechanical load and wall 
stretch. Plasma levels are used as a prognostic indicator in different stages and causes of 
cardiac disease.119 However, its role in detecting chemotherapy-induced cardiac morbidity has 
not been established yet.120•121 
In this prospective cohort study, we investigated echocardiographic and biochemical changes 
before and one year after start of cisplatin-containing chemotherapy for disseminated TC. 
PATIENTS AND METHODS 
Patients 
All consecutive patients with disseminated TC, scheduled to receive cisplatin-containing 
chemotherapy as first line therapy at the University Medical Centre Groningen, the 
Netherlands, between December 2000 and October 2004 were asked to participate in a study 
investigating chemotherapy-induced acute cardiovascular toxicity.a Exclusion criteria were 
extra-pulmonary visceral metastases, previous radiotherapy, pre-treatment history of cardiac 
disease, use of erythropoietin and an age older than 55 years at the start of chemotherapy. 
The study was approved by the local ethics committee and written informed consent was 
obtained from all participants. 
Following orchidectomy, all patients received three or four three-weekly courses of 
combination chemotherapy consisting of bleomycin (30 mg on days 2, 8 and 15), etoposide 
(100 mg/m2 on days 1 to 5 of each course) and cisplatin (20 mg/m2 on days 1 to 5 of each 
course). Patients were admitted to the hospital for hydration with 3 liters NaCL 0.9%/day 
during the first 6 days of each course. All patients received dexamethason and odansetron as 
standard anti-emetic therapy. 
Reference data were obtained from healthy male siblings of adult childhood cancer survivors, 
who had participated as control subjects in a cross-sectional study on late cardiovascular 
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sequelae of treatment for childhood cancer. Out of these healthy male siblings, a control group 
was selected with a comparable median age as the TC patients. Measurements in the controls 
were performed under similar circumstances and methods. 
Measurements 
Measurements were done within one week before start of chemotherapy and approximately 
one year after completion of treatment. 
Echocardiography 
Echocardiography was performed by a skilled technician at the same laboratory using 
conventional equipment (General Electrical VIVID 7 system, 2.5 MHz probe) and consisted of 
two-dimensional echocardiography, colour flow mapping and, since 2002, tissue velocity 
imaging.122 Left ventricular end-diastolic dimension (LVEDD, normal 36-54 mm), left ventricular 
end-systolic dimension (LVESD, normal 23-40 mm), posterior and septal wall thickness (normal 
7-11 mm) were measured on M-mode recordings obtained in the standard left ventricular 
parasternal long axis view. Parasternal, transverse and longitudinal dimensions of the left 
atrium were attained. 
For analysis of systolic function, the left ventricle was divided into 16 segments. Each segment 
was visually scored between 1 and 4 (1 = normokinesia, 2 = hypokinesia, 3 = akinesia, 4 = 
dyskinesia). The Wall Motion Score Index (WMSI) was the mean score for all analysed 
segments. A WMSI of 1.00 was considered normal. 
Diastolic function measurements included mitral valve inflow velocities in early (E) and late 
(atrial; A) diastole (E/A-ratio, normal > 1.00) and Tissue Velocity Imaging of early diastole (TVI 
Et). TVI Et was the mean of measurements at the septal, lateral, inferior and anterior mitral 
annulus (normal > 8.0 cm/s; decreases indicate deterioration of diastolic function). In addition 
E/E' was calculated from the peak E velocity and the mean TVI Et (normal <15; increases reflect 
declines in diastolic function; E/E' >15 is considered as diastolic dysfunction). E/E' is currently 
regarded as a sensitive method for assessing diastolic heart failure.123 
NT-pro BNP 
NT-proBNP (lower limit of detection 5.0 pmol/L; normal value < 14.75 pmol/L) was measured 
in plasma using an immunoassay (Roche Diagnostics, Mannheim, Germany), from samples that 
were drawn concomitant with the echocardiographic recordings. 
Cardiovascular ri sk f actors 
Cardiovascular risk factors were estimated before start of chemotherapy. 
Hypercholesterolemia was defined as a fasting level of cholesterol >6.5 mmol/L; diabetes 
mellitus as a fasting level of glucose > 7.0 mmol/L. Obesity as Body Mass Index (BMI) >27.8 
kg/m2 • Blood pressure was estimated as a single recording on one arm in supine position in a 
quiet room after a minimal rest period of 10 minutes. Furthermore, an ambulatory blood 
pressure (BP) device (Spacelab 90207; Spacelabs Inc., Redmond, WA, USA) was used to 
document BP every 30 minutes during a 24-hour period. The control subjects had a single 
blood pressure recording. The criteria for hypertension were defined as a mean 24-hour BP 




Statistical analyses were performed in SPSS inc. version 14. For comparisons the Chi-square 
test and the non-parametric Mann-Whitney test were used. To calculate changes within a 
patient the Wilcoxon's signed rank test was used on the paired samples, in those patients 
where both variables were available. Regressions were calculated with Spearman's correlation. 
Two-sided p-values �0.05 were considered to indicate significant differences. 
Post-hoc power analysis demonstrated that, with a power of 80% and a two-sided significance 
level {alpha) of p <0.05, a 3.3% change in TVI Et could be detected in 19 patients, with a 
correlation coefficient between two measurements under equal circumstances of � 0. 75 and 
variation-coefficient for TVI Et of 7.1%.124 
RESULTS 
Patients 
Between December 2000 and October 2004, 65 TC patients were enrolled in the study.8 In 54 
of these 65 patients an echocardiogram was performed before start of chemotherapy. Twelve 
out of 54 {22%) patients received no echocardiogram after completion of cisplatin-based 
chemotherapy, because of the following reasons: death {n=l), progressive disease {n=l) or 
logistic reasons {data not evaluable N=3; moved out of referral area n=l; not performed n=6). 
Therefore, 42 patients underwent an echocardiogram before and within one year after 
completion of cancer treatment. The baseline characteristics like age, disease status and 
echocardiographic parameters of the patients {n=12) who did not receive an echocardiogram 
after treatment were not different from the patients that completed two echocardiographic 
evaluations {data not shown). 
Baseline characteristics of the 42 patients with two echocardiographic evaluations are shown 
in Table 1. Of the 42 evaluable patients, 12 had pulmonary metastases, 1 underwent 
thoracotomy for resection of pulmonary lesions after completion of chemotherapy. The 
control group consisted of 42 healthy males, whose median age was 28 years {Table 2); none 
of them was known to have co-morbidity. 
Echocardiography 
Echocardiography pre-treatment 
Before start of treatment, one out of 33 patients had a WMSI >1.00 {3.0%). Four out of 41 
patients had abnormal wall motion {all local hypokinesia; 9.8%). Three out of 42 had valve 
dysfunction [pulmonal {n=2) and tricuspid valve insufficiency {n=l); 7.1%]. 
The E/ A-ratio was <1.00 in eight out of 42 patients {19.0%); one out of 22 assessed patients 
had a TVI Et <8.0 cm/s {4.5%). None of these 22 patients had an E/E' >15. Median values and 
ranges are summarised in Tables 2 and 3. 
Of the controls, one of 42 had had a WMSI >1.00. One out 42 had an E/A-ratio <1.00; one out 
of 42 had a TVI Et mean <8.00 cm/s. For median values and ranges, see Table 2. 
The median WMSI and TVI Et in patients and the controls was not different (p=0.259; p=0.713), 
whereas the median E/ A-ratio was higher in the controls (p<0.0001, Table 2). 
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Number of patients 
Age at start of treatment 
Median (range) 















3 or 4 x  BEPt 
2 x BEP, 1 x VIP* 
42 
27 (18-50) years 












Table 1. Characteristics of participating patients with testicular cancer. 
(*) Royal Marsden classification; (fl) According to the International Germ Cell Cancer Collaborative Group (IGCCCG); 
(t) BEP: Bleomycin, Etoposide, Cisplatin, the number of cycles was based on the prognostic classification; (*) VIP: 
Etoposide, /fosfamide, Cisplatin 
Patients Controls P-value• 
nt Median (range) n Median (range) 
Age 42 27 (18-50) 42 28 (18-42) 0.91 
Systolic blood pressure 30 133 (110-180) 42 115 (98-156) <0.0001 
Diastolic blood pressure 30 80 (50-130) 42 79 (6-96) 0.24 
Body Mass Index 30 24 (19-38) 42 25 (19-31) 0.66 
TV/ Et 22 12.0 (7-19) 42 12.4 (9-15) 0.71 
E/A ratio 42 1.38 (0.73-2.84) 42 1.69 {1.02-2.66) <0.0001 
WMS/ 33 1.00 (1.00-1.23) 42 1.00 (1.00) 0.26 
Table 2. Baseline characteristics and cardiac parameters of testicular cancer patients and healthy control subjects 
(*) Mann-Whitney test; (t) Number of patients in which the respective parameters were available 
Echocardiography post treatment 
Median 10 months after completion of treatment, four of 28 patients had a WMSI >1.00 
{14.3%). Seven out of 40 patients had wall motion abnormalities {17.5%, local and/or diffuse 
hypo- and akinesia). The E/ A-ratio was <1.00 in seven out of 41 patients (17 .1%); two out of 25 
assessed patients had a TVI Et <8 cm/s {8.0%). None of the 25 patients had an E/E' >15. 
Changes in echocardiography pre and post treatment 
Cardiac dimensions and the median WMSI did not change during the year after treatment 
{Table 3). The percentage of patients with wall motion abnormalities did not change {9.8 Vs 
17.5%; p=0.309), whereas the number of patients with a WMSI >1.00 increased (p=0.01). The 
seven patients with post-treatment wall motion abnormalities included the four patients with 
pre-treatment abnormalities; all of them had deterioration of wall motion abnormalities. Two 
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of them developed pulmonary embolisms during treatment.is Three patients newly developed 
wall motion abnormalities one year after treatment; one had had a myocardial infarction 
during chemotherapy. 
Paired observations of the TVI Et were available in 19 TC patients. The median TVI Et 
decreased significantly after treatment (p=0.002; Figure 1); the median E/ A-ratio did not 
change (see Table 3). In addition, the median E/E' increased (p=0.002; Table 3). 
Age correlated with pre-treatment E/ A-ratio (R=-0.50; p=0.001), but not with pre-treatment 
TVI Et (R=-0.27; p=0.219) or delta TVI Et (difference pre- and post treatment TVI Et; R=0.21; 
p=0.382). 
Before After P-value • 
nt Median ( Range) n Median ( Range) 
SYSTOLIC PARAMETERS 
WMS/ 33 1.00 (1.00-1.23) 28 1.00 (0.81-1.44) 0.273 
STRUCTURAL DIMENSIONS 
Septum (mm) 42 10 (6-12) 41 10 (7-14) 0.427 
Posterior wall (mm) 41 10 (8-12) 41 9 (7-11) 0.309 
LVEDD (mm) 42 so (41-57) 41 so (41-55) 0.861 
LVESD (mm) 41 32 (18-42) 41 32 (21-41) 0.741 
LA parasternal (mm) 42 35 (25-42) 41 35 (25-46) 0.198 
LA length (mm} 40 57 (44-69) 41 58 (46-69) 0.764 
LA transverse (mm) 24 38 (29-45) 31 39 (29-52) 0.267 
Heartbeat (bpm) 34 70 (48-105) 31 66 (48-105) 0.235 
Valve dysfunction (n} 42 3 (7.1%) 42 5 (11.9%) 0.457 
DIASTOLIC PARAMETERS 
Peak E velocity (emfs) 42 0.76 (0.58-1.06) 41 0.82 (0.58-1.31) 0.302 
Peak A velocity (emfs} 42 0.59 (0.31-0.99) 41 0.61 (0.35-1.38) 0.097 
£/A-ratio 42 1.38 (0.73-2.84) 41 1.35 (0.53-2.30) 0.259 
TV/ Et (emfs) * 22 12.0 (7-19) 25 10.0 (7-17) 0.002 
E/E' l 22 6.2 (3.8-12.4) 25 7.6 (4.1-13.1) 0.002 
BLOOD PRESSURE 11 
Systolic (mmHg) 42 129 (107-154) 38 123 (106-153) 0.011 
Diastolic (mmHg) 42 74 (58-99) 38 70 (54-106) 0.018 
Table 3. Echocardiographic parameters of testicular cancer patients at before and after chemotherapeutic 
treatment 
(*) Wilcoxon signed rank test; (t} Number of patients in which the respective parameters were available; (l) 19 
paired observations available; ('fl) 24 hour ambulatory blood pressure recordings 
NT pro-BNP 
The median level of NT-proBNP increased significantly [N=32; pre-treatment 5 pmol/L (range 
<5-242); post treatment 18 pmol/L (range <5-114); p=0.034, Figure 2]. One extreme pre-
treatment value (242 pmol/L) was in a patient with a TVI Et of 7 .0 cm/s pre-treatment. 
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Levels of NT-proBNP and delta NT-proBNP did not correlate with the echocardiographic 

























Figure 1. TVI Et in 19 patients pre- and post chemotherapy; open circles represent median values. Median TVI Et 
pre-treatment 12.0 cm/s (range 7-19), post treatment 10.0 emfs (range 7-17); p=0.002. 
Figure 2. Serum levels of NT-proBNP in 32 patients pre- and post treatment (normal S14.75 pmol/L); open circles 
represent median values. Median NT-proBNP pre-treatment 5 pmol/L (range <5-242); post treatment 18 pmol/L 
(range <5-114); p=0.034. 
Card iovascular r isk f actor s (CRF) 
Before treatment, CRF of the 42 patients consisted of obesity (n=G), smoking (n=14 current 
smokers; n=S former smokers) and hypercholesterolemia (n=l). The median BMI of the TC 
patients was 24.2 kg/m2 (see Table 2). Nine out of 42 patients (21%) had hypertension on 24-
hour ambulatory BP recordings; one of 42 patients was on antihypertensive medication (13-
blocker). None had diabetes mellitus. 
Seven out of 42 control subjects were obese; the median BMI was 25.0 kg/m2 (Table 2); which 
was not different from the TC patients (p=0.656). The systolic BP was significantly higher in the 
patients (p<0.0001); the diastolic BP was not different (p=0.237). 
One year post treatment, CRF consisted of obesity (n=B), smoking (current smokers n=ll) and 
hypercholesterolemia (n=3). Four out of 38 patients (11%) had hypertension on 24-hour BP 
recordings. 
Both systolic and diastolic BP decreased post treatment compared to baseline (see Table 3). 
The pre-treatment systolic blood pressure correlated with delta lVI (R=0.67, p=0.006) and the 
lVI Et at baseline (R=0.63, p=0.002). E/A-ratio and delta E/A-ratio did not correlate with both 
systolic and diastolic blood pressure. The E/A-ratio in TC patients pre-treatment correlated 
with the BMI pre-treatment (R=-0.49, p=0.001), which was also true for pre-treatment lVI Et 
and BMI (R=-0.50. p=0.019). The WMSI pre-treatment did not correlate with the BMI. 
Smokers had a lower E/A-ratio pre-treatment [E/A-ratio smokers 1.31 (range 0.74-2.42) Vs 
non-smokers 1.56 (0.87-2.41); p=0.039. The lVI Et as well as other echocardiographic 





Nuver et al described acute cardiovascular events in this patient group.a During treatment two 
patients had a myocardial infarction, three had pulmonary embolisms. Omission of patients 
with cardiovascular events from the analyses did not change the results significantly (data not 
shown). 
DISCUSSION 
In this group of testicular cancer patients we observed changes in TVI Et and E/E' within one 
year after cisplatin-based chemotherapy, representing a deterioration of diastolic cardiac 
function. Furthermore, serum levels of NT-proBNP increased. 
Several authors report changes in cardiovascular status within years to decades after 
chemotherapeutic treatment for TC,1•12-14 but little is known of early changes in cardiac 
function in these patients. Regarding treatment-related cardiotoxicity from various cancer 
treatments, it was recently postulated that diastolic cardiac function deteriorates prior to the 
development of systolic dysfunction. 51 In left ventricular dysfunction of various origins, a 
deterioration of diastolic function can be present in the absence of systolic impairment, 52 and 
sub-clinical diastolic dysfunction frequently precedes a drop in systolic parameters.125 
Echocardiography is a frequently used method for assessing cardiac function, which has the 
advantage that it enables a reliable estimation of diastolic function by means of more recently 
introduced parameters such as TVI Et and E/E'. Other diastolic parameters, like the E/ A-ratio, 
are largely dependent on preload conditions, 57'126 resulting in significant intra-individual 
variation. 
The TVI Et assesses the velocity of the myocardium at different angles from the mitral valve, 
instead of blood flow velocities, and is therefore independent of loading conditions, 57•127 
resulting in less intra-individual variation. This parameter is considered an important and 
reliable early predictor for the development cardiac dysfunction in other causes of cardiac 
disease.127 From several small studies in adult childhood cancer survivors it appeared to be a 
valuable parameter in defining diastolic (dys-) function.59•64•12a,iz9 E/E' is a derivative of TVI Et 
and the E velocity, thereby including the end-diastolic left ventricular filling pressure in 
addition to myocardial velocities. This parameter is currently regarded as a valuable non­
invasive method for diagnosing diastolic heart failure.123 Declines in diastolic cardiac function 
are reflected by increases in E/E' as well as decreases in TVI Et. 
The pre-treatment echocardiography parameters in our TC patient group corresponded with 
the same measurements in an age-matched group of healthy controls. In the patient group a 
correlation existed between age and pre-treatment E/ A-ratio, but not between age and TVr Et 
or delta TVI Et. This is relevant, as ageing is associated with a physiological decline in diastolic 
cardiac function.130 An age-dependent decrease in TVI Et has been demonstrated in healthy 
controls, but this has only been evaluated in cohorts with larger differences in age and with 
longer time-intervals.131 
Several cardiovascular risk factors can lead to declines in diastolic function, including 
hypertension and obesity.125 In this study, the pre-treatment systolic BP correlated with delta 
TVI Et. Contrarily, the BMI did not correlate with the changes in TVI Et. The significant decrease 
in systolic and diastolic BP on the 24 hour ambulatory recordings was also found in the larger 
study investigating chemotherapy-induced acute cardiovascular toxicity.a The causes for this 
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finding are not known, but may at least partly be attributed to a relatively high BP before start 
of treatment, which is confirmed by the finding of a higher systolic BP in the patients 
compared to the age-matched controls. This high BP might be due to stress before initiation of 
treatment. 
In this study we did not further investigate explanations for this cardiovascular toxicity. The 
main causes are thought to be related to direct damage to cardiomyocytes and/or the extra­
cellular matrix, as well as sub-clinical vascular injury that induces endothelial dysfunction. 
Furthermore, the presence of pre-treatment elevations in BP may have resulted in impaired 
relaxation of the left ventricle, thereby leading to diastolic function decline. Of note, the 
increase in serum NT-proBNP levels is in accordance with the picture of cardiac damage. 
It is unknown whether a deterioration of diastolic cardiac function during the first year after 
chemotherapy for TC will progress to clinically relevant cardiac disease. It can be hypothesised 
that the hearts of these relatively young patients can compensate for the chemotherapy­
induced damage. On the contrary, they are at increased risk of developing an unfavourable 
cardiovascular risk profile, 13'14'18'19 which can contribute to development of long-term cardiac 
failure. 
In conclusion, we observed significant changes in TVI Et and E/E' within one year after 
cisplatin-based treatment for TC, indicating a deterioration of diastolic cardiac function. The 
prognostic significance of this disturbed diastolic function after chemotherapy for future 
cardiovascular morbidity is not clear, but it might eventually lead to overt cardiac morbidity. 
Further longitudinal research in TC survivors is needed to obtain more insight in sub-clinical 
changes in cardiac function. 
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Longitudinal Changes in Cardiac Function 
SUMMARY 
Background 
Cross-sectional studies showed that treatment with cisplatin-based chemotherapy for 
testicular cancer is associated with an increased incidence of cardiac dysfunction. We 
investigated longitudinal progression of and contributing factors to cardiac dysfunction in 
testicular cancer survivors. 
Patients and methods 
Cardiac assessments were performed before, 10 months (range 7-15) and 6.9 years (range 4.9-
9.7) aft�r start of cisplatin-based chemotherapy, consisting of echocardiography [systolic 
function {Left Ventricular Ejection Fraction, LVEF), diastolic function {myocardial tissue 
velocities, TVI Et)] and plasma biomarkers [N-terminal Pro-Brain Natriuretic Peptide (NT­
proBNP), galectin-3]. 
Results 
In 37 patients [median age 34 years (range 24-51)] the incidence of abnormal TVI Et increased 
from 0% at baseline, 4.5% at 10 months, to 16.7% at 6.9 years post-chemotherapy (p=0.03). 
One patient developed LVEF <50%; no other systolic abnormalities occurred. Hypertension, 
obesity and age were associated with larger decreases in TVI Et. Changes in NT-proBNP and 
galectin-3 were not related to echocardiographic abnormalities. 
Conclusion 
In this longitudinal cohort study we observed a gradual decline in diastolic parameters after 
cisplatin-based chemotherapy for testicular cancer, whereas the rate of systolic dysfunction 
remains low. The association of larger declines in diastolic parameters with hypertension and 





The majority of patients with metastatic testicular cancer can be cured with cisplatin­
containing chemotherapy regimens. In the still growing population of testicular cancer 
survivors the occurrence of long-term treatment-related morbidity, like secondary 
malignancies and cardiovascular disease (CVD),7·12-14 is increasingly recognized.2'6 
Long-term testicular cancer survivors treated with chemotherapy have a higher prevalence of 
cardiac dysfunction compared to healthy age-matched controls and stage I testicular cancer 
patients, treated with orchidectomy only.13'36 In a cross-sectional study in 7-year 
chemotherapy-treated testicular cancer survivors, diastolic dysfunction was more prevalent 
than in controls. 36 
Early signs of cardiac damage were reported in testicular cancer patients after cisplatin-based 
chemotherapy. Within 10 months after start of treatment, cardiac diastolic function measured 
with tissue Doppler imaging deteriorated compared to baseline, without systolic 
dysfunction.132 However, so far it is unknown in what way these early declines in diastolic 
function progress to cardiac dysfunction over time, as data in this patient population have only 
been derived from cross-sectional studies. 
For anthracycline-related cardiomyopathy subclinical changes in diastolic function are 
considered to precede the development of systolic failure. 51 In the general population, 
diastolic abnormalities are associated with an increased rate of cardiovascular morbidity and 
mortality, including the development of systolic dysfunction.125'133 In addition to early 
echocardiographic changes, cardiospecific biomarkers in blood may point to (subclinical) 
dysfunction prior to clinically overt cardiac failure, and provide reveal mechanisms that 
contribute to this type of damage. Candidate markers include NT-proBNP,70 troponin,71 and 
galectin-3, a contemporary cardiac fibrosis marker.134 
Up to now, it is unknown if and in what way early chemotherapy-related declines in diastolic 
cardiac function progress over time. Therefore, we investigated longitudinal changes in cardiac 
function in a cohort of testicular cancer patients treated with cisplatin-based chemotherapy. 
Furthermore, we aimed to estimate which characteristics point to patients at increased risk for 
cardiac dysfunction in the long term. 
PATIENTS AND METHODS 
Patients 
All patients had been diagnosed with disseminated germ cell cancer. Following orchidectomy, 
four three-weekly courses of bleomycin (30 USP; days 2, 8, 15), etoposide (100 mg/m2; days 1-
5) and cisplatin (cisplatin 20 mg/m2; days 1-5) were given, the fourth course without 
bleomycin. They participated in a study evaluating early cardiovascular changes during 
cisplatin-based chemotherapy at the University Medical Center Groningen between 2000 and 
2004.8'132 All patients without signs of tumour activity during follow-up were sent a written 
invitation to undergo assessments at a routine follow-up visit to our outpatient clinic. Patients 
who needed second line or salvage chemotherapy, or who were diagnosed with other serious 
co-morbidities were not eligible. 
The local ethics committee approved the study, and written informed consent was obtained 
from all participants. 
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Measurements 
Echocardiography 
Transthoracic echocardiography was performed by a sonographer, using the VIVID-7 system 
(General Electric, Horton, Norway) and a 2.5 MHz probe. Assessments consisted of two­
dimensional echocardiography, colour flow mapping and tissue Doppler imaging.122 
Left ventricular ejection fraction (LVEF, normal >50%) was estimated by two independent 
experienced technicians, blinded for patient background and each other's estimation. The 
mean of both outcomes was taken into analysis. 
Diastolic function measurements included the following mitral valve inflow velocities: early (E) 
and late (atrial; A) diastole (E/A-ratio, normal > 1.00), Deceleration Time of the peak early flow 
(Dt), and lsovolemic Relaxation Time (IVRT). In addition, tissue velocity imaging of early 
diastole (TVI Et) with colour-coded tissue Doppler imaging was performed. TVI Et was the 
mean of septal and lateral TVI Et (normal >8.0 cm/s).123 Colour coded tissue Doppler imaging 
was done in all patients that were included after January 1st, 2002. Diastolic dysfunction was 
graded according to recommendations from the American Society of Echocardiography.123 
Cardiac biomarkers 
Blood samples were drawn concomitantly with the cardiac assessments. NT-proBNP (lower 
limit of detection 5.0 pg/ml) was measured in serum using an immunoassay (Roche 
Diagnostics, Mannheim, Germany). Galectin-3 was measured in EDTA plasma with an ELISA 
(BG Medicine, Inc., Waltham, Ma, USA) that measures human galectin-3-levels with high 
sensitivity (lower limit of detection 1.13 ng/ml), and without crossreactivity with collagens or 
other members of the galectin-family. 135 
Plasma levels of troponin I were measured during chemotherapy treatment (median 5.5 
times), as described earlier.8 Increases in this cardiomyocyte damage marker were used to 
explore whether acute increases in troponin I (>0.1 µg/L) were predictive for cardiac 
abnormalites post-chemotherapy. 
Cardiovascular risk factors 
Hypercholesterolemia was defined as a fasting cholesterol >6.5 mmol/L and/or use of 
cholesterol-lowering drugs; diabetes mellitus as a fasting glucose >7.0 mmol/L and/or use of 
glucose-lowering medication; obesity as Body Mass Index [BMI; calculated by 
weight(kg)/height(m)2] >27.8 kg/m2•136 Blood pressure (BP) was measured in supine position 
after a minimal rest period of 10 minutes. Hypertension was defined as BP systolic >150 mmHg 
and/or diastolic >95 mm Hg, and/or use of anti-hypertensive medication. For assessment of the 
metabolic syndrome the American Heart Association/National Heart, Lung and Blood Institute 
(AHA/NHLBI) classification was used.137 
Statistical analysis 
SPSS software package version 16.0 (SPSS Inc., Chicago, IL, USA) was used for statistical 
analyses. Non-normally distributed data are represented as median (range), comparisons 
between groups were tested using the Mann-Whitney U test or Kruskal-Wallis test. For intra­
individual changes the Wilcoxon's signed rank test was used. Univariate correlations were 
calculated with Spearman's correlation (r5) .  Univariate linear regression analysis was executed 
with change in TVI Et during follow-up as dependent variable. Systolic and diastolic blood 
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pressure, BMI and duration of follow-up were entered as independent variables into the 
model. Normality of the distribution was checked using normal probability plots of the 
residuals. In all analyses, two-sided p-values SO.OS were considered significant. 
RESULTS 
Patient characteristics 
A total of 65 patients were included in the initial study.8 In 54 patients baseline 
echocardiography assessments were available. In 37 of 54 patients cardiac follow-up 
investigations were performed at median 6.9 years (range 4.9-9.7) after start of chemotherapy 
(Figure 1). In 29 out of these 37 patients (78.4%) a second echocardiography was performed at 
a median of 10 months (range 7-15) after start of treatment, as reported previously.132 Patient­
and treatment related characteristics are presented in Table 1. Median age at the follow-up 
visit was 34 years (range 24-50). 
Study participation (N=54} 
Metastatic testicular cancer prior to cisplatin-
based chemotherapy 
June 2000 - December 2004 
Study complete (N=37} 
Median Interval 6.9 years (range 4.9-9. 7) 
August 2009 -June 2010 
Figure 1. Timing of study investigations and accrual 
Number of patients 
Age at start of treatment (years) 
Age at follow-up visit (years) 
Interval between assessments 
Baseline - 1st follow-up visit 
Baseline - 2nd follow-up visit 
Testicular cancer related characteristics 
Diagnosis 
I Study visit (N=29} 
I Median 10 months (rans• 6-15) after chemotherapy 
Study not comp�� /N•ll/ 
causes 
- Death [N•2; relapse, unknown (possible cardiac)) 
- Serious co-morbidity [N•2 (COPD, leukemia)] 
• Refuse to participate (N=S) 
- Could not be contacted (N=2) 




10 months (7-15) 
6.9 years (4.9-9.7) 
Non-seminoma 
Stage of disease * 
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Table 1 -continued 
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Table 1. Patient characteristics. Abbreviations: Bleomycin, Etoposide, Cisplatin (BEP; the number of cycles was 
based on the prognostic classification), Retriperitoneal Lymph Node Dissection (RPLND). 
(*) Royal Marsden classification; (t) According to International Germ Cell Cancer Collaborative Group (IGCCCG) 
Cardiovascular status a median of 6.9 years after chemotherapy 
Echocardiography findings 
At 6.9 years post-chemotherapy the median LVEF was 60% (range 38-65); one patient had an 
abnormal LVEF. All patients had normal diastolic function according to the American Society of 
Echocardiography criteria.123 17 Six patients (16.7%) had an abnormal TVI Et; six other patients 
(16.7%) had an abnormal E/A-ratio (Table 2). TVI Et correlated with E/A-ratio (rs= 0.62, 
p<0.0001), IVRT (rs= -0.34, p=0.008) and E/E' (rs= -0.56, p<0.0001). Besides one patient with 
previously diagnosed aortic valve regurgitation (Table 3), no other significant valvular disease 
was observed. 
BASELINE 10 MONTHS {Range 7-15) 6.9 YEARS (Range 4.9-9.7) 
N=37 N=29 N=37 
Median Ranae Abn(%) Median Range Abn (%) Median Ranse Abn (%) 
TV/ Et (cm/st 12.0 9.0-19.0 (0) 10.0• 7.0-17.0 (4.5) 10.s• 6.6-13.6 (16.7*) 
E/E' 6.7 3.2-11.1 (0) 7.3* 4.1-13.1 (0) 7.2 4.7-11.6 (0) 
E/A ratio 1.48 0.79-2.84 (21.6) 1.35 0.74-2.30 (13.8) 1.37 0.78-2.45 (16.7) 
Dt (msec) 181 143-302 198* 118-298 213* 136-282 
IVRT (msec) 76 58-111 88* 64-114 91*t 62-152 
Table 2. Echocardiographic parameters of diastolic function in testicular cancer patients before start of cisplatin­
based chemotherapy, median 10 months (range 7-15) and 6.9 years (range 4.9-9.7) after start of treatment. 
Abbreviations: Tissue Velocity Imaging of the early diastolic (TVI Et), ratio of early atrial blood flow velocity and TVI 
Et (E/E'), ratio of early and late atrial blood flow velocity (E/A-ratio), lsovolumetric Relaxation Time (IVRT), 
Deceleration time (Dt), abnormal (abn). 
(*) p <0.05 compared to baseline, Wilcoxon Signed Rank test; (t) p <0.05 compared to 10 months post­
chemotherapy, Wilcoxon Signed Rank test; (t) TV/ Et was measured from 2002 on; available for longitudinal 




The median serum NT-proBNP level was 13.0 pg/ml (range <5.0-66.0) at 6.9 years post­
chemotherapy. At the same time point, the median plasma level of galectin-3 was 11.6 ng/ml 
(range 6.6-18.7). NT-proBNP and galectin-3 did not correlate with echocardiography 
parameters (data not shown). 
Clin ical parameters and cardiovascular morbidity 
At follow-up, none of the patients experienced symptoms of cardiac dysfunction, except for a 
38-year old patient with dyspnoea on exertion (New York Heart Association class II). On 
echocardiography hypokinetic wall motion was seen, with LVEF of 38% and TVI Et of 7.7 cm/s. 
Upon these findings he was referred to a cardiologist. VOrmax revealed reduced exercise­
capacity, at 76% of the predicted value for age and gender. Anti-heart failure medication (J3-
blockade and ACE-inhibitor) was initiated. In this patient no other explanations for cardiac 
dysfunction apart from treatment with chemotherapy could be identified, in particular no 
signs of myocardial infarction. 
Four out of 37 patients (10.8%) developed a thrombo-embolic event during chemotherapy.132 
Echocardiography parameters, cardiac biomarkers and cardiovascular risk factors at 10 months 
and 6.9 years post-chemotherapy were not different in these patients versus patients without 
acute cardiovascular events. During follow-up, one patient developed a transient ischemic 
cerebral attack. Three other patients developed non-ischemic cardiovascular morbidity (Table 
3). One 35-year old patient died of a possible cardiac arrest one year after chemotherapy, 
although the cause of death was not confirmed by autopsy. 




Systolic LV 27 1 None Follow-up + n.a. LVEF 55% 
dysfunction by TVI Et 11.S cm/s 
cardiologist E/A-ratio 2.45 
Mild diffuse 
hypokinesia 
Aortic valve 43 4 Family Follow-up + 66.0 LVEF 60% 
insufficiency history by TVI Et 10.5 cm/s 
& stenosis cardiologist E/ A-ratio 1.30 
Peak gradient aortic 
valve 38 mm Hg 
Paroxysmal 27 6 Smoking Medication - 63.0 LVEF 60% 
atrial resistant; TVI Et 11.4 cm/s 
fibrillation pulmonary E/A-ratio 1.36 
vein 
isolation 
Systolic LV 38 7 None ACE-i and - 25.0 LVEF 38% 
dysfunction (FU P-blockade TVI Et 7.7 cm/s 
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Table 3 - continued 





















TVI Et 10.6 cm/s 
E/A-ratio 1.22 
Table 3. Characteristics of patients with (cardiovascular) morbidity after cisplatin-based chemotherapy for 
disseminated testicular cancer. Abbreviations; Cardiovascular Risk Factors (CRF), N-Terminal proBrain Natriuretic 
Peptide (NT-proBNP), Left Ventricular (LV), Atrial Fibrillation (AF), Cardiovascular Disease (CVD), Angiotensin 
Converting Enzyme inhibitor (ACE-i), not assessed (n.a.) (*) Rise in troponin I during cisplatin-based chemotherapy; 
(+) indicates a rise, (-) no change in troponin I levels; (t) Level of NT-proBNP at the follow-up visit median 6.9 years 
(range 4.9-9.7); (*) Time-point of diagnosis of cardiovascular morbidity 
Cardiovas cular ris k fa ctors 
At 6.9 years post-chemotherapy, six patients (16.2%) had hypertension (4 used 
antihypertensives, 2 had hypertension detected at the follow-up visit). Five patients had 
hypercholesterolemia (13.5%). Six patients (16.2%) were obese; the metabolic syndrome was 
present in seven patients (18.4%). Ten patients (27.0%) were active smokers. Other co­
morbidities were hypogonadism in two, diabetes mellitus type 2 in one, and hypothyroidism in 
one patient. 
At 6.9 years post-chemotherapy, TVI Et related to age (rs=-0.65, p<0.0001), diastolic BP (rs=-
0.35, p=0.038) and BMI (rs=-0.34, p=0.045). Hypertensive patients had a significantly lower TVI 
Et [hypertension: median 7.8 cm/s (range 7.2-10.6) vs. no hypertension: median 10.7 cm/s 
(range 6.6-13.6), p=0.016] and E/A-ratio [hypertension: median 1.06 (range 0.93-1.22) vs. no 
hypertension: median 1.44 (range 0.78-2.45), p=0.002]. Echocardiography parameters were 
not different between smokers and non-smokers, or between patients with and without the 
metabolic syndrome (data not shown). LVEF was not different in patients with or without 
cardiovascular risk factors (data not shown). 
L ongitudinal changes in cardiac s tatus 
Echocardiography 
Compared to baseline, median TVI Et at 10 months and at 6.9 years post-chemotherapy was 
significantly lower. TVI Et at 6.9 years post-chemotherapy was not different from the visit 10 
months post-chemotherapy (Figure 2, Table 2). Compared to baseline, the percentage of 
patients with a TVI Et <8.0 cm/s increased (Figure 2, Table 2); Dt and IVRT both also 
significantly increased over time. The median E/A-ratio did not change and median E/E' 
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Figure 2. Changes in TVI Et and prevalence of abnormal TVI Et (grey bars) as key parameter for diastolic function, at 
baseline, median 10 months (range 7-15) and median 6.9 years (range 4.9-9.7) after completion of cisplatin-based 
chemotherapy for metastatic testicular cancer. P-values are calculated with the Wilcoxon Signed Rank test, asterix 
indicates significant difference compared to baseline values (p=0.03). 
Cardiac biomarkers 
The median level of NT-proBNP did not change (Figure 3A). At baseline the median level of NT­
proBNP was <5 pg/ml (range <5-114.3), 8 pg/ml (range <5-74.4, p=0.20 compared to baseline) 
at 10 months post-chemotherapy, and 13 pg/ml (range <5-66, p=0.10 compared to baseline) 
at 6.9 years post-chemotherapy. 
Galectin-3 levels at baseline were not significantly different between IGCCCG prognosis groups 
[good prognosis: median 12.5 ng/ml (range 7.4-20.1; intermediate prognosis: median 13.4 
ng/ml (range 11.6-19.3); poor prognosis: median 15.4 ng/ml (N=l); p=0.79]. At baseline the 
median level of Galectin-3 was 12.7 ng/ml (range 7.4-20.1), 13.5 ng/ml (range 8.6-22.6, p=0.04 
compared to baseline) at 10 months after treatment, and 11.6 ng/ml (range 6.6-18.7, p=0.009 
compared to baseline) at 6.9 years post-chemotherapy. Galectin-3 levels were significantly 
lower at the 6.9 years post-chemotherapy, compared to the two previous assessments (Figure 
3B). 
A 









10 monthl (l'lftl•7•1S) &.9\'\latS (ran1•4.9-9,7) 
Figure 3. Cardiac biomarkers N-Terminal pro Brain Natriuretic Peptide (NT-proBNP, Figure 3A) and Galectin-3 
(Figure 3B), at baseline prior to start of cisplatin-based chemotherapy for metastatic testicular cancer, median 10 
months (range 6-15) post-chemotherapy and median 6.9 years (range 4.9-9.7) post-chemotherapy. P-values are 
calculated with the Wilcoxon Signed Rank test. 
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A ssoci ati on s  betw een ( chan ges in) echocardi ography, cardi ac bi omarkers an d cardi ovascular 
ri sk f actors 
Early changes in cardiac biomarkers vs. cardiac status at follow-up 
Levels of troponin I were measured during chemotherapy treatment in 31 out of 37 patients 
(83.8%). Seven of 31 patients (22.5%) had troponin >0.1 µg/L at one or more of sampling 
points. Three of five patients with cardiovascular morbidity during follow-up had had a rise in 
troponin I during chemotherapy (Table 3). Post-chemotherapy (changes in) echocardiography 
parameters, NT-proBNP and Galectin-3 were not different between patients with and without 
increases in troponin I during chemotherapy (data not shown). 
Abnormal systolic or diastolic parameters at follow-up were not associated with levels of, or 
rise in, NT-proBNP or Galectin-3 (data not shown). 
Blood pressure at 6.9 years post-chemotherapy vs. changes in diastolic cardiac status 
At 6.9 years post-chemotherapy, systolic BP (r5=-0.56, p=0.004), diastolic BP (r5=-0.49, p=0.014) 
and duration of follow-up (r5=-0.49, p=0.012) were related to larger declines in TVI Et (L\TVI Et) 
from baseline to the follow-up visit. Age was not related to L\TVI Et (r5=0.38, p=0.06). 
Correlations between L\TVI Et and systolic (r=-0.49, p=0.015) and diastolic BP (r=-0.47, p=0.021) 
at the visit 6.9 years post-chemotherapy persisted when a partial correlation controlling for 
follow-up duration was applied. 
Regression analysis in all patients showed that systolic BP (b= -0.15 (SE=0.04), p=0.001), 
diastolic BP (b= -0.21 (SE=0.07), p=0.003), BMI (b= -0.33 (SE=0.15), p=0.041) and follow-up 
duration (b= -2.24 (SE=0.95), p=0.027) were all independently associated with L\TVI Et at 6.9 
years post-chemotherapy. 
Echocardiography at baseline vs. cardiac status at follow-up 
No associations existed between echocardiography findings at the successive cardiac 
evaluations and (changes in) echocardiography parameters at previous assessments (data not 
shown). 
DISCUSSION 
This is the first study to perform prospective longitudinal cardiac follow-up in testicular cancer 
survivors treated with cisplatin-based chemotherapy. Compared to pre-chemotherapy, 
diastolic cardiac function measured with tissue Doppler imaging deteriorated during 10 
months and 6.9 years of follow-up. The observed declines in diastolic cardiac function were 
most pronounced in patients who developed cardiovascular risk factors like hypertension and 
obesity. At a median follow-up of 6.9 years after start of chemotherapy, the rate of systolic 
cardiac dysfunction was low, with 2.7% of the patients having a LVEF <50%. 
Different mechanisms may contribute to the observed subclinical declines in cardiac diastolic 
function. Firstly, chemotherapy may cause direct damage to cardiomyocytes, the extra-cellular 
matrix and coronary endothelium, resulting in impaired cardiac function. Several studies 
showed that cisplatin and bleomycin induce endothelial activation and apoptosis.24-27 Recent 
preclinical data suggest that cisplatin also damages cardiomyocytes in a direct way through 
mitochondrial damage and oxidative stress.138'139 Direct treatment-induced damage to the 
heart is also suggested by the observed increases in troponin I, a marker for cardiomyocyte 
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loss,71 in 23% of patients during chemotherapy. The initial decline in diastolic tissue velocities 
(TVI Et) and rise in NT-proBNP 10 months post-chemotherapy may also be attributed to direct 
chemotherapy-induced cardiotoxicity. Secondly, chemotherapy-treated testicular cancer 
survivors have a higher prevalence of cardiovascular risk factors compared to the general 
population and stage I testicular cancer patients.13'14'18'19 Cardiovascular risk factors like 
hypertension and obesity are associated with secondary cardiac (diastolic) dysfunction, 
because of increased pre- and afterload demands. In the current study, TVI Et at follow-up and 
�TVI Et were related to high blood pressure, supporting this possible mechanism. The finding 
that presence of hypertension and obesity is associated with a higher rate of diastolic 
dysfunction indicates that treatment of these risk factors may be effective to avoid further 
progression of diastolic dysfunction. In this study we used tissue Doppler imaging to 
characterize diastolic function. Several diastolic function parameters, e.g. E/ A-ratio and IVRT, 
are largely dependent on preload conditions, resulting in significant intra-individual variation 
and less reliable interpretation.57'126 TVI Et, currently regarded as one of the most sensitive 
diastolic function parameters, 123 is based on myocardial tissue velocities instead of blood flow. 
Therefore, interpretation of this parameter is less disturbed by hemodynamic conditions, 
making it a repeatable and solid estimation of cardiac status. 
A third mechanism for the decline in cardiac function is ageing, which is associated with a 
progressive decline in diastolic parameters.130 During ageing, physiological stiffening of the 
myocardium leads to delayed relaxation, and a more restrictive left ventricular filling pattern. 
An age-dependent decrease in TVI Et has been described in healthy controls and hypertensive 
subjects.131'140 In this longitudinal follow-up study we did not include a cohort of age matched 
healthy controls for direct comparison. In healthy controls a decrease in TVI Et of 1 cm/s per 
decade has been described.14° Comparing these data to the median �TVI Et in our patients, i.e. 
the median 2.0 cm/s decrease within 10 months post-chemotherapy, indicates that these 
patients have a larger diastolic function decline than can be expected in the general 
population. 
In the current study, one patient had an abnormal LVEF at 6.9 years post-chemotherapy, 
whereas one other patient had diffuse hypokinesia directly after completion of treatment. 
Furthermore, one patient died shortly after completion of treatment, possibly because of a 
cardiac arrest. In a previous cross-sectional study in 7-year testicular cancer survivors the rate 
of systolic dysfunction was low too.36 Collectively, these findings indicate that up to 7 years 
after cisplatin-based chemotherapy, screening for systolic dysfunction is not warranted. 
Galectin-3 is a contemporary marker for cardiac fibrosis that is involved in the progression of 
heart failure.134 Patients with disseminated malignancies have higher serum galectin-3-levels 
than healthy controls, caused by tumour-related cellular proliferation and migration.141 
Although we did not find a relation between galectin-3-levels and pre-chemotherapy 
metastatic burden, at baseline, galectin-3 may specifically relate to the metastatic malignancy. 
At 10 months post-chemotherapy, the levels may reflect treatment-induced cardiac fibrosis, as 
none of the patients had an active malignancy at that time-point. The lower galectin-3 levels at 
6.9 years post-chemotherapy implies that cardiomyocyte fibrosis is not likely to contribute to 
the development diastolic dysfunction in testicular cancer survivors. 
Subclinical changes in cardiac biomarkers or echocardiography parameters may precede late 
clinical dysfunction. When early changes are predictive for later abnormalities, such changes 
may be used to monitor patients more specifically. In this cohort we did not find associations 
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between early changes in cardiac biomarkers or echocardiography parameters and the 
development of cardiac abnormalities during follow-up. Explanations for the lack of predictive 
power between early, subclinical changes and later cardiac dysfunction may relate to the mild, 
subclinical cardiac abnormalities at the moment of follow-up. Furthermore, the small sample 
size results in low power to demonstrate such subtle differences, and the current follow-up 
duration is still relatively short, as events related to coronary artery disease manifest 15 years 
or more after chemotherapy. Furthermore, the hypothesis that different phenomena 
contribute to the development of declines in cardiac function, e.g. direct chemotherapy­
induced damage as well as secondary changes related to cardiovascular risk factors, implies 
that changes in cardiac function do not necessarily develop in a linear manner. 
In conclusion, diastolic cardiac function progressively deteriorates in testicular cancer survivors 
treated with cisplatin-based chemotherapy. Prolonged follow-up in this cohort is needed to 
estimate the predictive value and clinical implications of this diastolic cardiac dysfunction. The 
association between (changes in) diastolic function parameters with cardiovascular risk factors 
stresses the need to monitor and treat these risk factors, in order to minimize the 
development of late morbidity in successfully treated testicular cancer survivors. 
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Raynaud's Phenomenon as Marker for Atherosclerosis 
ABSTRACT 
Background 
Cross-sectional studies have demonstrated that cisplatin-based chemotherapy for testicular 
cancer is associated with an increased risk for cardiovascular disease. Longitudinal changes in 
subclinical parameters for atherosclerosis can reveal mechanisms and biomarkers for late 
cardiovascular disease. 
Methods 
Fifty testicular cancer patients underwent vascular evaluations before, median 11 months (8-
15) and 6.5 years {3.2-10.1) after bleomycin etoposide cisplatin (BEP) chemotherapy. 
Cardiovascular morbidity and risk factors, plasma biomarkers for endothelial activation, 
inflammation and pro-thrombotic state, and carotid lntima Media Thickness { IMT) were 
determined. 
Results 
During follow-up, the rate of clinical cardiovascular morbidity was low (2%); 28% developed 
secondary Raynaud's phenomenon. At 6.5 years post chemotherapy, diastolic blood pressure, 
endothelial activation markers and carotid IMT increased compared to 11 months. At 6.5 
years, median IMT in survivors equalled healthy males, although the age-related IMT 
progression was higher. Changes in IMT after BEP chemotherapy were associated with 
increases in serum lipids. Changes in plasma biomarkers were not related to clinical morbidity 
or changes in IMT. Presence of Raynaud's phenomenon was related to a higher carotid IMT 
during follow-up, and a higher age-related I MT-increase. 
Conclusion 
During 6.5-year follow-up after BEP chemotherapy, we observed an increase in subclinical 
signs of atherosclerosis in testicular cancer survivors. The age-related IMT progression was 
accelerated when compared to healthy males. The relation between IMT and Raynaud's 
phenomenon suggests that this phenomenon can serve as a clinical biomarker to identify 




In the growing population of testicular cancer survivors, late treatment-related complications 
such as cardiovascular disease (CVD)7·12-14 cause morbidity and impaired quality of life.2'6 In 
long-term Dutch testicular cancer survivors an estimated 20-year risk of 18% for CVD was 
reported, with a 2-fold increased risk for myocardial infarction in non-seminomatous testicular 
cancer survivors with an attained age below 55 years.142 In Norwegian long-term testicular 
cancer survivors, treatment with cisplatin-bleomycin-etoposide (SEP) chemotherapy was 
associated with a 5.9 times higher risk for myocardial infarction, compared to stage I 
chemotherapy-naive patients.16 
Chemotherapy-related endothelial damage contributes to the development of CVD in 
testicular cancer survivors.22-21 Subclinical signs of atherosclerosis can be found in these 
survivors prior to the manifestation of overt CVD.20•21 Identification of patients with subclinical 
atherosclerosis at increased risk for cardiovascular complications will be critical to select those 
who may benefit from interventions that slow or stop the progression towards overt CVD. 
Examples of subclinical atherosclerosis markers include structural aspects of vascular status, 
such as carotid Inti ma Media Thickness (IMT), 143 and plasma biomarkers for endothelial 
activation and systemic inflammation. Two cross-sectional studies in 7 year testicular cancer 
survivors treated with chemotherapy found no difference in median carotid IMT compared to 
healthy subjects and stage I testicular cancer survivors. 20•21 However, a prospective study 
showed an increase in carotid IMT of 0.02 mm and elevated levels of von Willebrand Factor 
(vWF) within 10 weeks after completion of SEP chemotherapy for testicular cancer.8 
This higher IMT progression rate indicates accelerated atherosclerosis. In the general 
population, ageing is associated with an increase in carotid IMT over time.118'144'145 Large 
increases have been related to an elevated risk for coronary events, and changes in IMT serve 
as intermediate endpoints for atherosclerosis pro- or regression in intervention studies.115-117 
This is the first longitudinal follow-up study on subclinical changes in cardiovascular status in 
testicular cancer survivors treated with SEP-chemotherapy. In this study we aim to evaluate 
changes in clinical morbidity, cardiovascular risk factors and plasma vascular biomarkers over 
time. Changes in these parameters are related to changes in carotid IMT, a structural 
biomarker for atherosclerosis, to identify mechanisms that contribute to atherosclerosis as 
well as markers that can be used to identify patients at increased risk for CVD. 
PATIENTS AND METHODS 
Patients 
All patients had been diagnosed with disseminated germ cell cancer. They had received four 
SEP courses lasting 3 weeks each (bleomycin [30 USP, days 2, 8 and 15]; etoposide [100 
mg/m2, days 1-5]; cisplatin [20 mg/m2, days 1-5], the fourth course without bleomycin). From 
2005 on, all patients in the International Germ Cell Cancer Collaborative Group (IGCCCG) good 
prognosis group received three SEP-courses. They participated in a study evaluating early 
cardiovascular changes during SEP chemotherapy at the University Medical Center Groningen 
between 2000 and 2007. 8'132 All patients without signs of tumor activity during follow-up, were 
sent a written invitation to undergo assessments at a routine follow-up visit to our outpatient 
clinic. Patients who needed second line or salvage chemotherapy, or who were diagnosed with 
other serious co-morbidities were not eligible. 
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The local ethics committee approved the study, and written informed consent was obtained 
from all participants. 
From a previous cross-sectional study in 7-year testicular cancer survivors, 21 data on 
cardiovascular risk factors and vascular status in a random selection of healthy age-matched 
males (n = 45) were used for comparison. 
Study related investigations 
Study related investigations were done at baseline and 1 year after initiation of chemotherapy. 
All participants had their follow-up visit between June 2009 and August 2010. Study 
assessments consisted of a standardized medical history, physical examination, fasting blood 
sampling and measurements of vascular status. 
Clin ical morbidity 
All patients were asked for cardiovascular morbidity, including presence or absence of 
Raynaud's phenomenon. Development of Raynaud's phenomenon secondary to BEP 
chemotherapy was defined as occurrence of peripheral discomfort and at least biphasic skin 
color change in fingers or hands (or toes or feet) after cold exposition, since start of treatment. 
Cardiovascular risk factors 
Hypercholesterolemia was defined as fasting cholesterol � 6.5 mmol/L and/or use of 
cholesterol-lowering drugs; diabetes mellitus as a fasting glucose � 7.0 mmol/L and/or use of 
glucose-lowering medication; obesity as Body Mass Index [BMI; calculated by weight 
(kg)/height (m)2] � 27.8 kg/m2• Blood pressure (BP) was estimated as single recording in supine 
position after a minimal rest period of 10 minutes. Hypertension was defined as BP systolic � 
150 mmHg and/or diastolic � 95 mm Hg, and/or use of anti-hypertensive medication. 
Total cholesterol, High Density Lipoprotein (HDL) and Low Density Lipoprotein (LDL) 
cholesterol, triglycerides, glucose (all in plasma) and insulin (plasma) were assessed as 
described elsewhere.19 HOMA-IR index (Homeostatic Model Assessment for Insulin Resistance 
= fasting insulin (mU/L) x fasting glucose (mmol/L)/22.5) was calculated as measure for insulin 
resistance. 
Plasma biomarkers for endothelial activation1 pro-thrombotic state and inflammation 
vWF antigen (reference values 50-150%) was measured in citrate plasma, as described 
earlier.21 The soluble adhesion molecules Vascular and Intra-Cellular Adhesion Molecule-1 
(sVCAM-1, slCAM-1) were assessed in EDTA-plasma (Fluorkine MAP• Human Adhesion 
Molecule Base Kit, R&D Systems Europe Ltd., Abingdon, UK). Plasminogen activator inhibitor 
type 1 (PAl-1) and tissue-type plasminogen activator (tPA) were measured in citrate plasma by 
ELISA.18 PAl-1/tPA-ratio was calculated as measure for pro-thrombotic activity. The 
inflammatory marker high-sensitivity C-reactive protein (hsCRP, reference values < 3.0 mg/L) 
was assessed in EDTA plasma by nephelometric assay.21 
Vascular structure: carotid /MT 
As parameter for vascular structure, IMT of the right common carotid artery was measured. 
From three repetitive measurements a mean IMT was calculated, as described previously.21 
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Statistical analy sis 
Changes in all study parameters were analyzed from the visit one year after initiation of 
chemotherapy up to the last follow-up visit. The one-year time point was used as a moment of 
vascular steady state, because the metastatic malignancy and acute chemotherapy-related 
effects influence hemodynamic and metabolic conditions initially. 
SPSS software package version 16.0 (SPSS Inc., Chicago, IL) was used for statistical analyses. 
Non-normally distributed data were represented as median (range), comparisons between 
groups were tested using the Mann-Whitney U test or Kruskal-Wallis test. For changes within 
groups the Wilcoxon's signed rank test was used. Univariate correlations were calculated with 
Spearman's correlation. Univariate linear regression analysis was executed with IMT at 6.5 
years post-chemotherapy as dependent variable. Variables that were significantly correlated 
with IMT in univariate analyses were entered as independent variables in a multiple linear 
regression model. Ageing is associated with a significant increase in IMT118'144'145 Therefore, to 
test for an interaction of ageing on the IMT between different groups (i.e. absence or presence 
of Raynaud's phenomenon, and between patients and controls), a variable for interaction was 
computed as age*presence/absence of Raynaud's phenomenon, and age*patient/control. 
Normality of the distribution was checked using normal probability plots of the residuals. P­
values s 0.05 were considered to be significant (tested 2-sided). 
RESULTS 
P atient char acter istics 
In total 78 patients were included in the initial study, of which 50 patients underwent 
complete study assessments at median 6.5 years (range 3.2-10.1) after chemotherapy (Fig 1). 
Study related investigations were performed in 46 out of 50 patients (92%) at a median of 11 
months (range 8-15) after initiation of chemotherapy. The median interval between the two 
follow-up visits was 5 .5 years (range 2.2-8.9). 
Table 1 summarizes patient and testicular cancer-related characteristics. All patients were 
initially diagnosed with disseminated testicular cancer. Of all patients, 44 {88%) were treated 
with four courses of BEP chemotherapy. 
Study participation (n=78) 
Metastatic testia.Jlar ancer prior to dsplatln-bued chemotherapy 
Medlan aae27.6yrs {ronge18.1-44.21 
June 2000-April 2006 
Study complete (n=SO) 
Study visit (nz.46) 
U months (range 8-15) aftermrt of chemotherapy 
Study not comp/,ted (n•2B/ 
Death (n-S. 3 relapse, 1 possible cardiac, 1 traffic acddent) 
Relapse (n•ll 
Serious co-mOf'bkfity (n•2, COPO, leukemia) 
MOW!outofreferralarea (n•2) 
Wlt:hdrawal from regular follow-up (n•l) 
Refuse topartldpate (n•3J 
1.cRlstlc(n•6) 
Incomplete assessment {n•BJ 
Follow-up medlin 6.5 yrs (range 3.2•10.1) after start of chemotherapy 
Median aa• 34.5 (ronge 22.1•50.6) 
June 2009-June 2010 
Figure 1. Patient accrual and timing of study-related investigations. 
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No of patients 
Age at start of chemotherapy treatment 
Age at follow-up visit 
Interval between assessments 
Baseline - 1st follow-up visit months 
Baseline - 2nd follow-up visit 
Testicular cancer related characteristics 
Diagnosis 










3 BEP * 
4 BEP *§ 
Surgery post-chemotherapy 
Resection of residual 
masses 




11 months (8-15) 













(*) Royal Marsden classification; (t) According to the International Germ Cell Cancer Collaborative Group (IGCCCG}; 
(:t) BEP; Bleomycin, Etoposide, Cisplatin; (§) In IGCCCG good prognosis: fourth BEP-course without bleomycin 
L ongitudinal changes in cardiovascular parameters aft er BEP chemotherapy 
Cardiovascular morbidity 
During chemotherapy, five out of 50 patients {10%) developed a thrombo-embolic event and 
one {2%) an arterial event, as reported previously.21 One patient acutely died of a likely cardiac 
cause 1 year post-chemotherapy; no autopsy was performed. 
During follow-up, one patient {2%) experienced an atherosclerotic vascular event {transient 
ischemic attack) for which he received medical treatment with a platelet aggregation inhibitor, 
ACE inhibitor and a statin. Four patients {8%) developed non-ischemic cardiac morbidity. Two 
had left ventricular dysfunction; in both patients no other explanations for cardiac dysfunction 
apart from treatment with chemotherapy could be identified, in particular no signs of 
myocardial infarction. Furthermore, one patient had aortic valve insufficiency and one had 
paroxysmal atrial fibrillation. All were in regular follow-up by a cardiologist. 
Fourteen patients {28%) reported having Raynaud's phenomenon since treatment with BEP­
chemothera py. 
Cardiovascular risk factors 
At 6.5 years post chemotherapy, median diastolic BP was significantly higher than 11 months 
post chemotherapy, whereas systolic BP did not change {Table 2). Thirteen patients {26%) had 
hypertension at 6.5 years post chemotherapy; 10 {20%) newly developed hypertension after 
chemotherapy. During follow-up the median BMI did not change. Seven patients were obese 
{14%), of which three {6%) developed obesity after chemotherapy. Median plasma glucose 
levels increased. One patient {2%) had been diagnosed with type 2 diabetes mellitus after 
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chemotherapy, for which he received oral glucose-lowering medication. Median levels of total 
cholesterol did not change. Dyslipidemia was present in six out of 48 patients (12.5%); all 
newly developed dyslipidemia after chemotherapy. Sixteen patients (32%) were active 
smokers; all had been smoking prior to start of treatment. 
Plasma vascular biomarkers for endothelial activation� pro-thrombotic state and inflammation 
Median levels of slCAM-1 and sVCAM-1 were higher at 6.5 years compared to 11 months post 
chemotherapy (Table 2). The PAl-1/tPA ratio was lower at 6.5 years post chemotherapy, 
indicating a less pro-thrombotic state. Median plasma levels of vWF and hsCRP did not change. 
Vascular structure: /MT 
The median IMT was significantly higher at 6.5 years post chemotherapy [0.59 mm (range 
0.44-0.94)] than at 11 months post-chemotherapy [median 0.53 mm (range 0.41-0.90), P < 
0.001] and at baseline [median 0.54 mm (range 0.40-0.96), P = .004]. The median annual 
change in IMT (AIMT) from 11 months to 6.5 years post chemotherapy was 0.007 mm/year 
(range -0.044 - 0.059). 
I 11 months (range 8-15) 6.5 years (range 3.2-10.1) Median Range Median Range 
CARDIOVASCULAR RISKFACTORS 
BMl (kg/m2) 25.3 18.9-38.0 25.5 20.2-41.7 
Systolic BP (mmHg) 125 100-170 124 100-180 
Diastolic BP (mmHg) 74 60-100 so• 60-105 
Glucose 4.7 2.6-5.8 5.5* 3.6-7.4 
HOMA-JR 2.4 0.1-9.5 2.2 0.1-10.3 
Total cholesterol (mmof/L) 4.7 3.2-7.8 4.8 3.4-7.3 
PLASMA VASCULAR BIOMARKERS 
s/CAM-1 (ng/ml} 373 159-727 423* 260 
sVCAM-1 (ng/ml) 795 312-1165 895* 591 
vWF (%) 87 52-237 99 37-204 
PAl/tPA ratio 3.2 1.2-14.0 2.6* 0.8-6.7 
hsCRP (mg/L) 0.7 0.2-8.9 0.8 0.2-4.7 
Table 2. Median levels of cardiovascular risk factors and plasma vascular biomarkers in testicular cancer patients 11 
months and 6.5 years after treatment with cisplatin-based chemotherapy. Abbreviations: body mass index (BMI); 
blood pressure (BP); soluble inter cellular adhesion molecule (slCAM-1); soluble vascular cellular adhesion molecule 
(sVCAM-1); von Willebrand Factor (vWF); plasminogen activator inhibitor type 1 (PAl-1); tissue-type plasminogen 
activator (tPA); high-sensitivity C-reactive protein (hsCRP). (*) P-value <0.05, Wilcoxon signed rank test 
Characteristics associated w ith IMT at 6.5 y ears post-chemotherapy and annual AIMT 
/MT and 11/MT: associations with clin ical parameters 
In patients with cardiovascular morbidity during and/or after chemotherapy completion, no 
differences existed in IMT or in AIMT, compared to patients without cardiovascular morbidity 
(data not shown). 
Patients with Raynaud's phenomenon (n = 14) had a higher IMT at 11 months post 
chemotherapy, whereas IMT at baseline and 6.5 years post chemotherapy was not significantly 
higher (Fig 2A). Regression analysis in patients with presence or absence Raynaud's 
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phenomenon showed that age was independently associated with IMT in both groups 
[Raynaud: b = 0.12 (SE = 0.004), P = .009; no Raynaud: b = 0.006 (SE = 0.002), P = .002; Fig 2B], 
with a higher age-related increase in IMT in patients with Raynaud's phenomenon. No 
differences were found in age, cardiovascular risk factors, (changes in) plasma vascular 
biomarkers or l\lMT from 11 months to 6.5 years post chemotherapy between patients with 
presence or absence of Raynaud's phenomenon (data not shown). 
In a multiple linear regression model with IMT as dependent variable, age was independently 
associated with IMT [b = 0.008 (SE = 0.002), P < .0001], whereas presence or absence of 
Raynaud's phenomenon was not [b = 0.05 (SE = 0.028), P = .08]. Introduction of a variable for 
the interaction between age and presence/absence of Raynaud's phenomenon revealed a 
median differential age-related !MT-increase of 0.005 mm in patients with Raynaud's 
phenomenon, which was not significantly different from patients without this symptom [b = 





























Figure 2A. Fourteen patients (28%) developed Raynaud's phenomenon after treatment with BEP-chemotherapy. 
Carotid lntima Media Thickness (IMT) is significantly higher at 11 months post-chemotherapy, whereas this 
difference is not significant at baseline or 6.5 years post-chemotherapy. Dots indicate median values, lines the inter­
quartile range; P-values are calculated with Mann-Whitney test. 
Figure ZB. Relations between IMT at median 6.5 post-chemotherapy and age in patients with presence or absence 
of Raynaud's phenomenon secondary to BEP-chemotherapy. 
/MT and Ll/MT: association with cardiovascular risk factors 
At both post chemotherapy visits, IMT was correlated with age (11 months: rs = 0.46; 6.5 years: 
rs = 0.52; both P < .01) and total cholesterol (11 months: rs = 0.35; 6.5 years: rs = 0.29; both P < 
.05). At 6.5 years post chemotherapy, IMT was correlated with BMI and lipid levels, but not 
with BP (Table 3). Patients with a high IMT (highest quartile, i.e. > 0.67 mm) at 6.5 years post­
chemotherapy had higher lipid levels at the two post chemotherapy visits (Fig 3). In regression 
analysis in all patients, age [b = 0.009 (SE = 0.002), P < .0001] and total cholesterol [b = 0.031 
(SE = 0.015), P = .045] were independently associated with IMT at 6.5 years post 
chemotherapy. 
l\lMT from 11 months to 6.5 years post-chemotherapy was inversely associated with follow-up 
duration (rs = -0.32, P = .04), but not with age (rs = -0.04, P = .79). l\lMT was significantly 
correlated with changes in triglycerides, LDL- and HDL-cholesterol from 11 months to 6.5 years 
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post-chemotherapy, but not with changes in BMI and BP (Table 4). Presence of cardiovascular 
risk factors was not associated with differences in �IMT (data not shown). 
Testicular cancer survivors Healthy males 
Rs with IMT P-value Rs with IMT P-value 
Age 0.52 <0.0001 0.47 0.001 
BMl (kg/m2) 0.28 0.05 0.35 0.02 
Systolic BP (mmHg) 0.21 NS 0.04 NS 
Diastolic BP (mmHg) 0.15 NS 0.29 NS 
Total cholesterol (mmol/L) 0.29 0.04 0.19 NS 
HDL-cholesterol (mmoVL) -0.17 NS 0.16 NS 
LDL-cholesterol (mmoVL) 0.33 0.03 0.11 NS 
Triglycerides (mmol/L) 0.33 0.02 -0.05 NS 
Table 3. Univariate Spearman correlation coefficients between carotid IMT and determinants for IMT in testicular 
cancer survivors 6.5 years post-chemotherapy (n=50) and in healthy age-matched males (n=45). Abbreviations: 
Body Mass Index (BMI); Blood Pressure (BP); High Density Lipoprotein (HDL); Low Density Lipoprotein (LDL); Not 
Significant (NS; P-value >0.05) 
Median change (range) ffs with 41MT P-value 
LI BM/ (kg/mz) 0.26 (-7.9-6.3) 0.27 0.09 
LI Systolic BP (mmHg) 0.0 (-45-65) 0.05 0.75 
LI Diastolic BP (mmHg) 3 (-25-31) -0.14 0.40 
LI Total cholesterol (mmol/L) 0.2 (-3.7-1.4) 0.46 0.002 
LI HDL-cho/esterol (mmol/L) 0 (-0.8-0.7) -0.40 0.02 
LI LDL-cholesterol (mmol/L) 0.4 (-2.2-1.1) 0.40 0.018 
LI Triglycerides (mmoVL) 0.1 (-2.4-1.6) -0.12 0.44 
Table 4. Univariate Spearman correlation coefficients between change in carotid lntima Media Thickness (l11MT) in 
testicular cancer survivors from 11 months to 6.5 years post-chemotherapy, and changes in determinants of IMT 
over the same period. Abbreviations: Body Mass Index (BMI); Blood Pressure (BP); High Density Lipoprotein (HDL); 
Low Density Lipoprotein (LDL) 
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Figure 3. Patients with a high IMT (highest quartile, i.e. >0.67 mm) at 6.5 years post-chemotherapy have a more 
unfavorable lipid profile at the two post-chemotherapy visits. Bars indicate median concentrations; asterixes 
indicate significance (P <0.05, Mann-Whitney U test). 
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/MT and f)./MT: associations with plasma vascular biomarkers 
Absolute levels of, or changes in, none of plasma vascular biomarkers for endothelial 
activation, pro-thrombotic state and inflammation were associated with �IMT or the IMT at 
6.5 years post-chemotherapy (data not shown). 
Cross-sectional comparison between IMT in 6.5-year testicular cancer survivors vs. healthy 
males 
At 6.5 years post chemotherapy, testicular cancer survivors had a median IMT that was 
comparable to healthy age matched males [testicu lar cancer: median 0.59 mm (range 0.44-
0.94); controls: median 0.59 mm (range 0.38-0.97); P = .93] .  In healthy males, IMT was 
correlated with age and BMI, but not with l ipids or BP (Table 3). 
Linear regression analysis showed that age was independently associated with IMT in both 
testicu lar cancer survivors [b = 0.09 (SE = 0.02), P < .0001] and healthy males [b = 0.06 (SE = 
0.02), P = .003], with a steeper slope for survivors (Fig 4). In a multiple linear regression model 
with IMT as dependent variable, age [b = 0.007 (SE = 0.001), P < .0001], but not the patient 
group was significantly associated with IMT [b = 0.015 (SE = 0.019), P = .45] . Next, a variable for 
the interaction between age and patient/controls was introduced in this model with IMT at 6.5 
years post chemotherapy as dependent variable. This revealed a median differential IMT 
increase of 0.003 mm/year in patients compared to controls, which was not significantly 
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Figure 4. Relations between IMT and age in 6.5-year testicular cancer survivors and in healthy age-matched males. 
DISCUSSION 
We observed an increase in subclinical signs for atherosclerosis over 6.5 years of follow-up 
after BEP chemotherapy for testicu lar cancer. Compared to healthy ma les, these survivors 
have signs of accelerated atherosclerosis, with a higher age-related increase in IMT. In patients 
who developed Raynaud's phenomenon after BEP chemotherapy, carotid IMT and the age­
related increase in IMT were higher compared to patients without these complaints. This 
relation suggests that presence of th is symptom can serve as a clinical biomarker that is 
associated with accelerated atherosclerosis. 
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So far, data on the incidence of subclinical atherosclerosis in testicular cancer survivors has 
only been derived from cross-sectional studies. A previous study reported early changes in 
vascular parameters, i.e. increase in IMT and levels of vWF,8 suggesting that these patients 
have accelerated atherosclerosis progression already shortly after SEP chemotherapy. 
Carotid IMT is a marker of the systemic atherosclerotic burden that is associated with 
established cardiovascular risk factors, and an independent predictor for CVD endpoints in the 
general population.143 Changes in IMT serve as intermediate endpoint for atherosclerosis pro­
or regression in intervention studies•115-117 and large increases in IMT over time are related to 
an elevated risk for coronary events.115 Physiological increases in IMT occur in each person 
during ageing, whereas an enhanced progression rate reflects accelerated atherosclerosis.27 
Overall, the median IMT at 6.5 years post chemotherapy was not different in testicular cancer 
survivors compared to healthy age-matched males. This finding is in line with data from two 
cross-sectional studies in 7 year chemotherapy-treated testicular cancer survivors.20•21 
However, we found a higher age-related increase in median IMT in testicular cancer survivors 
compared to healthy males. This effect was not significant, most likely due to the small sample 
size. However, this finding is of importance, as a higher age-related increase in IMT was shown 
to be a sign for accelerated atherosclerosis in patients with familial hypercholesterolemia146 
and systemic lupus erytomatosus.147 
Because of this accelerated atherosclerosis, interventions that slow this progression may be 
indicated and should be investigated. A potentially useful target to slow down further 
progression of atherosclerosis may be treatment with statins, as the annual IMT progression 
rate in our cohort was related to changes in serum lipids. This rationale is strengthened by the 
observation that patients with a high IMT at 6.5 years post-chemotherapy had a more 
unfavorable serum lipid profile already at 11 months post treatment. In a large population 
based cohort independent associations between �IMT and changes in LDL-cholesterol and 
triglycerides have also been reported, 144 confirming that changes in lipid levels are associated 
with progression of subclinical atherosclerosis. 
Raynaud's phenomenon is characterized by episodic vasospasm of the fingers and/or toes, 
typically precipitated by exposure to cold.148 Already in the early 1980's, shortly after 
introduction of bleomycin- and cisplatin-based regimens for testicular cancer, the occurrence 
of secondary Raynaud's phenomenon was reported.10'149 The incidence of 28% in our patients 
is in line with data from large cohorts, where 20-40% of testicular cancer survivors have 
Raynaud's phenomenon.10•150•151 We scored Raynaud's phenomenon with a standardized 
history form for clinical symptoms, comparable to other studies.150•151 This way all clinically 
relevant cases were detected. Additional investigation with cooling plethysmography or nail 
fold capillary microscopy would be of interest for future studies, to more precisely objectify 
these complaints and characterize possible associated structural micro vascular abnormalities. 
Interestingly we found that patients with Raynaud's phenomenon had a higher carotid IMT 11 
months post chemotherapy compared to patients without these complaints, whereas IMT 6.5 
years post chemotherapy was not significantly higher. At this last follow-up visit, the median 
age-related IMT increase in patients with presence of Raynaud's phenomenon was higher, 
although the effect of this interaction was not statistically different. Nevertheless, these 
associations suggest that presence of Raynaud's phenomenon in our cohort is associated with 
objective signs for enhanced atherosclerosis. A study in patients with primary and secondary 
(due to scleroderma) forms of Raynaud's phenomenon found that carotid artery features were 
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only different in case of secondary Raynaud's phenomenon.152 The development of Raynaud's 
phenomenon secondary to BEP chemotherapy may relate to peripheral endothelial damage. 
As both IMT as well as Raynaud's phenomenon result from endothelial damage, our findings 
suggest that presence of Raynaud's phenomenon can be a surrogate biomarker for subclinical 
atherosclerosis in testicular cancer survivors. The presence of Raynaud's phenomenon may 
point to patients at increased risk for early development of CVD. 
Measurement of plasma vascular biomarkers is a convenient method to monitor for subclinical 
changes in endothelial status. Moreover, changes in specific markers, e.g. endothelial 
activation, inflammation or fibrinolysis, may point to mechanisms contributing to 
chemotherapy-related CVD. Previously, increases in levels of vWF 10 weeks after completion 
of BEP chemotherapy were reported.8 In our study endothelial activation markers increased 
during follow-up, in line with earlier studies reporting on elevated plasma slCAM-116 and vWF15 
levels in 7 year testicular cancer survivors. Next to endothelial activation, systemic 
inflammation is thought to contribute to progression of atherosclerosis. Recently, high levels 
of hsCRP were associated with a increased risk for later cardiovascular events in longer term 
testicular cancer survivors.153 In our study median hsCRP levels did not change over time. Two 
previous studies reported conflicting findings on levels of hsCRP in chemotherapy treated 
testicular cancer survivors.20•21 Therefore this marker seems not suitable as early parameter for 
subclinical atherosclerosis. Overall, the lack of associations between (changes in) plasma 
biomarkers and clinical parameters or carotid IMT can be due to relatively short follow-up 
duration. Furthermore, the heterogeneous mechanisms that contribute to the development of 
atherosclerosis in testicular cancer survivors, such as direct endothelial damage22-21 and 
development of cardiovascular risk factors, 16'18'19 implies that these changes do not necessarily 
develop in a linear manner. 
In conclusion, we observed an increase in subclinical signs for atherosclerosis over 6.5 years of 
follow-up after BEP chemotherapy for testicular cancer. Testicular cancer survivors have signs 
of accelerated atherosclerosis when compared to healthy males. In patients who developed 
Raynaud's phenomenon after BEP chemotherapy, carotid IMT and the age-related increase in 
IMT were higher compared to patients without this symptom. The relation between IMT and 
Raynaud's phenomenon suggests that presence of this symptom can serve as a clinical 
biomarker to identify survivors with augmented atherosclerosis, who may benefit from 
intervention. 
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ABSTRACT 
Background: The metabolic syndrome may increase the risk for cardiovascular disease in 
testicular cancer (TC) survivors. 
Objective: To investigate the prevalence of the metabolic syndrome in TC survivors; its 
development and vascular implications. 
Design: Retrospective cohort study. 
Setting: A University Medical Center. 
Patients: TC survivors treated with platinum-based chemotherapy at the University Medical 
Center Groningen with a follow-up �3 years were eligible (n=370, study I). A subgroup aged 
<60 years and followed 3-20 years (n=173, study II) was compared to controls from the general 
Dutch male population (n=l,085). 
Measurements: In study I TC survivors were evaluated for development of cardiovascular risk 
factors. In Study II the subgroup was compared to controls from the general male population 
for metabolic syndrome prevalence and evaluated for vascular structure and function, and 
testosterone levels. 
Results: I n  TC survivors (study I) 50% had developed a body mass index >25 kg/m2, 24% 
hypercholesterolemia and 30% hypertension, after median follow-up of respectively 1.6, 0.9 
and 5.1 years. At median follow-up of 5 years (study II) 25% has the metabolic syndrome (age­
adjusted odds ratio (OR) 2.2 (95% Cl 1.5-3.3) compared to controls). Survivors with metabolic 
syndrome have features of inflammation and pro-thrombotic state, increased carotid artery 
intima-media thickness and decreased baroreflex sensitivity. Survivors with testosterone levels 
<15 nmol/L (22%) have an increased risk for the metabolic syndrome (OR 4.1, 95% Cl 1.8-9.3). 
Limitation: Retrospective design of this study. 
Conclusion: The study suggest that the metabolic syndrome occurs at earlier age in TC 
survivors treated with chemotherapy compared to controls and is accompanied by 
inflammatory and pro-thrombotic features, and signs of atherosclerosis. This emphasises the 




Cardiovascular disease is a frequent late effect after treatment for testicular cancer with an 
estimated 20-year risk of about 18% in Dutch testicular cancer survivors.103 Coronary heart 
disease is particularly common (estimated 20-year risk 10%) with approximately two-fold 
increased risk for myocardial infarctions in non-seminomatous testicular cancer survivors with 
attained age <55 years.103 Consequently, cardiovascular disease represents a threat to life 
expectancy and quality of life of a large proportion of survivors. Both mediastinal 
radiotherapy1°3 and platinum-based chemotherapy regimens12•103 are associated with 
increased cardiovascular disease risk compared to treatment with surgery alone. This 
increased cardiovascular disease risk may be related to accelerated atherosclerosis.21 
Platinum-based chemotherapy is associated with increased prevalence of excessive weight 
gain, 154 dyslipidemia13, hypertension13'154 and insulin resistance.13 These factors are the core 
components of the metabolic syndrome, which is associated with increased risk for 
atherosclerotic disease in the general population.155 Central obesity with visceral adipose 
tissue deposition may have an important role. Its hyperlipolytic state and excess of free fatty 
acids contribute to insulin resistance. In addition, visceral adipose tissue produces pro­
inflammatory and pro-thrombotic factors.155•156 
We previously reported on increased prevalence of the metabolic syndrome in testicular 
cancer survivors compared to healthy controls at median 7 years after chemotherapy. 19 In a 
Norwegian cohort of testicular cancer survivors with median follow-up of 11 years only 
survivors treated with cumulative cisplatin dose >850 mg showed increased risk for metabolic 
syndrome compared to healthy controls.157 In both studies testosterone levels were inversely 
associated with the metabolic syndrome.18 
Information on the metabolic syndrome and its effects on vascular function and development 
of overt cardiovascular disease in cancer survivors is scarce. Insight into etiological and/or 
contributing factors may help to identify survivors at increased risk for the metabolic 
syndrome.31 In order to develop guidelines for follow-up on cardiovascular risk factors in 
testicular cancer survivors, information is also needed on development over time of such 
factors.6 
In this study we present data on cardiovascular risk factors and the metabolic syndrome in 
long-term (�3 years) non-seminomatous testicular cancer survivors treated with platinum­
based chemotherapy: the development over time of cardiovascular risk factors (study I), the 
prevalence of metabolic syndrome compared to the general male population, its associated 
features, and implications for vascular structure and function, and its relation to gonadal 
function (study II). 
METHODS 
Patients 
Patients were selected from our cohort of long-term survivors of disseminated non­
seminomatous testicular cancer treated with platinum-based chemotherapy at University 
Medical Center Groningen, between January 1977 and April 2004 (n=439) (Figure 1). For the 
retrospective evaluation of the development of cardiovascular risk factors (study I) patients 
had to have a follow-up duration of �3 years. Patients with coronary heart disease [defined as 
myocardial infarction or coronary artery disease (proven by angiography, or by treatment with 
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angioplasty or bypass surgery)] before start of chemotherapy were excluded. The metabolic 
syndrome and its associated features (study I I) were cross-sectionaly assessed in a subgroup of 
study I .  Inclusion criteria were attained age <60 years and follow-up of maximum 20 years. 
Exclusion criteria were history of cardiac disease before or after chemotherapy, radiotherapy 
to head, neck and/or mediastinum, and participation in a previous study on cardiovascu lar risk 
profile.13 The medical eth ical committee approved the study and participants gave written 
informed consent. 
C ont rol populati on 
Control data concerning the metabolic syndrome in the genera l population were avai lable 
from two studies: men 28-60 years old from a representative sample of the Groningen 
population of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study158'159 
and, in order to cover a lso for young testicular cancer survivors, men 18-42 years old 
participating as sibling controls to a study on late cardiovascular effects in childhood cancer 
survivors. Controls with a history of myocardial infarction or coronary artery disease were 
excluded. In 1,020 out of 1,120 participants of the PREVEND study and in 65 out of 68 in the 
chi ldhood cancer survivor study, sufficient cross-sectional data were avai lable on waist 
circumference, blood pressure, fasting lipid and glucose levels and medication use, to allow for 
evaluation of presence or absence of the metabolic syndrome. The resu lting control group 
existed of 1,085 men with a median age of 44 years (range 18-59) .  
Evaluati on of t he development o f  cardi ovascular ri sk f act ors {St udy I )  
Medical records, updated from general practitioners' files, were evaluated for disease- and 
treatment-related characteristics and follow-up data. Cardiovascular risk factors overweight, 
hypercholesterolemia and hypertension were retrospectively evaluated for presence pre­
chemotherapy and development during follow-up. With respect to overweight, body mass 
index (BMI; calculated by weight(kg)/height(m)2) >27.8 kg/m 2 was recorded, the latter 
corresponding with an earlier US National Institutes of Health defin ition for overweight136 and 
used in the early phase of establishment of the cohort.13 Hypertension was defined as blood 
pressure systolic >150 mmHg and/or diastolic >95 mmHg13'160 and/or use of antihypertensive 
drugs, and hypercholesterolemia as non-fasting cholesterol levels >6.5 mmol/L at �3 separate 
time points and/or use of cholesterol-lowering drugs. Follow-up duration was calculated from 
start of chemotherapy to last assessment of each risk factor and in case of overweight, 
hypertension or hypercholesterolemia also to date of this d iagnosis. 
A ssessment of t he met aboli c sy ndrome and it s associ at ed f eat ures (St udy I I) 
Cross-sectional evaluation consisted of a medica l history focused on medication use, smoking 
behavior and family history for cardiovascu lar disease (positive in case of parent or 
brother/sister with coronary heart disease, cardiac death or cerebrovascular accident at age 
<60 years) and assessment of weight, height, waist circumference (at umbil ica l level), hip 
circumference (at broadest part) and blood pressure. 
Fasting blood samples were analyzed for HDL-cholesterol and triglycerides (plasma), glucose 
(plasma) and insulin (serum) .  Leptin and adiponectin were determined by ELISA {#EZHL-80SK 
and #EZHADP-61K, Linco Research, St. Charles, MO, US, EDTA plasma). In addition, markers for 
inflammation, pro-thrombotic state and endothelial activation were determined. H igh-
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sensitivity C-reactive protein (hsCRP, serum), fibrinogen, Von Willebrand Factor (vWF) antigen, 
Plasminogen Activator Type-1 (PAl-1) antigen, and tissue-type Plasminogen Activator (t-PA) 
antigen (citrate plasma) were measured as described previously.21 Urinary albumin excretion 
and creatinine clearance were determined from a 24-h urine sample. 21 
For assessment of the metabolic syndrome the American Heart Association/National Heart, 
Lung and Blood Institute (AHA/NHLBI) classification137 was used with presence of the 
metabolic syndrome in case of �3 of the following criteria: central obesity (waist circumference 
�102 cm), high triglycerides (�1.7 mmol/L or medication), low HDL-cholesterol (<1.03 mmol/L 
or medication), high blood pressure (systolic �130 mmHg or diastolic �85 mmHg or 
medication), and high glucose (�5.6 mmol/L or medication). In addition, waist/hip ratio was 
calculated as measure for central obesity, HOMA-IR index (Homeostatic Model Assessment for 
Insulin Resistance = fasting insulin (mU/L) x fasting glucose (mmol/L)/22.5) for insulin 
resistance and PAl-1/tPA ratio for pro-thrombotic state. As potential risk factor gonadal 
function was analyzed by measuring serum total testosterone, luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH). 
As measure for cardiovascular autonomic function, baroreflex sensitivity (BRS) at rest in supine 
position was determined.36 To assess vascular structure and function, the intima-media 
thickness {IMT) of the common carotid artery was measured and carotid distensibility, 
compliance and stiffness calculated, as described previously.21 
Statistical methods 
The cumulative risk for cardiovascular risk factors in testicular cancer survivors (study I) was 
plotted according to the Kaplan-Meier procedure. Presence of a risk factor at last assessment 
was considered an event, with follow-up duration calculated from start of chemotherapy to 
diagnosis of the risk factor. When the risk factor was already present pre-chemotherapy, 
follow-up duration was set to zero. Median follow-up until development of each risk factor 
was calculated for testicular cancer survivors in whom the risk factor developed after 
completion of chemotherapy. 
The risk for the metabolic syndrome and its components in testicular cancer survivors (study II) 
was compared to general population data by binary logistic regression analysis with 
adjustment for age. Testicular cancer survivors with metabolic syndrome were compared to 
survivors without metabolic syndrome with respect to associated features, vascular structure 
and function, and gonadal function using the non-parametric Mann-Whitney U test for 
continuous data and the X2 test for categorical data. The association between metabolic 
syndrome and markers for inflammation, pro-thrombotic state, endothelial activation, and 
vascular structure and function was further analyzed using linear regression analysis with 
metabolic syndrome as independent variable and adjustment for age. The effect of gonadal 
function on the risk for the metabolic syndrome and its components was tested with binary 
logistic regression analysis. Receiver-Operator-Characteristic curve analysis was used to 
estimate the optimal cut-off value for total testosterone levels in order to differentiate 
between persons with and without metabolic syndrome. Statistical analyses were performed 
with SPSS for Windows 16.0 (SPSS Inc., Chicago, IL, US). For all analyses, a 2-tailed p-value 
<0.05 was considered significant. 
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RESULTS 
Study population characteristics 
The original cohort of 439 non-seminomatous testicular cancer patients treated with platinum­
based chemotherapy includes 370 patients with absence of pre-treatment history of coronary 
heart disease and follow-up �3 years (study I) (Figure 1). From the subgroup of 212 patients 
approached for participation in the study on the metabolic syndrome (study II), 173 patients 
(82%) gave informed consent. Baseline disease- and treatment-related characteristics and 
follow-up data for the two study populations are shown in Supplementary table 1. 
Original population (N = 439) 
D1ssem1nated Non-semmomatous Tesbcular Cancer 
Platinum-based chemotherapy < Apnl 2004 
Exclusions for Study I (n = 69) 
! Total follow-up period < 3 years due to death (n = 65) Total follow-up period < 3 years due to loss to follow-up (n=2) 
Study I (N = 370) Coronary heart disease pre-chemotherapy {n = 2) 
Development of cardiovascular risk factors 
(retrospective evaluation) Exclusions for Study II (n = 119) 
Age .: 60 years and/or total follow-up penod > 20 years (n = 46) 
Coronary heart disease after chemotherapy or other cardiac disease (n = 16) 
Radiotherapy head/neck (n = 2) 
Previous participation to study on cardiovascular risk factors (n = 55) 
Not amenable for partIcIpatIon (n = 39) 
Deceased (n = 16) 
Lost to follow-up {n =10) 
Active cancer (n = 5) 
Psychosocial reasons (n = B) 
Survivors approached for study participation (N = 212) 
! I No informed consent for Study II (n = 39} I 
Study II (N = 173) 
The metabolic syndrome and associated features 
(cross-sectional evaluation) 
Figure 1. Flow diagram of included patients. 
Development of cardiovascular risk factors (Study I) 
Assessments of overweight, hypercholesterolemia and hypertension were available until 
median follow-up of 9.1 years (range 0.2-28.9). At last assessment the prevalence of risk 
factors was: BMI >27.8 kg/m2 85/359 (24%, new in 15% of the patients compared to pre­
chemotherapy), hypercholesterolemia 87/361 (24%, new in 14%) and hypertension 106/359 
(30%, new in 23%). 
Figure 2 shows cumulative risks for the risk factors from start of chemotherapy. Median time 
to the development of BMI >27.8 kg/m2 is 1.7 years (range 0.2-28.4), for hypercholesterolemia 
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Figure 2. Cumulative risk of cardiovascular risk factors overweight, hypercholesterolemia and hypertension from 
start of chemotherapy (study I). Data are shown for patients in whom data on the concerned risk factors at start of 
chemotherapy are available. 
The metabolic syndrome and associated features (Study II) 
Prevalence 
At median follow-up of 5 years (range 3-20) and attained age of 37 years (range 19-59) the 
prevalence of the metabolic syndrome was 44/173 (25%). The prevalence increases with 
ascending age, from 13.3% in survivors 18-30 years old to around 35% in survivors 40-60 years 
old (Figure 3A). High blood pressure is the most frequent component of the metabolic 
syndrome {59%), followed by low HDL-cholesterol (44%), high triglycerides (29%), central 
obesity {17%) and high glucose levels (14%) (Figure 3B; Table 1). All components tend to 
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Figure 3. Prevalence of the metabolic syndrome in testicular cancer survivors and in controls according to age 
category (A) and prevalence of its separate components (B) (study II). 
(*) p <0.05 compared to controls (X2 test) 
Adjusted for age, testicular cancer survivors show an increased risk for the metabolic 
syndrome compared to the general population with an odds ratio of 2.2 {95% confidence 
interval 1.5-3.3) (Table 1). This effect corresponds with 12.9 years' increase in age compared to 
the control population. Testicular cancer survivors especially have an increased risk for high 
blood pressure (Table 1). 
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Dependent variable Prevalence Odds ratio 95% CI p-value 
Metabolic syndrome 44/173 (25%) 2.2 1.5-3.3 0.0001 
Separate components 
High blood pressure 100/171 (59%) 2.5 1.8-3.6 <0.0001 
Low HDL-cholesterol 76/173 (44%) 1.7 1.2-2.3 0.003 
High triglycerides 50/173 (29%) 1.2 0.8-1.7 0.424 
Central obesity 29/170 (17%) 1.9 1.2-3.1 0.005 
High glucose 24/170 (14%) 2.3 1.4-3.7 0.002 
Table 1. Prevalence of and risk for the metabolic syndrome and its separate components after chemotherapy for 
testicular cancer (study II, N=173). The risks are expressed as age-adjusted odds ratios compared to the control 
population with 95% confidence interval (95% Cl) and p-value (binary logistic regression). 
Metabolic syndrome associated features 
There is no difference in smoking behavior and family history for cardiovascular disease 
between survivors with and without metabolic syndrome. Survivors with metabolic syndrome 
have more central obesity, reflected by a higher waist/hip ratio, higher plasma leptin and 
lower plasma adiponectin, and increased HOMA-IR index {Table 2). 
The association of metabolic syndrome with inflammation, pro-thrombotic state, endothelial 
activation, and signs of vascular damage was analyzed with adjustment for age. In presence of 
metabolic syndrome pro-thrombotic markers fibrinogen and PAl-1/tPA ratio are increased. 




Survivor characteristics and cardiovascular risk factors 
Age at start chemotherapy (years) 29 (18-48) 
Follow-up duration (years) 7 (3-20) 
Age at study participation (years) 40 (23-57) 
Smoking habits 
Current smoker 14/44 (32%) 
Ex-smoker 11/44 (25%) 
Life-long nonsmoker 19/44 (43%) 
Positive family history CVD 6/42 (14%) 
Metabolic features 
BMI (kg/m2) 28.4 (22.9-38. 7) 
Waist/hip ratio 0.99 (0.83-1.12) 
























Table 2 - continued 
Characteristics • 
Metabolic syndrome Metabolic syndrome 
p-valuet 
present (44) absent (129) 
Metabolic features 
Adiponectin (µg/ml) 5.00 (2.04-11.19) 7.23 (2.76-17.40) <0.0001 
HOMA-IR index 3.30 (1.56-23.86) 2.19 (0.20-2.04) <0.0001 
Gonadal function 
Testosterone supplementation 1/44 (2%) 8/129 (6%) 0.451 
Total testosterone (nmol/L)* 15 (9-31) 18 (4-37) <0.0001 
Testosterone <15 nmol/L* 19/43 (44%) 17/121 (14%) 0.0002 
FSH (U/L)* 16.80 (4.34-47.50) 13.90 (2.38-7.50) 0.452 
LH (U/L)* 6.42 (2.47-18.70) 5.45 (1.59-33.10) 0.190 
Table 2. Comparison between testicular cancer survivors with the metabolic syndrome and testicular cancer 
survivors without the metabolic syndrome with respect to survivor characteristics, cardiovascular risk factors, 
metabolic features and gonadal function (study II). 
(*) Median (range) or n/N (%); (t) Mann-Whitney U test for continuous data and X2 test for categorical data; (:t) For 
testicular cancer survivors not receiving testosterone supplementation 
Testicular cancer survivors with metabolic syndrome do not differ with respect to creatinine 
clearance or urinary albumin excretion. In contrast, presence of metabolic syndrome is 
associated with lower baroreflex sensitivity at rest and increased carotid artery intima-media 
thickness (Table 3). 
Gonadal function 
Median total testosterone level is lower in presence of metabolic syndrome (excluding 
survivors with testosterone supplementation (n=9)) (Table 2; Supplementary figure 1). A cut­
off value of total testosterone <15 nmol/L was considered best discriminating for the 
metabolic syndrome (area under the Receiver-Operator-Characteristic curve 0.65 (95% Cl 0.55-
0. 74), area under the Receiver-Operator-Characteristic curve of age 0.65 {95% Cl 0.55-0.75). 
Unsupplemented total testosterone <15 nmol/L is associated with an age-adjusted odds ratio 
of 4.1 (95% Cl 1.8-9.3; p=0.001) for the metabolic syndrome (Supplementary Table 2). Low 
testosterone shows association with central obesity (odds ratio=5.7 {95% Cl 2.3-14.1); 
p<0.001) and high glucose levels (odds ratio=2.9 {95% Cl 1.1-7.5); p=0.031). 
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Associated features• Metabolic Metabolic 




Markers for inflammation, pro-thrombotic state and endothelial cell activation 
hsCRP (mg/l} 1.6 {0.2 - 13.4) 1.1 {0.26 - 31.8) 0.36 (-0.75 - 1-47) 0.52 
vWF (%} 98 {28 - 220) 96 {37 - 296) -5 (-21 - 10) 0.52 
Fibrinogen (g/l} 3.2 (1.5 - 5.0) 2.8 (1.2 - 6.3) 0.24 (0.01 - 0.46) 0.04 
tPA (ng/ml) 11.0 (3. 7 - 21.0) 6.5 {1.5 - 21.0) 3.5 (2.3 - 4.6) <0.0001 
PAl-1 (ng/ml) 57 {8 - 312) 19 (3 - 62) 42.1 (29.0 - 55.3) <0.0001 
PAl-1/tPA ratio 5.4 {1.5 - 31.6) 3.2 {0.5 -17.1) 3.1 (1.7 - 4.6) <0.0001 
Vascular function and structure 
Creatinine clearance 




5.5 (0.1 - 615.3) 4.6 (0.1 - 345.4) 7.67 (-12.67 - 28.09) 
(mg/24h) 
n=169 0.46 
BRS (In) at rest 
n=166 2.3 {0.8 - 3.6) 2.6 {0.8 - 3.6) -0.21 (-0.41 - -0.01) 0.04 
(ln(ms/mmHg)) 
Carotid /MT (mm) n=157 0.62 (0.45 - 1.05) 0.57 {0.38 - 1.12) 0.044 {0.003 - 0.084) 0.03 
Carotid compliance 
n=142 8.36 (4.29 - 17.85) 10. 74 (3. 70 - 30.67) -1.45 {-3.02 - 0.13) 0.o7 
(µm/mmHg) 
Carotid distensibility 
n=144 6.62 {3.36 - 9. 78) 7.74 (3.41 - 16.84) -0.62 {-1.37 - 0.14) 0.11 
(%) 
Carotid stiffness n=137 7.22 {3.92 - 13-24) 6.50 (3.24 - 12.51) 0.33 (-0.42 - 1.08) 0.39 
Table 3. Markers of inflammation, pro-thrombotic state, endothelial cell activation, and vascular function and 
structure {study II) according to presence or absence of the metabolic syndrome. 
(*) Median (range); (t) Co-effficient B (95% confidence interval) and p-value for the association between the 
metabolic syndrome and concerning feature (linear regression with metabolic syndrome as independent variable 
and adjustment for age) 
DISCUSSION 
Our cross-sectional assessment of the metabolic syndrome (study II) shows that this syndrome 
and its components central obesity, low HDL-cholesterol, high blood pressure and high glucose 
levels are more prevalent in testicular cancer survivors than in the general population. At 
median follow-up of 5 years 25% of the survivors have the metabolic syndrome. The risk for 
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the metabolic syndrome in testicular cancer survivors is 2.2 (95% Cl 1.5-3.3) times higher than 
in the general population, corresponding with the risk of men 12.9 years older. This suggests 
development of metabolic risk factors at earlier age. 
Retrospective evaluation of the development of cardiovascular risk factors (study I) shows that 
overweight and hypercholesterolemia develop mainly within the first 5 years after platinum­
based chemotherapy, after median follow-up of 1.7 years for BMI >27.8 kg/m2 and 0.9 years 
for hypercholesterolemia. The cumulative risks of overweight and hypercholesterolemia show 
a plateau after a follow-up period around 10 years. In contrast, hypertension develops later, 
after median follow-up of 5.1 years, and does not show a plateau with prolonged follow-up. 
The later appearance of hypertension may be related to its development secondary to other 
metabolic risk factors. Moreover, hypertension may reflect the long-term effect of direct 
chemotherapy-induced endothelial damage. 
A considerable proportion of the testicular cancer survivors with overweight, 
hypercholesterolemia or hypertension at the end of follow-up already had these risk factors at 
start of chemotherapy. Unfortunately, it is unknown whether the pre-chemotherapy 
prevalence of these factors is representative for the age-matched general population. On the 
one hand, presence of cancer may contribute to lower cholesterol levels and lower BMI as 
previously described.161 On the other hand, the metabolic syndrome and its components are 
increasingly recognized as risk factors for the development of several cancer types162 and may 
be consequently overrepresented in cancer patients. 
Although we have no longitudinal data on the development over time of cardiovascular risk 
factors in the general population, our data suggest that the metabolic syndrome develops at 
earlier age in testicular cancer survivors _(study II) and that development of cardiovascular risk 
factors can already be observed during the first years of follow-up (study I). 
In line with previous studies we have found an association between total testosterone levels 
and metabolic syndrome in testicular cancer survivors.18'19 In the general population low 
testosterone levels are predictive for the development of metabolic syndrome.163-165 Our data 
show that survivors with unsupplemented total testosterone <15 nmol/L (22% of the 
evaluated survivors) have an approximately 4 times increased risk for the metabolic syndrome, 
particularly associated with central obesity. We hypothesize that decrease in testosterone 
levels and secondary central, visceral fat deposition have an important role in the 
development of the metabolic syndrome. Unsupplemented testosterone <15 nmol/L also 
shows an association with high glucose levels. This corresponds with the independent 
association of low to normal testosterone levels with insulin resistance, as observed in older 
men.166 
Testicular cancer survivors with metabolic syndrome show features of central, visceral fat 
deposition: increased waist-hip ratio, elevated levels of leptin (adipose tissue hormone giving 
feedback at hypothalamic level on energy intake and expenditure), decreased levels of 
adiponectin (adipose tissue hormone with anti-inflammatory and insulin-sensitizing effects), 
and insulin resistance (increased HOMA-IR index). Decreased adiponectin levels and increased 
fibrinogen levels are associated with an inflammatory state. The observed increase in both 
fibrinogen and PAl-1/tPA-ratio may contribute to a pro-thrombotic state. Low-grade 
inflammation and pro-thrombotic state are closely linked in the patho-biology of 
atherosclerosis.167'168 The observed association with increased carotid intima-media thickness 
and decreased baroreflex sensitivity underscores the potential clinical relevance of the 
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metabolic syndrome in testicular cancer survivors. Increase in intima-media thickness is an 
accepted marker of early atherosclerosis169 and decrease in baroreflex sensitivity170•111 has also 
been associated with atherosclerosis. Both are considered unfavourable predictors for 
cardiovascular disease. 
Although our data suggest a role of the increased prevalence of cardiovascular risk factors in 
the development of cardiovascular disease in testicular cancer survivors treated with platinum­
based chemotherapy, prolonged follow-up is needed to assess whether subclinical signs of 
atherosclerosis eventually progress to overt cardiovascular disease. The homogeneity of the 
study population, most survivors having been treated with the current standard regimen BEP, 
excludes analysis of direct toxic effects of chemotherapy on the vasculature. Cisplatin as well 
as bleomycin can induce endothelial damage. 24'172'173 Since cisplatin in plasma remains 
detectable up to 20 years after chemotherapy28 and may still be partially in reactive form, 174 
we hypothesise there is an ongoing process of platinum-induced direct vascular toxicity. 
The current observations on cardiovascular risk factors and metabolic syndrome in long-term 
testicular cancer survivors suggest that detection and timely treatment from start of 
chemotherapy and during follow-up may contribute to reduction of cardiovascular disease risk. 
Overweight and hypercholesterolemia can be detected mainly within the first 5 years after 
chemotherapy. However, the risk for hypertension, that may also be a sign of developed 
vascular damage, extends beyond a follow-up period of 10 years. Therefore, extended follow­
up, in close collaboration with primary care physicians, seems necessary. 
By implementing prolonged follow-up it will become clear whether testicular cancer survivors 
with metabolic syndrome will have a higher cardiovascular disease risk than testicular cancer 
survivors without, and than individuals with metabolic syndrome in the general population. If 
previous treatment for testicular cancer turns out to be an additional cardiovascular risk 
factor, treatment indications for the metabolic syndrome may be more stringent for testicular 
cancer survivors. In addition, a randomised, placebo-controlled trial may help to evaluate 
whether testosterone supplementation contributes to prevention or treatment of metabolic 
syndrome in testicular cancer survivors. 
In conclusion, the metabolic syndrome is more prevalent and appears to develop at earlier age 
in testicular cancer survivors treated with platinum-based chemotherapy compared to the 
general population. It is associated with subclinical, unfavourable changes in intima-media 
thickness and baroreflex sensitivity, which may precede overt cardiovascular disease. The early 
development of overweight and dyslipidemia advocates the development of guidelines on 
detection and treatment from the start of chemotherapy and during follow-up. In addition, 
close collaboration with primary care physicians seems necessary with respect to extended 
follow-up and treatment of cardiovascular risk factors. Low testosterone and its association 
with central obesity appear to play a central role in the development of the metabolic 
syndrome and is a target for future intervention studies. 
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SUPPLEMENTARY FIGURES AND TABLES 
Study I Study II 
(n = 370) (n = 173) 
Baseline characteristics 
Age at start chemotherapy 
Median (range) 28 (16-64) 28 (16-52) 
(years) 
Chemotherapy regimen• 
BEP/EP n (%) 262 (71%) 159 (92%) 
PVB 27 (7%) 0 (0%) 
PVB+ 42 (11%) 0 (0%) 
PVB/BEP 15 (4%) 1 (1%) 
Other 24 (7%) 13 (7%) 
Follow-up data 
Follow-up duration (years) Median (range) 12 (3-29) 5 (3-20) 
Age at end follow-up (years) Median (range) 42 (19-73) 37 (19-59) 
Deceased n (%) 25 (7%) not applicable 
Death of testicular cancer 14 (4%) 
Coronary heart disease {CHD) n (%) 19 (5%) not applicable 
Age at CHD (years) Median (range) 49 (30-62) 
Follow-up duration at CHD 
Median (range) 15 (0-28) 
(years) 
Appendix table 1. Baseline characteristics and follow-up data of the testicular cancer patients in study I and the 
subpopulation included in study II. 
(*) Chemotherapy regimen: BEP = bleomycin, etoposide, cisplatin; EP = etoposide, cisplatin; PVB = cisplatin, 
vinblastin, bleomycin; PVB+ = PVB followed by maintenance therapy with cisplatin and vinblastin; PVB/BEP = 
alternating courses of PVB and BEP; Other = CEB (carboplatin, etoposide, bleomycin) or BOP/VIP (bleomycin, 
vincristin, cisplatin I etoposide, ifosfamide, cisplatin) 
Dependent variable Odds ratio 95% CI p-value 
Metabolic syndrome 4.1 1.8-9.3 0.001 
Central obesity 5.7 2.3-14.1 0.0001 
High blood pressure 1.3 0.6-3.0 0.49 
Low HDL cholesterol 1.1 0.5-2.4 0.80 
High triglycerides 2.0 0.9-4.5 0.08 
High glucose 2.9 1.1-7.5 0.03 
Appendix table 2. Age-adjusted risk for the metabolic syndrome and its components in testicular cancer survivors 
with unsupplemented total testosterone levels <15 nmol/L (n=36). Risks are expressed as age-adjusted odds ratios 
compared to testicular cancer survivors with unsupplemented total testosterone levels :.!:15 nmol/L (n=128) with 
95% confidence interval (95%CI) and p-value (binary logistic regression). (Study II) 
- 95 -
Metabolic Syndrome after Platinum-based Chemotherapy 
100% - metabolic syndrome - no metabolic syndrome 
80% 
-� 







0 1 0  15 20 25 30 35 
Testosterone (nmol/L) 
Appendix figure 1. Total testosterone level with respect to cumulative percentage of testicular cancer survivors 
with the metabolic syndrome and of testicular cancer survivors without the metabolic syndrome (excluding 
survivors with testosterone supplementation). 
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Changes in Genes and Pathways by Cisplatin and Bleomycin 
ABSTRACT 
B ackg round 
Chemotherapy-related endothelial damage contributes to the development of cardiovascular 
morbidity in testicular cancer patients. We aimed to obtain insight in relevant molecular 
events and search for candidate biomarkers of this endothelial damage. 
Meth ods and materials 
Human microvascular endothelial cells (HMEC-1) were exposed to bleomycin or cisplatin (IC10, 
ICso, ICgo), with untreated samples as control. Custom-made 18K cDNA microarrays were used, 
and read with an Affymetrix GMS428 scanner. Gene expression differences were analysed at 
the single gene level and in gene sets clustered in biological pathways. Validation was 
performed by qRT-PCR. A specific ELISA was used to measure protein levels of a candidate 
biomarker in testicular cancer patient plasma, collected before, during and after bleomycin­
etoposide-cisplatin (BEP) chemotherapy. 
R esults 
Expression data for 16k genes were available. Several genes were significantly differentially 
expressed in more than one experimental setting, e.g. GDF15, ATF3 and AREG. Enriched gene 
sets included the 'P53 signaling' and 'Type I Diabetes Mellitus' pathways. qRT-PCR for GDF15, 
ATF3 and AREG confirmed the cDNA microarray findings. In testicular cancer patients, GDFlS 
plasma levels increased during and after BEP-chemotherapy. 
Conclusions 
In this cDNA microarray analysis in HMEC-1 exposed to bleomycin or cisplatin, expression 
changed in single genes, e.g. GDF15, ATF3 and AREG, and in biological pathways involved in 
cell death and inflammation. The observed changes in plasma GDFlS-protein levels in 
testicular cancer patients indicate that this pre-clinical approach can guide the search for 
relevant biomarkers for endothelial damage. Further in vitro and in vivo exploration of vascular 
pathobiology and conformation is warranted. This strategy may facilitate the rationale towards 
selection of targets for intervention, and the introduction of early biomarkers for 




The introduction of platinum-based chemotherapy in the late seventies has resulted in high 
cure rates in patients with metastatic testicular cancer. However, this chemotherapy coincides 
with side-effects, resulting in morbidity in successfully treated testicular cancer patients. 2 
Relevant issues are the increased risks for second malignancies and cardiovascular disease 
(CVD).7•12-14 CVD can arise during or shortly after treatment,9'102 as well as in the long term.12-
14,16,11,36,103 
One of the mechanisms considered responsible for treatment-related cardiovascular 
complications is direct endothelial damage. In addition to induction of endothelial cell death, 22-
24 both bleomycin24'26'172 and cisplatin24'25'27'175 indirectly influence endothelial cell function, e.g. 
through interference with inflammatory and fibrinolytic factors. Ultimately, this 
chemotherapy-induced cellular activation can progress to endothelial dysfunction, accelerated 
atherosclerosis and overt CVD. 
A potentially useful approach to unravel factors involved in chemotherapy-related endothelial 
damage is large-scale gene expression profiling. With gene or cDNA microarray analysis, 
expression-differences upon exposure to a stimulus can be measured. One of the strengths of 
this approach is that genes with altered expression can be identified without a priori 
assumptions. 
Several methodological approaches can be used to analyse gene expression data. In the 
conventional method of analyzing microarray-data the top few individual genes that are highly 
differentially expressed between phenotypes are reviewed. Such individual genes can be 
relevant. In addition, it is increasingly realized that small but coordinated changes in a set of 
genes clustered in a single pathway can have significant biological relevance. Integrating genes 
into functional sets enables consideration of all the available genomic information, rather than 
only the genes passing a certain significance threshold. 
In this report we investigated the potential of cDNA microarray analysis to identify biological 
mechanisms underlying the development of chemotherapy-related endothelial damage. We 
studied the effects of bleomycin and cisplatin on the human microvascular endothelial cell line 
(HMEC-1) cell with cDNA gene expression profiling. To elucidate biological circuits that 
underlie endothelial cell responses, we not only studied the effects on single genes but also on 
clusters of gene sets involved in cellular pathways. Thereafter, changes in protein expression 
of a selected candidate gene were studied in testicular cancer patient plasma during and after 
bleomycin-etoposide-cisplatin (BEP) chemotherapy. 
MATERIALS AND METHODS 
Cell line model 
HMEC-1 is an immortalized human dermal microvascular endothelial cell line that retains its 
morphologic and functional endothelial cell characteristics during several passages.176 Cells 
were grown as a monolayer in MCDB-131 medium {lnvitrogen, Merelbeke Belgium) 
supplemented with 10% Fetal Calf Serum (Bodinco, Alkmaar, the Netherlands), 10 mM L­
glutamine (lnvitrogen, Merelbeke, Belgium), 1 µg/ml hydrocortisone {Sigma-Aldrich, 
Amsterdam, the Netherlands) and 10 ng/ml human Epidermal Growth Factor (R&D Systems, 
Abingdon, UK), and were cultured at 37°C in a humidified atmosphere containing 5% CO2• 
Experiments were performed between passages 15-30. 
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In an acute exposure model, HMEC-1 were left untreated as controls, or were treated with 0.3 
(IC5o) or 1.5 µg/ml (IC90) bleomycin and 2.6 (ICso) or 12.9 µM (ICgo) cisplatin for 6, 24, and 48 
hours (Figure lA). In addition, in a chronic exposure model, lower doses were administered 
(ICl0; bleomycin 0.06 µg/ml or cisplatin 0.52 µM,) twice weekly; cells were collected for 
analysis at day 30 (Figure 1B). Administration of cisplatin had to be withheld at the 7th 
administration because of considerable cell death. Bleomycin could be administered without 
interruption. 
cDNA mi cro array ex peri ments 
Total RNA was isolated from the HMEC-1 cell lines by a RNeasy kit (Qiagen) and pooled for 
each time-point and drug from 2 independent experiments. After purification (Qiaquick PCR 
purification kit, Qiagen), amplified RNA (cRNA) samples were transformed to cDNA with 
reverse transcriptase, independently labeled with Cy3 (green) and CyS (red), randomized and 
hybridized to the custom-made 18K cDNA microarrays. Fluorescent images of the microarray 
slides were obtained with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA) for 
both fluorophores, signal intensities for each spot were quantified by dedicated IMAGENE 5.6 
software (Biodiscovery, Marina del Rey, CA). 
A Acute 
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Figure 1. Experimental design: immortalized human dermal microvascular endothelial cells (HMEC-1) were exposed 
to bleomycin [0.3 (IC50), 1.5 µg/mL (IC90)] or cisplatin [2.6 (IC50), 12.9 µM (IC90)] for 6, 24 and 48 hours (acute 
exposure, A). Additionally, over the course of 30 days HMEC-1 was exposed to 0.06 µg/mL bleomycin (IC10) or 0.52 
µM cisplatin (IC10) twice weekly (chronic exposure, B). In both experiments untreated samples served as controls. 
(*) RNA-isolation and cDNA microarray experiments; (t) RNA-isolation and qRT-PCR 
Quantile normalization was applied to log2 transformed Cy3 and Cy5 intensities. Operon v2.0 
(Human Genome Oligo Set V2) probe identifiers were converted to official gene symbols. 
Expression values of multiple probes targeting a single gene were averaged, resulting in a total 
of 15,950 distinct genes. Subsequently, expression data obtained from multiple hybridizations 
(n=4) of the same HMEC-1 specimen were averaged. 
Class comparison 
For class comparison in-house software was used. Analyses for samples exposed to cisplatin 
and bleomycin were performed in the same manner. 
In the acute exposure setting, differentially expressed genes between HMEC-1 untreated 
samples and samples exposed to the different drug dosages (i.e. IC50 and SxlCso) were tested 
with the non-parametric Cuzick test for linear trend, resulting in a 2-score and a P-value. This 
test was done for cells collected after 6 (t=6), 24 (t=24) and 48 (t=48) hours. For all three time-
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points the 2-score resulting from the Cuzick tests was summed (i.e. !Z = Zt=G + Zt=24 + Zt=48); 
thereby selecting a constraint on genes that changed in a consistent direction with increasing 
concentrations over time. Genes were ranked according to their !Z-score. 
In the chronic exposure model, a t-test was performed on gene expression levels obtained 
from samples exposed to the drugs (IC10 cisplatin or bleomycin) versus the untreated control 
samples that were collected after 30 days incubation. Results of these genes were ranked 
according to P-value. 
Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA)177 was executed with GSEA 2.0 software package (Broad 
Institute of MIT and Harvard, Cambridge, MA). Expression data of all 15,950 genes were 
compared against functional gene sets to determine whether any of these sets were enriched 
in HMEC-1 treated with cisplatin or bleomycin in the acute as well as the chronic exposure 
model. The comparison was performed using 169 gene sets from Kyoto Encyclopedia of Genes 
and Genomes database (KEGG; http://www.genome.jp/kegg/). Statistical significance of 
enrichment was determined using an empirical gene-based permutation test using 1000 
permutations. A false discovery rate (FDR) was calculated for each functional gene set, which 
represent the estimated probability that a given enrichment score represents a false positive 
finding. We report gene sets with a FDR S0.10 and a P-value S0.025. This FDR implies that an 
experiment is valid at least 9 out of 10 times. 
Q uantitative R eal T ime PCR 
Next, differential gene expression from three genes found in the single gene analysis was 
evaluated by quantitative Real Time PCR (qRT-PCR). For this purpose, 12 RNA samples included 
in the cDNA microarray analysis were used (Figure lA and 18). Samples were DNAse treated to 
eliminate genomic DNA-contamination, and subsequently, RNA was reverse transcribed into 
cDNA. qRT-PCR was performed using Applied Biosystems TaqMan assays, according to the 
manufacturers protocol. Master Mix, primers and TaqMan probes were purchased from 
Applied Biosystems (Nieuwerkerk a/d IJssel, the Netherlands) The genes and their respective 
assay numbers were Growth Differentiation Factor 15 (GDF15; Hs 00171132_ml), Activating 
Transcription Factor 3 (ATF3; Hs 00231069_ml), Amphiregulin (AREG; Hs 00155832_ml) and 
of the housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Hs 
02758991_gl). All experiments were performed in triplicate using ABI PRISM® 7900 HT 
Sequence Detection System, with the following cycling conditions: 2 min at 50 °C, 10 min at 95 
°C, followed by 40 cycles of 15 sec at 95 °C and 1 min at 60 °C. Relative quantity of target genes 
was calculated by dividing the mean cycle threshold (CT) for the gene of interest by the mean 
CT-value for the housekeeping gene GAPDH. Thereafter, expression of the untreated sample at 
t=6 or d2 was set at 1.00, and relative expression-differences were calculated. 
GDF15 protein levels in plasma of testicular cancer patients during and aft er BEP­
chemotherapy 
From a prospective study on early chemotherapy-related cardiovascular changes in 41 
testicular cancer patients treated with bleomycin- and cisplatin-based regimens, EDTA plasma 
was serially collected and stored in -20°C until analysis. The local medical ethics committee 
approved this study, and informed consent was obtained from all participants. Following 
- 101 -
Changes in Genes and Pathways by Cisp/atin and Bleomycin 
orchidectomy, all patients received, depending on their International Germ Cell Cancer 
Collaborative Group (IGCCCG) prognosis group, three or four three-weekly courses of BEP­
chemotherapy [bleomycin (30 USP; days 2, 8, 15), etoposide (100 mg/m2; days 1-5) and 
cisplatin (20 mg/m2; days 1-5)]. During the first 6 days of each course patients were hydrated 
with 4 L NaCl 0.9%/day and received daily anti-emetic therapy with dexamethason and 
ondansetron. Blood samples were drawn at day 1, 8 and 15 of the first chemotherapy course, 
day 1 and 8 of the second and third course, [cldl (= baseline), cld8, cld15, c2dl, etc.], one 
month after completion and one year after start of chemotherapy. Reference data were 
obtained from healthy male siblings of adult childhood cancer survivors, who had participated 
as control subjects in a cross-sectional study on late cardiovascular sequelae of treatment for 
childhood cancer. Out of these healthy male siblings, a control group was selected with a 
comparable median age as the testicular cancer patients. Measurements in the controls were 
performed as described above. 
Plasma GDF15-levels were determined by sandwich enzyme-linked immunosorbent assay 
(ELISA) with a commercially available kit (R&D Systems, Abingdon, UK). Furthermore, these 
GDF15 levels were related to plasma markers for endothelial activation [von Willebrand Factor 
(vWF), measured as described earlier]8 and systemic inflammation [high-sensitivity C-Reactive 
Protein (hsCRP), as described earlier]21• 
For analysis of changes in plasma GDF15-levels, SPSS software package version 16.0 (SPSS Inc., 
Chicago, IL) was used. Non-normally distributed data were represented as median (range). For 
comparisons between groups the non-parametric Mann-Whitney U test or Kruskal-Wallis test 
was applied, as appropriate. The Wilcoxon's signed rank test was used for intra-individual 
changes in GDF15. Two-sided P-values �0.05 were considered significant. 
RESULTS 
cDNA mi cro array 
Class comparison 
The top 50 of most differentially expressed genes in the acute and chronic exposure models 
for bleomycin and cisplatin are summarised in Table 1. Figure 2 shows overlapping genes in the 
top 50s of the different models. From this analysis three candidate genes were selected for 
further exploration, e.g. GDF15, ATF3 and AREG. 
BLEOMYCIN -ACUTE BLEOMYCIN - CHRONIC CISPLATIN -ACUTE CISPLATIN - CHRONIC 
Gene IZ Gene P-value Gene IZ Gene P-value 
ATF3 *§ 1' 9.574 CYP1B1 1' <0.0001 CORT 1' 9.577 MXl t -!, <0.0001 
KIAA1370 1' 9.574 KLF12 1' <0.0001 TREM2 1' 9.222 GPR87 -!, <0.0001 
RRAD 1' 9.552 PRSS35 § 1' <0.001 ATF3 *:j: 1' 9.039 IFl27 -!, <0.0001 
C12orf5 1' 9.476 GL52 -!, <0.001 AVPll 1' 8.757 JMJD4 1' <0.001 
GDF15 § 1' 9.454 ENPP4 1' <0.001 AKl * 1' 8.658 FAM15A -!, <0.001 
GPR87 1' 9.454 ZMATl 1' <0.001 VASN 1' 8.653 OAS3 -!, <0.001 
MDM2 1' 9.356 TMEM184C 1' <0.001 SESN2 * 1' 8.633 MX2 -!, <0.001 
SESN2 * 1' 9.258 ADAM12 t 1' <0.001 LRDD 1' 8.633 HLA-F -!, <0.001 
COL7Al 1' 9.16 RABllFIPl 1' <0.001 AREG :j: 1' 8.633 AREG t:j: -!, <0.001 
ATG16L2 1' 9.16 PTGER2 1' <0.001 PLCDl 1' 8.586 LOC1576 1' <0.001 
AKl * 1' 9.16 SERPINB2 1' <0.001 ADM 1' 8.549 ALKBH8 1' <0.001 
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Table 1 - continued 
BLEOMYCIN - ACUTE BLEOMYON - CHRONIC CISPLATIN - ACUTE CISPLATIN - CHRONIC 
Gene IZ Gene P-value Gene IZ Gene P-value 
FAS 1' 8.964 SCFD2 1' <0.01 LRRTM2 1' 8.524 ABCC4 1' <0.001 
LIF 1' 8.964 KRTAP4-8 1' <0.01 DEDD2 1' 8.457 HIST2BE ..1, <0.001 
VWCE 1' 8.866 C10orf136 1' <0.01 RALGDS 1' 8.37 RFTl 1' <0.001 
TP531NP1 1' 8.817 HESl t ..1, <0.01 DNAJB2 1' 8.364 LRRC38 1' <0.001 
VDR 1' 8.811 COL1A2 1' <0.01 MSXl 1' 8.328 SNAll t ..1, <0.001 
C4orf18 1' 8.768 HIST1H2BJ 1' <0.01 MST150 1' 8.322 C19orf42 1' <0.01 
FERMTl 1' 8.734 RBPJL 1' <0.01 NR4A3 1' 8.157 LOC1171 ..1, <0.01 
FUCAl 1' 8.691 CRTACl ..1, <0.01 FDXR 1' 8.143 SIAE ..1, <0.01 
MCC 1' 8.691 CCDC148 t ..1, <0.01 ITPKA 1' 8.143 IQGAP2 ..1, <0.01 
NELF 1' 8.691 RORl 1' <0.01 KREMEN2 * 1' 8.143 POLAl 1' <0.01 
BTG2 1' 8.691 EDNl ..1, <0.01 SLC31A2 1' 8.126 PDK4 ..1, <0.01 
TGFBRl 1' 8.691 TGFB2 § 1' <0.01 CEACAMl 1' 8.107 ATF3 H ..1, <0.01 
TMEM131 1' 8.572 PRKCZ 1' <0.01 IRF5 1' 8.101 TNFSFlO ..1, <0.01 
CDHlO 1' 8.572 MARVELD2 1' <0.01 FOXL2 1' 8.101 DHX37 1' <0.01 
FZD2 ..1, -7.775 ATF3 t§ ..1, <0.01 VCAMl • ..1, -8.432 TOM4L 1' <0.01 
C3orf36 ..1, -7.809 CD82 ..1, <0.01 C7orf10 ..1, -8.437 IFIT3 ..1, <0.01 
TRIB2 • ..1, -7.817 XTP3TPA 1' <0.01 C3orf26 ..1, -8.438 IFl44L ..1, <0.01 
SMA5 ..1, -7.835 SPTANl ..1, <0.01 MYRIP ..1, -8.535 TNC t 1' <0.01 
NDRG4 ..1, -7.869 KIAA1655 1' <0.01 RORl ..1, -8.56 KREMEN2* ..1, <0.01 
EBPL ..1, -7.873 00B2 ..1, <0.01 QKI ..1, -8.597 HNMT ..1, <0.01 
TGFB2 § ..1, -7.912 SNAll t ..1, <0.01 TRIB2 • ..1, -8.628 BRD9 1' <0.01 
MYCN ..1, -7.971 STC2 1' <0.01 CDKALl ..1, -8.647 BEX2 ..1, <0.01 
SEMA3A • ..1, -7.971 TNC t 1' <0.01 TFPI ..1, -8.658 MGC33894 ..1, <0.01 
GIMAP2 ..1, -7.992 LRRIQl ..1, <0.01 LTBPl ..1, -8.664 DUSPl t ..1, <0.01 
ZFP36 ..1, -8.001 ASMT 1' <0.01 PLKl ..1, -8.686 C7orf54 ..1, <0.01 
UBE2G2 ..1, -8.044 GATA6 1' <0.01 NAVl ..1, -8.714 104 1' <0.01 
RNASEl ..1, -8.069 GDF15 t§ ..1, <0.01 PAPPA ..1, -8.726 CCDC148 t ..1, <0.01 
MXD3 ..1, -8.21 PCDHGA3 ..1, <0.01 PIFl • ..1, -8.765 MDM2 ..1, <0.01 
HIST12AM ..1, -8.218 DDX19A 1' <0.01 DHRSX ..1, -8.891 PRAPl ..1, <0.01 
C14orf94 ..1, -8.222 RARB 1' <0.01 GMDS ..1, -8.928 FOS ..1, <0.01 
PIFl * ..1, -8.261 CCND2 ..1, <0.01 LAMA4 ..1, -9.02 HESl t ..1, <0.01 
OASL ..1, -8.265 BCSll 1' <0.01 DKFZP0335 ..1, -9.02 ASPA ..1, <0.01 
PRSS35 § ..1, -8.44 BIRC7 1' <0.01 CD9 ..1, -9.051 GDF15 t ..1, <0.01 
CLEC14A • ..1, -8.482 MXl t ..1, <0.01 FAT4 ..1, -9.124 COL9A3 ..1, <0.01 
HOXD8 ..1, -8.679 RERG 1' <0.01 DOCKl ..1, -9.222 LGALS9 ..1, <0.01 
HISTlHlD ..1, -8.713 ADAMTS12 1' <0.01 SMAD7 ..1, -9.32 NR4Al ..1, <0.01 
CLEC3B ..1, -8.866 DUSPl t ..1, <0.01 FHOD3 ..1, -9.381 ADAM12 t 1' <0.01 
VCAMl • ..1, -9.16 AREG t ..1, <0.01 CLEC14A • ..1, -9.418 RNASE7 ..1, <0.01 
C9orf3 ..1, -9.552 OSBPLlA 1' <0.01 SEMA3A • ..1, -9.418 HHATL ..1, <0.01 
Table 1. Top 50 genes with largest difference in expression in the different exposure settings in HMEC-1. 
(*) Overlapping genes in the acute exposure model for both drugs; ft) Overlapping genes in the chronic exposure 
model for both drugs; (:t) Overlapping genes in the acute and chronic exposure models for cisplatin; (§) Overlapping 
genes in the acute and chronic exposure models for bleomycin. 
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Figure 2. Results from the class comparison analysis: overlapping genes from top SO's of most differentially 
expressed genes in HMEC-1, resulting from acute and chronic exposure to bleomycin and cisplatin. 
cDNA microarray - GSEA 
Pathways enriched at a FDR S0.10 and P-value S0.025 in the GSEA are summarised in Table 2. 
In the acute exposure model to bleomycin, six pathways were enriched (all upregulated), while 
no pathways were enriched in the chronic setting with the set criteria for FDR. For cisplatin, 12 
pathways were enriched in the acute exposure model (upregulated n=3, downregulated n=9) 
while six pathways were enriched in the chronic exposure model (all downregulated). 
Both the 'p53-pathway' and the 'Type I Diabetes Mellitus' gene sets were upregulated in acute 
exposure to bleomycin and cisplatin, and downregulated in chronic exposure to cisplatin. 
Genes included in this gene set are summarised in Appendix I. 
qRT-PCR 
To validate changes in expression of GDF15, ATF3 and AREG we performed qRT-PCR. In the 
acute exposure model, mRNA-expression of all three genes decreased in untreated cells at 
t=48 compared to t=6 (Figure 3A). Contrarily, in cells exposed to bleomycin or cisplatin, mRNA­
expression increased at t=48 compared to t=6, except for ATF3 after exposure to bleomycin. At 
t=48 mRNA-expression of all three genes in treated cells was higher compared to untreated 
cells at the same time-point. 
In the chronic exposure model, mRNA-expression of GDF15, ATF3 and AREG increased in 
untreated cells at day 30 compared to day 2 (Figure 3B). In cells exposed to bleomycin or 
cisplatin these increases were also observed, with the exception of AREG-expression in 
cisplatin-treated cells. Compared to untreated cells, mRNA-expression of all genes in treated 
cells at day 2 and day 30 was higher. Overall, this qRT-PCR confirms that exposure to 




Gene Set Enrichment Analysis BLEOMYCIN - ACUTE CISPLATIN - ACUTE CISPLATIN-CHRONIC 
FDR P-value FDR P-value FDR P-value 
Cellular Processes; Cell 
Communication 
Adherens junction .J, 0.07 0.003 
Focal adhesion .J, 0.04 <0.0001 
Cellular Processes; Cell Growth and 
Death 
p53 signaling pathway 1' 0.001 <0.0001 1' 0.02 <0.0001 .J, 0.1 <0.001 
Environmental Information 
Processing; Signal Transduction 
TGF-beta signaling pathway .J, 0.05 <0.0001 
Genetic Information Processing; 
Folding. Sorting and Degradation 
Ubiquitin mediated proteolysis .J, 0.04 0.001 
Human Diseases 
Endometrial cancer .J, 0.04 <0.0001 
Cholera infection 1' 0.10 0.005 
Type I diabetes me/litus 1' 0.07 <0.0001 1' 0.05 <0.0001 .J, 0.01 <0.001 
Neurodegerative disease .J, 0.09 0.008 
Prion diseases .J, 0.08 0.01 
Metabolism; carbohydrate 
Metabolism 
Butanoate metabolism 1' 0.02 <0.0001 
Glyoxylate and dicarboxylate 
.J, 0.09 0.02 
metabolism 





N-Glycan biosynthesis .J, 0.08 <0.0001 
Linoleic acid metabolism 1' 0.08 0.005 1' 0.09 0.01 
Polyunsatyrated fatty acid 
.J, 0.04 0.002 
biosynthesis 
Organismal Systems; Immune 
System 








Table 2. Gene Set Enrichment Analysis on gene expression profiles from HMEC-1 in acute and chronic exposure to 
bleomycin and cisplatin, using pathway definitions from KEGG. No pathways were enriched according to these 
criteria in chronic exposure to bleomycin. 
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Figure 3. Changes in mRNA-expression of three genes from the top 50 of most differentially expressed genes in the 
class comparison analysis in acute (A) and chronic (B) exposure to bleomycin or cisplatin. The fold increase in 
expression of each gene is relative to mRNA-expression in untreated cells at t=6 or d=2. Abbreviations: Growth­
Differentiation Factor 15 (GDF15), Activating Transcription Factor 3 (ATF3), Amphiregulin (AREG). 
P lasma GDF15- levels i n  testi cular cancer pati ents treated wi th SEP- chemotherapy 
Based on differences in gene expression in the cDNA microarray analysis and qRT-PCR, we 
measured plasma protein levels of GDF15 during BEP-chemotherapy in testicular cancer 
patients. Baseline (i.e. pre-chemotherapy) GDF15-levels in testicular cancer patients were not 
different from healthy age-matched males (Figure 4A). Patients in the IGCCCG good prognosis 
group had lower baseline GDF15-levels than patients in intermediate or poor prognosis groups 
[good prognosis: median 362.9 pg/ml (range 197.6-1059.5; n=33), intermediate/poor 
prognosis: median 689.1 pg/ml (range 186.8-1935.0; n=8); P=0.04]. Pre-chemotherapy GDF15-











Figure 4A. Plasma levels of GDF15 in patients with metastatic testicular cancer prior to start of SEP-chemotherapy, 
compared to healthy age-matched males. 
During BEP-chemotherapy, GDF15-levels increased compared to baseline, with significantly 
higher levels 1 months and 1 year post-chemotherapy (Figure 4B, Table 3) . Compared to pre­
chemotherapy, plasma levels of vWF and hsCRP changed significantly during treatment (Table 
3). After completion of chemotherapy, vWF-levels remained persistently elevated, whereas 
hsCRP returned to pre-chemotherapy values. At baseline, levels of GDF15 were related to 
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levels of vWF (rs= 0.35; P=0.03) and hsCRP (rs= 0.39; P=0.014). Throughout treatment, levels of 
GDF15 correlated with hsCRP at cld8 (rs= 0.44; P=0.01) and with vWF at c3d8 (rs= 0.40; 
P=0.017). At the follow-up visit one month after completion of chemotherapy, levels of GDF15 
and vWF were strongly correlated (rs= 0.56; P=0.001), whereas this relation was not found for 
GDF15 and hsCRP (rs= 0.18; P=0.28). One year after start of treatment, no relation between 
GDF15-levels and vWF or hsCRP (rs= 0.28; P=0.12; rs= 0.10; P=0.57) was found. 
B * 
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Figure 48. Changes in plasma protein GDF15-levels before, during and after completion of SEP-chemotherapy for 
testicular cancer. The sample at cldl is drawn before initiation of chemotherapy. (*) p<0.05 compared to baseline 
value or indicated time-point (Wilcoxon signed rank test. 
GDF15 (pg/ml) vWF (%) hsCRP (mg/L) 
Median Range Median Range Median Range 
Course 1 day 1 (=baseline) 383.1 186.8-1935.0 100 42-297 2.0 0.2-87.1 
Course 1 day 8 3473.7 * 1344.5-9028.3 164 * 56-319 0.6 * 0.2-4.9 
Course 1 day 15 1587.2 * 655.2-4014.9 145 * 57-394 4.2 t 1.1-101.0 
Course 2 day 1 1145.5 * 593.6-3074.5 143 * 34-360 5.1 1.1-39.8 
Course 2 day 8 4898.0 * 2183.0-10794.9 197 * 66-464 0.6 * 0.2-21.1 
Course 3 day 1 2067.7 * 639.0-4918.0 194 * 66-440 3.7 0.3-39.9 
Course 3 day 8 5542.8 * 702.3-18958.9 197 * 81-419 0.6 0.2-25.7 
One month 1009.6 * 409.7-4737.1 135 * 56-249 2.2 0.4-29.1 
One year 395.2 ** 246.9-913.2 115 *:J: 49-218 1.5 0.2-14.3 
Table 3. Levels of Growth Differentiation Factor 15 (GDF, pg/ml), von Willebrand Factor (vWF, %) and high­
sensitivity C-Reactive Protein (hsCRP, mg/L) before, during and after completion of bleomycin- and cisplatin-based 
chemotherapy for testicular cancer. 
(*) P<0.01 compared to baseline, Wilcoxon Signed Rank test; (t) P<0.05 compared to baseline, Wilcoxon Signed Rank 
test; (:t) P<0.01 compared to one month after completion of chemotherapy, Wilcoxon Signed Rank test; (§) P<0.05 
compared to one month after completion of chemotherapy, Wilcoxon Signed Rank test 
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DISCUSSION 
This study shows that acute and chronic exposure to bleomycin and cisplatin induces changes 
in gene expression in HMEC-1, as measured with cDNA microarray analysis. We found several 
single genes with significant changes in expression upon exposure to these drugs, i.e. GDF15, 
ATF3 and AREG. In addition, GSEA revealed clusters of genes involved in apoptotic and 
inflammatory pathways that were affected in this model. Furthermore, we showed for one of 
the relevant genes that SEP-chemotherapy did indeed affect plasma protein levels of GDFlS in 
testicular cancer patients, apparent from increases during chemotherapy. Taken together, 
these experiments show that cDNA microarray studies in this endothelial cell model are a 
useful strategy to explore mechanisms related to and select candidate biomarkers involved in 
chemotherapy-related endothelial damage. 
cDNA microarray analysis provides information on changes in single genes as well as in clusters 
of genes involved in biological pathways, affected by exposure to a pathogenic stimulus like 
chemotherapeutic drugs. This analysis permits the evaluation of effects on various relevant cell 
types, e.g. tumour cells or endothelial cells. The advantage of this method is that changes in 
gene expression are assessed without a priori assumptions, rather than using a candidate­
based approach based on data obtained from the literature. This permits the finding of 
unknown genes and pathways related to the development of drug-related vascular damage. In 
our class comparison analysis for the acute exposure model, a constraint was put on genes 
that had a changed RNA expression in a consistent direction by using the sum of the linear 
tests for trend (IZ). Hereby, genes are selected with changes in RNA expression in a consistent 
direction with increasing concentrations over time (i.e. untreated, IC50, IC90 after 6, 24 and 48 
hours). In the chronic exposure model, changes in RNA expression were estimated by 
calculating differences between cells exposed to lower concentrations (IC10) of cytostatics over 
30 days compared to untreated cells, as the time-course of the experiment by itself may also 
change RNA-expression. With these methods used for class comparison, expression of several 
genes changed significantly after exposition to bleomycin or cisplatin, with a number of 
overlapping genes in different experimental settings, i.e. GDF15, ATF3 and AREG. 
Next to exploring differences in expression of individual genes as biomarkers for 
chemotherapy-related endothelial damage, we aimed to analyze smaller but coordinated 
changes in sets of genes involved in biological pathways.177 Using GSEA, a powerful and robust 
tool for comparison of RNA expression, differences were compared against functional gene 
sets that are defined in the KEGG-database. In this analysis, several gene sets were significantly 
enriched at the set criteria for FDR, including 'p53 pathway' and 'Type I Diabetes Mellitus' in 
acute exposure to bleomycin and cisplatin, and chronic exposure to cisplatin. The finding that 
p53-related genes were affected by cisplatin as well as bleomycin illustrated the validity of our 
approach, as both drugs excert their key therapeutic effect by cellular apoptosis induction. The 
enriched 'Type I Diabetes Mellitus' gene set includes several genes involved in inflammatory 
processes, e.g. HLA-molecules, interleukins and TNF, indicating that bleomycin and cisplatin 
induce an inflammatory response in endothelial cells. This finding is completely in line with 
studies in testicular cancer patients treated with cisplatin-based regimens, which showed 
higher rates of systemic inflammation and endothelial dysfunction.8•20•21 As circulating platinum 
remains detectable in the circulation years to decades after cisplatin treatment, 28 long-term 
testicular cancer survivors may well have ongoing vascular damage and chronic low-grade 
endothelial inflammation. When chronic inflammatory responses prove to be an important 
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pathogenic factor for the development of chemotherapy-induced endothelial damage, 
intervention with anti-inflammatory drugs is a rationale approach to alleviate these effects. 
Based on our microarray findings we studied plasma protein levels of GDF15 in testicular 
cancer patients before and during treatment with BEP-chemotherapy. The increases in GDF15 
throughout treatment as well as post-chemotherapy may partly relate to cancer-related 
mechanisms, as GDFlS was higher in patients with more advanced disease stage. However, 
GDF15-levels correlated with proteins known to reflect chemotherapy-related endothelial 
damage in testicular cancer patients, vWF and hsCRP.8'21 This supports the hypothesis that the 
increases in GDF15 may importantly relate to systemic endothelial damage. 
The cytokine GDF15 is a member of the transforming growth factor P (TGFP) family. 
Stimulation of several cell types, e.g. by Tumor Necrosis Factor a (TNFa), interleukins or pro­
inflammatory cytokines results in increased GDFlS-expression.178 Release of GDF15 can induce 
anti-inflammatory, anti-apoptotic and anti-proliferative effects, thereby exerting 
vasculoprotective mechanisms. Therefore, increases in GDF15-plasma levels in our patient 
cohort may well result from increased production by endothelial cells and/or macrophages, to 
compensate for chemotherapy-related damage. In cardiovascular medicine, plasma levels of 
GDF15 are explored as a predictive marker for risk of death or other adverse events in patients 
presenting with symptomatic coronary events, 179'180 as well as for cardiovascular events in 
otherwise healthy subjects.181 A number of other studies suggest that GDF15 plays a relevant 
role in cardiovascular damage.182 In a study evaluating gene expression changes in prostate 
cancer samples pre- and post docetaxel/mitoxantrone treatment, GDF15 was one of highest 
upregulated genes post-treatment, 183 illustrating that cytostatics can influence GDF15-
expression. 
Further exploration of the role of ATF3 and AREG may provide more insight in mechanisms of 
chemotherapy-related endothelial damage. Data from the literature support the relevance of 
the gene ATF3 in this context. ATF3 is a downstream member of the MAP-kinase signalling 
pathway that encodes for a nuclear factor that stimulates transcription upon cellular stress. 
Fast upregulation of ATF3 is a central stress response in different endothelial cell models, 
induced by various noxious stimuli.184-189 Interference with ATF3-levels protected cells from 
apoptosis induction, e.g. induced by TN Fa in HUVEC, 190 by cisplatin in a human glioblastoma 
cell line, 185 or related to doxorubicin in cardiomyocytes.191 Interestingly, increased ATF3-
expression measured immunohistochemically was found in atherosclerotic areas of human 
iliac arteries.186 Few studies addressed AREG, a member of the epidermal growth factors 
receptors that plays an important role in cellular proliferation and survival. Breast cancer cells 
exposed to cisplatin secreted the AREG-protein over extended periods of time, i.e. up to 72 
hours after exposition.192 
In conclusion, cDNA microarray analysis on HMEC-1 facilitates exploration of genes and 
pathways associated with cisplatin- and bleomycin-related endothelial damage. Several genes 
were found to be differentially expressed after exposition to these drugs, e.g. GDF15, ATF3 and 
AREG. In GSEA, clusters of genes involved in cell death and inflammation were affected. The 
observed changes in plasma GDF15-protein levels in testicular cancer patients indicate that 
this pre-clinical approach can be translated to a clinical setting. Further in vitro and in vivo 
exploration is warranted. Eventually, this may facilitate the rationale towards selection of 
targets for intervention, and the introduction of early surrogate biomarkers for chemotherapy­
related endothelial damage. 
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Appendix table 1. Genes included in the 'p53 pathway' and 'Type I Diabetes Mellitus pathway' gene sets in the 
KEGG database, ranked in alphabetical order. 
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Since the introduction of platinum-based chemotherapy regimens in the late 1970's,4 
metastatic testicular cancer has become a highly curable malignancy with a 10-year survival 
rate of around 80%.2'5 As a result of this favourable prognosis and together with a still 
increasing incidence, 1'5 the population of successfully treated testicular cancer survivors is 
steadily growing. Because of a normal life-expectancy when cured from testicular cancer, the 
risk for treatment-related complications in these patients is increasingly recognized. 2•6 
Examples of these side-effects are infertility, neurotoxicity, second malignancies and 
cardiovascular disease (CVD).6•7 
Acute cardiovascular complications during or shortly after completion of chemotherapy can 
manifest as arterial or venous thrombo-embolic events.8'9 Moreover, the development of 
Raynaud's phenomenon10 and the occurrence of sometimes even fatal pulmonary toxicity11 
cause unwanted side-effects of this curative treatment. In addition to early events, testicular 
cancer survivors have an increased risk for late CVD16'193 and subclinical signs for 
atherosclerosis.18-21 
Both clinical8 and pre-clinical22-27 studies have shown that direct chemotherapy-related 
endothelial damage is an important mechanism for the development of these vascular 
complications. Furthermore, cardiovascular risk factors and endocrine disturbances can 
contribute to cardiovascular morbidity observed in long-term testicular cancer survivors.31 
Early recognition and possibly prevention of these treatment-related complications is needed 
to conserve an optimal health condition of testicular cancer survivors. The development of 
CVD is a gradual process, and early interventions may slow down or stop the progression 
towards overt clinical morbidity. Biomarkers for treatment-related cardiovascular damage can 
identify patients at increased risk for CVD, and guide treatment and follow-up schedules. In 
addition, specific biomarkers can increase insight in the pathogenesis of vascular 
complications, and point to possible targets for intervention. Furthermore, such biomarkers 
may be used as surrogate markers for cardiovascular disease, and thereby facilitate 
intervention studies that are aimed to decrease the incidence of chemotherapy-related CVD. 
SUMMARY 
The studies described in this thesis aim to search for early biomarkers of subclinical treatment­
related cardiovascular damage in testicular cancer patients treated with cisplatin-based 
chemotherapy. 
Up to now, the most commonly used method for evaluation of cancer treatment-related 
cardiovascular damage is measurement of the Left Ventricular Ejection Fraction (LVEF). 
However, the LVEF may underestimate actual cardiac damage as subclinical changes in cardiac 
function can occur with a preserved systolic function. In Chapter 2 we summarised 
advantages, disadvantages, and the Level of Evidence35 for the use of different methods. This 
literature review confirmed that current monitoring strategies for detection of cardiovascular 
damage are mainly based on moderate evidence. Therefore, studies are needed that explore 
reliable and sensitive monitoring strategies for early detection of cancer treatment-related 
cardiovascular damage. 
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We prospectively measured changes in a comprehensive panel of biomarkers involved in 
various aspects of vascular pathobiology, e.g. circulating endothelial cells (CECs) in blood and 
plasma biomarkers for endothelial activation, inflammation and pro-thrombotic state in 
testicular cancer patients treated with bleomycin-etoposide-cisplatin (BEP) chemotherapy 
(Chapter 3). Within this panel of vascular biomarkers, changes in levels of CECs and vWF as 
well as increases in carotid IMT may point to testicular cancer patients with augmented 
endothelial damage. These biomarkers should be included in studies addressing the cisplatin 
chemotherapy-related damage phenotype in testicular cancer patients, consisting of 
accelerated atherosclerosis and cardiovascular morbidity. Extended follow-up studies will 
reveal the predictive value of early rises in CECs and persistent endothelial activation for late 
CVD in this patient cohort. Eventually, such a marker panel should identify patients in whom 
active intervention to alleviate or prevent chemotherapy-related CVD is indicated. 
Long-term testicular cancer survivors have an increased incidence of cardiac dysfunction.13'36 
We prospectively measured early changes in cardiac function in testicular cancer patients by 
means of sensitive echocardiography parameters and serum levels of the cardiac biomarker N­
Terminal pro Brain Natriuretic Peptide (NT-proBNP). At a median of 10 months after BEP­
chemotherapy, diastolic function significantly declined and NT-proBNP-levels were higher than 
baseline (Chapter 4). Next, over a median follow-up of 7 years, the incidence of abnormal 
diastolic parameters significantly increased in this patient cohort (Chapter S). Overall the rate 
of systolic dysfunction remained low, with one out of 37 patients (2.7%) with an abnormal 
LVEF. Changes in plasma levels of the cardiac biomarkers NT-proBNP, troponin and galectin-3 
were not predictive for late cardiac abnormalities. At both post-chemotherapy cardiac 
evaluations, declines in diastolic function parameters were larger in the presence or 
development of hypertension and obesity. These associations stress the need to monitor and 
treat cardiovascular risk factors in testicular cancer survivors. 
Carotid IMT is a measure for systemic atherosclerotic burden and an independent predictive 
marker for cardiovascular endpoints in the general population.143 Accelerated increases in IMT 
may identify subjects with a higher risk for CVD. During a 7-year longitudinal follow-up of 
testicular cancer survivors treated with BEP-chemotherapy, carotid IMT significantly increased 
(Chapter 6). At 7 years their median IMT was not different from healthy males, whereas these 
survivors had a higher age-related yearly increase in IMT. The IMT progression rate was 
associated with increases in serum lipids, revealing a potential target for intervention. Patients 
who developed Raynaud's phenomenon after chemotherapy had a higher IMT during follow­
up and a steeper age-related increase in IMT. This association suggests that Raynaud's 
phenomenon may be a surrogate clinical marker for chemotherapy-related endothelial 
damage, and patients who develop this phenomenon may be more prone to develop CVD. 
The metabolic syndrome is a cluster of cardiovascular risk factors that are associated with a 
higher risk for CVD. We investigated the prevalence and associated features of this syndrome 
in a cross-sectional study in �3 year post-chemotherapy testicular cancer survivors. The 
incidence of the metabolic syndrome was 25%, which is 2-fold higher than in a healthy age­
matched reference population (Chapter 7). Separate components of the metabolic syndrome 
developed relatively early; after a median number of follow-up years of 1.7 for obesity, 0.9 for 
hypercholesterolemia and 5.1 for hypertension. Presence of the metabolic syndrome was 
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associated with higher levels of systemic inflammation, a more pro-thrombotic state and 
higher carotid IMT. This early development and higher rate of metabolic syndrome emphasises 
the need for guidelines on early detection and treatment of these risk factors. 
To obtain more insight in molecular events involved in chemotherapy-related endothelial 
damage, we performed a cDNA microarray analysis in human microvascular endothelial cells 
(HMEC-1) exposed to bleomycin or cisplatin. In this preliminary study, significant changes in 
expression occurred in single genes, e.g. GDF15, ATF3 and AREG. Furthermore, biological 
pathways involved in cell death and inflammation were affected (Chapter 8). With qRT-PCR 
the differences in gene expression in GDF15, ATF3 and AREG were validated. In addition, we 
measured changes in protein levels of the cytokine encoded for by the GFD15-gene. These 
protein levels increased in plasma of testicular cancer patients during treatment with BEP­
chemotherapy. This study indicates that cDNA microarray analysis offers the road towards a 
translational approach to investigate and explore new candidate biomarkers and mechanisms 
for chemotherapy-related endothelial damage. Further in vitro and in vivo exploration is 
warranted. Eventually, this may facilitate the rationale towards targets for intervention, and 
the introduction of surrogate biomarkers for early vascular damage. 
GENERAL DISCUSSION & FUTURE PERSPECTIVES 
Strategies to decrease the development of cardiovascular complications in testicular cancer 
patients 
Progression from endothelial dysfunction towards overt CVD is a gradual process, starting with 
early endothelial activation and followed by a silent progression over the course of years. 29•30 
By detection of chemotherapy-related endothelial damage in an early and still reversible 
phase, those patients who have an increased risk for CVD can be identified. 
Figure 1 shows a hypothetical scheme that summarises different strategies to decrease the 
rate of cardiovascular damage during and after a potentially toxic cancer treatment. The 
different lines represent the timing of vascular complications. First, patients may develop early 
signs of vascular damage and endothelial dysfunction during SEP-chemotherapy (line I). 
Furthermore, late endothelial dysfunction may arise during follow-up, i.e. years to decades 
after completion of treatment (line II). In addition, a group of patients have a normal, 
physiological decrease in endothelial function during ageing (line Ill). In the following section, 
aspects of the strategies to decrease cardiovascular complications (numbers 1 to 5 in Figure 1) 
will be discussed, and new insights from the studies described in this thesis will be addressed. 
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Figure 1. Hypothetical schematic representation of changes in endothelial status in testicular cancer patients 
treated with SEP-chemotherapy. (I) Early endothelial dysfunction; (II) Late endothelial dysfunction; (Ill) Physiological 
decrease in endothelial function during ageing. Green bars indicate factors that contribute to the development of 
endothelial dysfunction. Different strategies to reduce endothelial damage progression are indicated with numbers 
1 to 5. (1) estimation of a baseline risk; (2) subclinical changes; (3) temporary phenomena; (4) 
intervention/prevention (5) follow-up schedules. 
1. Estimation of a baseline risk f or cardiovascular damage 
Prior to initiation of BEP-chemotherapy, a baseline risk for treatment-related complications 
includes patient-related characteristics and risk factors for CVD. These consist of a medical 
history of CVD, presence of cardiovascular risk factors and risk behaviour such as smoking, a 
cholesterol-rich diet and sedentary life style. In our study on early changes in cardiac function 
after BEP-chemotherapy, a high pre-treatment blood pressure was associated with larger 
declines in diastolic parameters (Chapter 4). This finding stresses the relevance of 
cardiovascular risk factors already at this early stage. 
A promising strategy in this regard is identification of specific genetic variations, i.e. Single 
Nucleotide Polymorphisms (SNPs), that modulate the susceptibility for treatment-related 
cardiovascular damage. Candidate SNPs relate to variations in pharmacokinetics and 
pharmacodynamics of cytostatics, a baseline tendency to develop CVD, and capacity for repair 
of treatment-related damage.6 Although some studies investigated candidate SNPs, up to now 
no firm relations between specific variations and the risk for cardiovascular complications have 
been established .194'195'196 
2. Changes in biomarkers fo r subclinical cardiovascular damage 
Biomarkers for endothelial activation 
Plasma levels of endothelial activation markers increase during BEP-chemotherapy and remain 
persistently higher than baseline up to one year post-chemotherapy (Chapter 3). Furthermore, 
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during 7-year follow-up levels of soluble adhesion molecules increase compared to 11 months 
post-chemotherapy (Chapter 6). Taken together, data from these studies indicate that 
increases in markers for endothelial activation indicate subclinical vascular damage during and 
after treatment, which may mechanistically contribute to atherosclerosis. 
Biomarkers for systemic inflammation 
We observed significant changes in plasma levels of high-sensitivity C-reactive protein (hsCRP) 
during BEP-courses, whereas levels returned to baseline afterwards (Chapter 3). During a 
longitudinal 7-year follow-up, median hsCRP-levels did not change (Chapter 6). In this study no 
associations existed between hsCRP and the development of clinical morbidity, although in our 
cross-sectional analysis on prevalence of the metabolic syndrome patients with this syndrome 
had higher hsCRP-levels (Chapter 7). Overall, although a recent published paper showed 
promising findings on the role of hsCRP-levels as early predictive marker for treatment-related 
CVD,33 findings from the current studies do not provide supportive data on the use of hsCRP as 
marker for subclinical vascular damage. 
Biomarker for vascular structure: carotid /MT 
Median IMT does not change up to one year after BEP-chemotherapy (Chapter 3), however, a 
subgroup of patients had increases in their IMT (41%) as well as larger increases in CECs during 
chemotherapy. Additionally, IMT was higher in testicular cancer survivors with the metabolic 
syndrome, a subgroup at increased risk for CVD (Chapter 7). In our follow-up study in 7-year 
testicular cancer survivors the median IMT increased during follow-up, but was not different 
from healthy subjects (Chapter 6), in line with previous reports.20•21 Interestingly, testicular 
cancer survivors had a higher age-related increase in IMT. This may point to accelerated 
atherosclerosis. Moreover, 7-year survivors with Raynaud's phenomenon secondary to 
chemotherapy had a higher IMT and a steeper !MT-increase than patients without this 
phenomenon. Because of the proposed common cause for both increases in IMT and the 
development of Raynaud's phenomenon, i.e. chemotherapy-related endothelial damage, this 
important observation deserves further study. Possibly, development of this phenomenon 
after chemotherapy may be a convenient clinical biomarker for patients with a higher risk for 
treatment-related CVD. Taking data from our different studies together we conclude that 
carotid IMT is a marker that is affected in a subgroup of patients with augmented vascular 
damage, whereas short-term changes in IMT are not distinctive as a single subclinical 
biomarker for vascular damage. 
Biomarkers for cardiac status 
Long-term testicular cancer survivors have a higher rate of diastolic cardiac dysfunction.13'36 So 
far no clinical studies have investigated whether BEP-chemotherapy induces early changes in 
cardiac status, whereas early signs for endothelial damage have been reported. Although we 
observed a decline in diastolic cardiac parameters within 10 months after BEP-chemotherapy 
(Chapter 4), early changes in cardiac biomarkers and echocardiography parameters were not 
predictive for late systolic or diastolic dysfunction (Chapter 5). Cardiac abnormalities were mild 
in 7-year survivors, however, prolonged follow-up is needed to explore whether these 
subclinical diastolic abnormalities will further progress to clinical cardiac dysfunction. 
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3. Temporary phenomena for cardiovascular damage during BEP-chemotherapy 
Vascular damage: release of CECs 
CECs are shed from the vessel wall upon endothelial injury, and increased numbers in the 
blood can be regarded a temporary sign of chemotherapy-related vascular damage. Levels of 
CECs increase during and after completion of BEP-chemotherapy (Chapter 3), with larger 
changes in patients with increases in their carotid IMT and with acute treatment-related 
cardiovascular events. Moreover, cumulative changes in CECs correlate with other vascular 
damage biomarkers, such as vWF and slCAM-1. Therefore, temporary increases in CEC-levels 
may well be useful as marker for early treatment-related vascular damage. 
Cardiac damage: troponin 
Increases in serum levels of troponin, released from damaged cardiomyocytes, are a 
temporary sign for cardiac injury.71 Increases in troponin I occurred in 23% of patients during 
BEP-chemotherapy, however, these increases were not associated with changes in 
echocardiography parameters or clinical cardiac morbidity during follow-up (Chapter 5). This 
may relate to presence of mainly mild cardiac abnormalities at follow-up, as well as the 
additional contribution of cardiovascular risk factors to the declines in diastolic cardiac 
function parameters. 
4. Prevention of cardiovascular damage during and after completion of BEP-chemotherapy 
So far, no intervention studies have investigated strategies to prevent cardiovascular damage 
during BEP-chemotherapy. Two approaches can be feasible, i.e. concomitant treatment with a 
vasculo-protective drug or treatment with less toxic regimens. 
The relation between carotid !MT-progression and increases in serum lipids in testicular cancer 
survivors (Chapter 6) provides a rationale for intervention with a statin to decrease the 
development of accelerated atherosclerosis. Statins have lipid-lowering as well as anti­
inflammatory properties, thereby exerting endothelial protection via pleiotropic effects. 197 
Additional candidates for prevention of chemotherapy-related endothelial damage can be 
drugs with proven effects on decreasing the progression of atherosclerosis in other patient 
populations, e.g. oral antidiabetic agents like metformin.198 
Alternatively, treatment with less toxic regimens can lower the risk for vascular complications. 
In this respect, an alternative regimen consists of 4 cycles of etoposide-cisplatin (EP) 
combination chemotherapy in IGCCC good prognosis testicular cancer patients, instead of 3 
BEP-courses. Both regimens are comparable in terms of anti-tumour efficacy.199 However, the 
higher cumulative cisplatin-dose in the 4xEP-regimen is offset by the absence of bleomycin, 
which may relevantly contribute to the amount of endothelial damage. In a large cohort of 
testicular cancer survivors, the cumulative bleomycin-dose was the only significant predictor 
for development of Raynaud's phenomenon.151 In addition, one study reported that in a group 
of 82 testicular cancer patients treated with the 4xEP-regimen, none developed Raynaud's 
phenomenon.200 The finding from our longitudinal follow-up study that development of this 
symptom is associated with a higher carotid IMT also indicates that omission of bleomycin 
from the treatment regimens causes less vascular damage. Besides systemic endothelial 
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damage, the 4xEP-regimen prohibits development of pulmonary toxicity, a sometimes fatal 
complication.11 
Prior to initiation of such intervention trails, a suitable endpoint for endothelial damage has to 
be defined. Based on the findings in our prospective study in a comprehensive panel of 
biomarkers (Chapter 3), patients with early increases in CECs, persisting high vWF-levels and an 
!MT-increase after BEP-chemotherapy appear to represent a subgroup with augmented 
vascular damage. In this respect, a combination of these markers may serve as a biomarker 
panel to nail-down the vascular damage phenotype and serve as an intermediate endpoint for 
treatment-related endothelial damage. 
5. F ollow-up aft er completion of treatment 
Most chemotherapy-treated patients will remain under oncological follow-up for 10 years 
after treatment. In addition to detection of a possible tumour recurrence, recognition of 
potential late treatment-related effects can be pursued. Up to now no data is scarce on the 
design of an effective follow-up schedule. For childhood cancer survivors a detailed consensus­
based guideline has been developed providing individualised recommendations on the 
contents and frequency of follow-up visits.45 These recommendations can serve as a 
framework for adult cancer survivor follow-up. 
Monitoring for and treatment of cardiovascular risk factors during follow-up is crucial to lower 
the chance of progression of overt CVD. In our studies we observed associations between the 
development of cardiovascular risk factors, a higher !MT-progression rate (Chapter 6) and 
larger declines in diastolic cardiac function (Chapter 5), underscoring the relevance of these 
risk factors in the risk for late CVD. In the absence of evidence-based recommendations, a 
pragmatic approach can be pursued by estimation of cardiovascular risk factors at routine 
visits to the outpatient clinic. This can be done at regular intervals, e.g. every two years, 
starting at one year after start of BEP-chemotherapy. At these visits presence of risk factors for 
CVD, such as traditional risk factors and risk behaviour, can be determined and treated 
according to guidelines for the general population. Because of the signs of accelerated 
atherosclerosis in testicular cancer survivors (Chapter 6 & 7), even more stringent thresholds 
for cardiovascular risk factors may be indicated, such as used in secondary prevention. 
Through a joint collaboration between oncologists, general practitioners, internists, vascular 
specialists and cardiologists, optimal care for these survivors can be pursued. This 
collaboration can be based on a shared care model as is currently investigated and 
implemented in childhood cancer survivors.201 
T esticular cancer as a model f or healthy cancer survivorship 
In addition to pursuing healthy survivorship for testicular cancer patients, findings from these 
studies may be translated to other young adult cancer populations with a favourable cancer­
related prognosis, such as adjuvantly treated breast, cervical or colorectal cancer patients. 
So far, childhood cancer survivors studies have generated most data on late complications 
after cancer treatmens.45•202 However, these findings can not be directly translated to the 
(young) adult cancer patient population, as treatment regimens for childhood cancer largely 
differ from regimens used in adult cancer patients. Moreover, specific risks in childhood cancer 
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survivors relate to the immaturity of the organ systems. Testicular cancer patients are a young 
and fairly homogeneous population with little additional co-morbidities. These patients are 
treated with uniform treatment regimens and remain under active surveillance for several 
years after completion of treatment, usually in referral hospitals experienced in treatment of 
this patient population. By exploring mechanisms and biomarkers for treatment-related 
complications in testicular cancer patients, this population is a model to pave the way for 
effective evidence-based strategies to decrease the development of treatment-related 
complications in young adult cancer survivors. 
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Zaadbal (testis) kanker is de meest voorkomende vorm van kanker bij mannen van 20-35 jaar 
oud. Door de ontwikkeling van platinabevattende chemotherapieschema's eind jaren zeventig4 
is uitgezaaide testiskanker een goed te behandelen vorm van kanker geworden, met een 10-
jaars overleving van ongeveer 80%.2'5 Als gevolg van deze gunstige prognose en een stijgende 
incidentie1'5 wordt de groep testiskankeroverlevers steeds groter. Omdat zij in principe een 
normale levensverwachting hebben wordt het risico op nadelige gevolgen van de behandeling 
bij deze overlevers in toenemende mate van belang geacht. 2'6 Belangrijke voorbeelden van 
deze nadelige gevolgen zijn verminderde vruchtbaarheid, schade aan zenuwtakjes en een 
verhoogd risico op het ontwikkelen van tweede tumoren en hart- en vaatziekten.6'7 
Bij testiskankerpatienten kunnen tijdens of kort na behandeling met chemotherapie 
cardiovasculaire problemen ontstaan, zoals arteriele of veneuze thrombo-embolische 
complicaties.8'9 Daarnaast zijn het optreden van het fenomeen van Raynaud10 en (soms fataal 
verlopende) longschade11 voorbeelden van uitingen van vasculaire schade door deze curatieve 
behandeling. Naast vroege cardiovasculaire complicaties hebben testiskankeroverlevers een 
verhoogd risico op hart- en vaatziekten na voltooiing van de chemotherapiebehandeling.16•193 
Verschillende studies hebben bovendien aangetoond dat testiskankeroverlevers meer 
subklinische atherosclerose hebben dan gezonde mannen van dezelfde leeftijd.18·21 
Uit zowel patienten- als laboratoriumonderzoek is duidelijk geworden dat schade aan de 
bekleding van bloedvaten (endotheel) door chemotherapie een belangrijk mechanisme is voor 
het ontstaan van vasculaire complicaties. Naast directe endotheelschade kunnen 
cardiovasculaire risicofactoren (zoals overgewicht, hypertensie, dyslipidemie en 
insulineresistentie) en hormonale veranderingen bijdragen aan het optreden van hart- en 
vaatziekten bij testiskankeroverlevers.31 
Het ontstaan van hart- en vaatziekten is een geleidelijk proces. Endotheelschade kan 
aanleiding geven tot subklinische veranderingen aan de vaatwand, die zich in de loop van 
verscheidene jaren verder kan ontwikkelen tot klinisch relevante atherosclerose. Vroegtijdige 
herkenning van patienten met een verhoogd risico op het ontwikkelen van atherosclerose is 
belangrijk, omdat hiermee het ontstaan van deze behandelingsgerelateerde complicaties kan 
worden vertraagd of tot staan gebracht. 
Gevoelige voorspellers (biomarkers) voor het optreden van behandelingsgerelateerde 
endotheelschade zouden kunnen worden gebruikt om per patient het risico op het ontstaan 
van cardiovasculaire complicaties in te schatten. Als zulke biomarkers beschikbaar zijn kunnen 
de behandeling en follow-up van testiskankerpatienten worden geoptimaliseerd en 
ge"individualiseerd. Ook kunnen specifieke biomarkers inzicht geven in de wijze waarop 
chemotherapiegerelateerde endotheelschade ontstaat, en daarmee aanknopingspunten 
bieden voor het voorkomen van deze complicaties. Uiteindelijk zouden zulke biomarkers ook 
kunnen dienen als maat voor de uitgebreidheid van de endotheelschade die ontstaat door 
kankerbehandelingen. Hiermee kunnen interventiestudies kunnen worden uitgevoerd om de 
mate van cardiovasculaire schade door chemotherapie te verminderen of te voorkomen. 
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DOEL VAN HET PROEFSCHRIFT 
Dit proefschrift is gericht op het vinden van gevoelige biomarkers voor subklinische 
behandelingsgerelateerde cardiovasculaire schade bij testiskankerpatienten behandeld met 
cisplatinebevattende chemotherapie. 
SAMENVATTING 
Het bepalen van de linker ventrikel ejectiefractie is de meest gebruikte manier om 
cardiovasculaire schade door kankerbehandelingen te meten. Het nadeel van de ejectiefractie 
is dat deze methode de toegebrachte hartschade kan onderschatten, omdat subklinische 
schade aan het hart niet direct hoeft te leiden tot een verminderde pompfunctie. In hoofdstuk 
2 hebben we een overzicht gegeven van de voor- en nadelen van verschillende methoden, 
waaronder de ejectiefractie, waarmee cardiovasculaire schade tijdens en na 
kankerbehandelingen kan worden gemeten. Ook zoeken we naar bewijs in de literatuur voor 
de toepasbaarheid van de verschillende meetmethoden. Onze literatuurstudie laat zien dat de 
op dit moment gebruikte methoden om cardiovasculaire schade te meten slechts weinig harde 
wetenschappelijke onderbouwing hebben. Op basis van deze bevindingen benadrukken we het 
belang van het doen van onderzoek naar betrouwbare en gevoelige methoden om 
cardiovasculaire schade door kankerbehandelingen te meten. 
Veranderingen in biomarkers voor subklinische vaatschade kunnen warden gebruikt om 
patienten aan te wijzen die een verhoogd risico op chemotherapiegerelateerde complicaties 
hebben. In een studie bij testiskankerpatienten hebben we veranderingen in een panel van 
verschillende vasculaire biomarkers gemeten. Dit panel bestond uit circulerende 
endotheelcellen (CECs), plasma biomarkers voor endotheelactivatie, inflammatie en 
verhoogde stollingsneiging en de vaatstructuur (lntima Media Dikte van de arteria carotis 
[IMT]; hoofdstuk 3). In deze studie bleken de patienten waarin de CECs, markers voor 
endotheelactivatie en de IMT toenamen te behoren tot een subgroep met een hogere mate 
van chemotherapiegerelateerde vaatschade. Door deze groep langer te vervolgen zal duidelijk 
worden of veranderingen in CECs en de biomarkers voor endotheelactivatie het ontstaan van 
late cardiovasculaire problemen bij testiskankeroverlevers kunnen voorspellen. 
Lange termijn testiskankeroverlevers hebben een verhoogde kans om diastolische dysfunctie 
van het hart te ontwikkelen.13'36 We hebben bij testiskankerpatienten vroege veranderingen in 
hartfunctie gemeten met echocardiografie, en onderzocht of deze veranderingen mogelijk een 
voorbode zijn voor latere cardiale dysfunctie. Binnen een jaar na start van chemotherapie 
vonden we een verslechtering van de hartfunctie, gemeten met gevoelige diastolische 
parameters en de biomarker N-terminal pro Brain natriuretisch peptide (NT-proBNP) in het 
bloed (hoofdstuk 4). Vervolgens hebben we bij deze patienten mediaan 7 jaar na start van de 
behandeling opnieuw een echocardiogram gemaakt. In deze periode bleek de incidentie van 
een abnormale diastolische functie toegenomen te zijn (hoofdstuk 5). Het aantal patienten 
met een abnormale pompfunctie bleef laag aangezien slechts een van de 37 patienten (2,7%) 
een te lage linker ventrikel ejectiefractie had. Stijgingen van cardiale biomarkers in het bloed 
bleken niet voorspellend te zijn voor het later optreden van een abnormale hartfunctie. Wei 
vonden we in beide studies dat een verslechtering van de diastolische hartfunctie het meest 
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uitgesproken was bij patienten die hoge bloeddruk en overgewicht hadden ontwikkeld. Deze 
bevindingen benadrukken het belang van aandacht voor het opsporing en behandeling van 
cardiovasculaire risicofactoren bij testiskankeroverlevers. 
De IMT van de arteria carotis is een biomarker voor atherosclerose: een dikkere IMT geldt als 
onafhankelijke voorspeller voor het optreden van cardiovasculaire events in de algemene 
populatie.143 Een versnelde toename van de IMT is een teken van atherosclerose, en is 
geassocieerd met een hoger risico op hart- en vaatziekten. We hebben bij een groep 
testiskankerpatienten de IMT v66r, 11 maanden en 7 jaar na chemotherapiebehandelin� 
gemeten. Tijdens deze longitudinale follow-up nam de IMT toe (hoofdstuk 6). Vergeleken met 
een groep gezonde mannen van dezelfde leeftijd was de mediane IMT bij de 7-jaars meting 
niet verschillend, maar wel bleek de leeftijdsgerelateerde toename van de IMT groter bij de 
testiskankeroverlevers. De mediane jaarlijkse IMT toename na behandeling was gerelateerd 
aan veranderingen in serum lipiden. Het bleek dat patienten die het fenomeen van Raynaud 
hadden ontwikkeld na de chemotherapiebehandeling een hogere IMT hadden tijdens follow­
up, en een hogere leeftijdsgerelateerde toename van de IMT. Deze relatie zou kunnen 
betekenen dat het fenomeen van Raynaud een klinische biomarker voor atherosclerose bij 
testiskankeroverlevers kan zijn. 
Testiskankeroverlevers hebben een hogere prevalentie van het metabool syndroom dan 
gezonde mannelijke leeftijdsgenoten. Het metabool syndroom is een cluster van 
cardiovasculaire risicofactoren, en is geassocieerd met een toegenomen risico op het ontstaan 
van hart- en vaatziekten. In hoofdstuk 7 wordt beschreven dat in een groep 
testiskankeroverlevers die tenminste 3 jaar na de chemotherapiebehandeling zijn, het 
metabool syndroom aanwezig is bij 25%. Oat is twee keer hoger dan in een groep gezonde 
mannen van dezelfde leeftijd. Afzonderlijke componenten van het metabool syndroom traden 
in deze patientengroep relatief snel na de chemotherapiebehandeling al op: overgewicht na 
mediaan 1.7, hypercholesterolemie na mediaan 0.9 en hypertensie na 5.1 jaar. Patienten met 
het metabool syndroom hadden een dikkere IMT en hogere inflammatie- en 
stollingsparameters in het bloed. Het snelle optreden en het verhoogde voorkomen van het 
metabool syndroom bij testiskankeroverlevers benadrukt opnieuw het belang van vroegtijdige 
opsporing en behandeling van deze risicofactoren. Het ontwikkelen van richtlijnen waarin 
systematisch aandacht wordt besteed aan het optreden van deze risicofactoren lijkt van 
belang, om de kans op hart- en vaatziekten bij testiskankeroverlevers te verminderen. 
Om inzicht te krijgen in moleculaire processen die een rol spelen bij het ontstaan van 
chemotherapiegerelateerde schade hebben we een cDNA microarray analyse uitgevoerd bij 
endotheelcellen die waren blootgesteld aan de cytostatica bleomycine en cisplatine. In deze 
analyse vonden we significante veranderingen in genexpressie van vele genen, waarbij de 
genen GDF15, ATF3 en AREG uit verschillende experimenten naar voren kwamen. Daarnaast 
vonden we veranderingen in cellulaire signaalroutes die betrokken zijn bij celdood en 
inflammatie (hoofdstuk 8). Vervolgens bestudeerde we daarom de eiwitconcentratie van 
GDF15. Dit cytokine bleek, net als het RNA in vitro, toe te nemen in het plasma van 
testiskankerpatienten tijdens de behandeling met bleomycine- en cisplatine. Deze studie laat 
zien dat cDNA microarray analyse een techniek is die richting kan geven om op een zinvolle 
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'translationele' manier te zoeken naar nieuwe biomarkers voor chemotherapiegerelateerde 
vaatschade. Ook kan deze methode meer inzicht bieden in de cellulaire processen die een rol 
spelen bij het ontstaan van endotheelschade door chemotherapie. Aanvullend onderzoek in 
het laboratorium en bij patienten is gewenst om deze bevindingen verder te analyseren. 
In hoofdstuk 9 vatten we de bevindingen uit de voorgaande hoofdstukken samen. Daarna 
schetsen we een model waarin verschillende manieren waarop cardiovasculaire schade tijdens 
en na kankerbehandelingen worden weergegeven. Aan de hand van dit model worden de 
bevindingen uit onze studies en uit de literatuur samengevat. 
Met de studies zoals beschreven in dit proefschrift zijn we meer te weten gekomen over 
mechanismen die bijdragen aan het ontstaan van cardiovasculaire complicaties bij 
testiskankerpatienten. Daarnaast hebben we verschillende biomarkers gevonden die mogelijk 
een rol kunnen spelen bij het eerder opsporen van chemotherapiegerelateerde 
cardiovasculaire schade. Patienten met testiskanker zijn over het algemeen een jonge en 
relatief homogene populatie, die meestal weinig andere comorbiditeit heeft. Deze mannen 
worden met standaard chemotherapieschema's behandeld, en blijven vaak nog tot jaren na 
hun behandeling onder controle bij een medisch oncoloog. Onderzoek in deze populatie kan 
model staan voor onderzoek naar lange termijn effecten in andere groepen kankeroverlevers. 
Uiteindelijk kunnen bevindingen bij deze patienten als basis dienen voor het ontwikkelen van 
'evidence-based' strategieen om de kans op behandelingsgerelateerde complicaties bij 
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